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Chronic Obstructive Pulmonary Disease (COPD) remains one of the leading causes of 
mortality globally and places a high burden on patient quality of life. Neutrophils have been 
linked to multiple facets of disease pathology and are abundant in lung secretions of 
patients with COPD. However, recurrent infection and the lack of inflammatory resolution 
in COPD suggest neutrophil dysfunction. In addition, these patients also commonly present 
with other chronic diseases, termed multimorbidity, such as diabetes and cardiovascular 
disease and changes in circulating neutrophils may provide a link between these diseases. 
This thesis aimed to investigate changes in peripheral neutrophil phenotype in healthy 
ageing and COPD, with a focus on how multimorbidity may influence these changes. 
Systemic neutrophil activation, senescence and maturity status appeared unaltered in 
stable COPD compared to healthy controls and did not suggest an accelerated ageing 
phenotype. However, expression of a key chemokine receptor, CXCR2, was shown to be 
reduced and impacted by the presence of multimorbidity in these patients and further 
reduced during exacerbations. Multiple changes in both surface and gene expression were 
also seen during an exacerbation, suggesting the neutrophil phenotype can be altered by 
both chronic and acute inflammation. 
In addition, an activated phenotype was observed when neutrophils from healthy 
individuals were incubated with plasma from patients with COPD, suggesting systemic 
inflammation in patients with COPD was present and was able to activate neutrophils, 
further highlighting changes in the neutrophil phenotype due to chronic disease.  
 
Differences in the neutrophil phenotype described here demonstrate the heterogeneity of 
neutrophils, as well as the different impact caused by multimorbidity. Altered phenotypes 
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McGettrick and Sapey, 2020b) and have been adapted for this thesis. Original rights to 
figures retained upon publication (see Appendix for full author agreement). 
Chapter 4: Chapter 4 is an expanded version of the data that was published as “The 
Importance of validating antibody panels: Anti-PD-L1 clone binds the AF700 fluorophore” 
(Hughes, McGettrick and Sapey, 2020a). 
Chapter 5: The data relating to healthy volunteers and patients with COPD in this chapter 
are being submitted for publication at the time of writing this thesis. Some of these data are 
also published as conference abstracts: (Hughes et al., 2019; McIver et al., 2019). 
Chapter 6: The data relating to patients with COPD and AECOPD in this chapter are being 
submitted for publication at the time of writing this thesis. In addition, some of the cell 
surface expression data collected from neutrophils from patients with AECOPD were done 
by William McIver, an intercalating medic in our group, under laboratory supervision of 
myself. In addition, migration data in patients with AECOPD and stable COPD were 
performed by William McIver and Georgia Walton, previous students within the group, and 
are for reference only within the introduction to this chapter. 
Some of these data are also published as conference abstracts: (Hughes et al., 2019; McIver 
et al., 2019). 
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Why do some people, with a seemingly poor lifestyle and many of the risk factors for chronic 
lung disease, never develop lung disease, whilst others do? Is there a gene or a protein that is 
lost or broken, or a cell that does not work properly? What is it that means some people ‘age’ 
well? These questions form the basis of this thesis and seeking these answers is part of my 
personal motivation for undertaking this project. Whilst it is not possible to provide definitive 
answers to these questions in three years, this thesis aims to shed some light on what the 
answers might be by investigating the neutrophil, a white blood cell, and the role it plays in 
Chronic Obstructive Pulmonary Disease (COPD). This thesis focusses on neutrophil 
phenotypes based on the surface expression of key proteins linked to neutrophil functions, 
gene expression, and how these cells migrate towards chemical signals, known as chemotaxis. 
Within this, the question of “are all patients with COPD the same” is addressed in a novel way 
– highlighting differences in the underlying biology of the neutrophil in the context of 
multimorbidity. 
1.1 The Neutrophil 
The immune system is made of many different cells each performing specific, yet overlapping, 
functions to aid protection from infection and tissue damage; a system that develops 
throughout childhood into adulthood (Simon, Hollander and McMichael, 2015). The 
neutrophil is a white blood cell that is part of the first response to inflammation (Wang, 2018) 
and is collectively referred to as a granulocyte alongside eosinophils and basophils. 
Neutrophils form a major component of the immune system and account for over half of all 
circulating white blood cells in healthy individuals (Shah, Burg and Pillinger, 2017). It was 
previously thought that neutrophils, whilst providing an important function, were blunt 
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instruments against pathogens with limited functional heterogeneity (Smith, 1994). Since 
then, many studies have uncovered heterogeneity that exists within neutrophil populations 
(Christoffersson and Phillipson, 2018; Rosales, 2018), having implications for roles neutrophils 
play in both health and disease. There may, for instance, be a particular phenotype of cells 
that are more pro-inflammatory, less capable of controlling infection or cause more collateral 
damage – areas that require further exploration. 
1.1.1 Neutrophil maturation 
Neutrophils mature from haematopoietic stem cells in the bone marrow entering the 
circulation at a rate of around 1x109 neutrophils/kg every day under homeostatic conditions 
(Dancey et al., 1976). Upon release into the blood, they are terminally differentiated cells in 
permanent cell cycle arrest (Klausen et al., 2004). The production of mature granulocytes is 
tightly controlled by transcription factors (such as CCAAT/enhancer-binding protein) and is 
influenced by cytokines (Ward et al., 2000). The importance of cytokines, such as granulocyte-
colony stimulating factor (G-CSF), have been demonstrated using mice lacking the G-CSF 
receptor, resulting in a reduction of mature neutrophils (Liu et al., 1996).  
Neutrophil development can be divided into three main stages: the pre-mitotic pool or stem-
cell pool; the mitotic pool and the post-mitotic pool (Figure 1.1). Each stage can be identified 
by a combination of surface markers, cyclin-dependant kinase (CDK) expression and granule 
production (Bainton, Ullyot and Farquhar, 1971; Klausen et al., 2004). Haematopoietic stem 
cells express high levels of a surface glycoprotein, cluster of differentiation (CD)34 (Civin et al., 
1984), that is subsequently lost during maturation (Figure 1.1).  The pre-mitotic pool consists 
of myeloblasts, promyelocytes and myelocytes that are all able to undergo cell division. 
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Myeloblasts and promyelocytes express CDK6 and are self-replicating, developing into 
myelocytes that no longer express CDK6 and are limited to the production of neutrophils, 
monocytes and macrophage depending on the conditions within the bone marrow (Nakamura 
et al., 1996). Development then enters the post-mitotic phase and marks the beginning of 
neutrophil-committed cell types as cells begin to lose all CDK expression and become unable 
to replicate. During this stage, cells continue to acquire the fundamental features of 
neutrophils, such as granules and a segmented nucleus (Borregaard and Cowland, 1997; Ward 
et al., 2000; Carvalho et al., 2015). Band cells, with a distinct banded nuclear morphology, are 
also referred to as immature neutrophils and directly proceed mature neutrophils. The 
appearance of band cells in the blood is usually only observed during acute inflammation, such 
as sepsis or systemic inflammatory response syndrome (SIRS) (Mare et al., 2015). Finally, 
mature neutrophils develop a distinct multi-lobular nucleus, lose expression of C-X-C 
containing receptor (CXCR)4 and gain expression of an endopeptidase, CD10 (Elghetany et al., 
2004; Strydom and Rankin, 2013). These changes in phenotype during maturation enable 
neutrophils to respond appropriately to infection and tissue damage in the body once they 
enter the circulation. 
1.1.2 Neutrophil release into the circulation 
As with maturation, release into the circulation is regulated by cytokines and changes in the 
external environment. It is thought two main receptors control neutrophil release into the 
bloodstream: CXCR4 and CXCR2 (Suratt et al., 2004); demonstrated in vivo both in mice (Eash 
et al., 2010) and zebrafish (Isles et al., 2019). Retention of immature neutrophils in the bone 
marrow is governed primarily by CXCR4, a receptor for C-X-C containing ligand (CXCL)12 (also 
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known as stromal-derived factor 1, SDF-1), which is highly expressed in haematopoietic cells 
and not in peripheral blood neutrophils (Patel et al., 2001; Sugiyama et al., 2006). As CXCR4 
expression decreases with neutrophil maturation, neutrophils no longer respond to this 
retention signal (Suratt et al., 2004). Concurrently, an increase in expression of CXCR2, the 
receptor for multiple cytokines in humans such as interleukin-8 (IL-8; CXCL8), CXCL1 and 
CXCL2, allows migration of neutrophils into the bloodstream (Martin et al., 2003; Eash et al., 
2010). G-CSF also plays an important role in regulating neutrophil release (Semerad et al., 
2002) and mice injected with G-CSF show rapid neutrophilia, a response that is absent in 
CXCR2 knock-out mice (Eash et al., 2010; Köhler et al., 2011), demonstrating the dependence 
on CXCR2 for neutrophil mobilisation.  
Whilst there has been some debate in the literature around the exact half-life of neutrophils 
in circulation (Pillay et al., 2010, 2011; Tofts et al., 2011; Tak et al., 2013), it is generally 
accepted that an individual neutrophil persists for around 24-72 hours in the circulation 
(Dancey et al., 1976; Suratt et al., 2001). This short half-life, therefore, requires a large 
turnover of neutrophils in health to maintain circulating neutrophil numbers. Precisely what 
happens to neutrophils as they age either in the circulation, tissue and after responding to an 
inflammatory stimulus (referred to as senescence) is a topic of debate, however, this process 
and the associated intricacies within the context of COPD will be discussed later. 
1.1.3 Sentinel role 
With large numbers of circulating neutrophils in the blood, what is their function in health? 
Neutrophils are usually one of the first cells recruited to sites of inflammation (Aulakh, 2018) 
and play an important sentinel role because of the wide range of danger and pattern 
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recognition receptors they are capable of expressing (Hartl et al., 2008). More recent findings 
have also revealed that phenotypically distinct neutrophils in mice - with higher expression of 
major histocompatibility class II (MHC-II) molecules - may also patrol healthy uninflamed 
tissue (Lok et al., 2019), but the extent to which this happens in human is unknown.  
1.2 Overview of Neutrophil Function 
Neutrophils play an active role in protecting the body from pathogens in response to 
inflammatory signals and do this through several key functions (Hughes, Sapey and Stockley, 
2019), including phagocytosis (van Kessel, Bestebroer and van Strijp, 2014), reactive oxygen 
species (ROS) production (El-Benna et al., 2016) and NETosis (Delgado-Rizo et al., 2017). 
Neutrophils are thought to exist in three states of activity dependant on their environment: 
(i) quiescent, where cells are in tissue or circulating in homeostasis; (ii) primed, where an initial 
activation signal is received; and (iii) activated, where effector responses can be deployed 
(Sapey and Stockley, 2014). A healthy response requires not only rapid activation but accurate 
migration, controlled effector functions and then the resolution of inflammation and tissue 
repair (Figure 1.2; Jones et al., 2016). Understanding how neutrophils function in health 
provides an important lens to identify changes that occur with ageing and chronic disease. To 
this end, how neutrophils function in the context of healthy development and response to 
infection, with a focus on the lung, will now be explored.  
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Figure 1.1: Overview of neutrophil maturation 
 
As neutrophils mature, several distinct phenotypic changes occur. In the pre-mitotic pool, 
myeloblasts have high chemokine-motif CXC receptor 4 (CXCR4) and CD34 expression, 
along with cyclin-dependent kinase (CDK) 2, 4 and 6 expression, allowing proliferation. The 
promyelocyte is the first stage where granule production occurs, beginning with the 
primary or azurophil granules. Myelocytes still maintain replicative potential, but CDK 
expression is reduced and CDK6 is absent. In this stage, specific granule production also 
begins. Replicative potential is lost with metamyelocytes, despite residual CDK expression. 
This change is accompanied with the loss of CD34 expression and increased granule 
production. The next stage of development to immature neutrophils (band cells) includes 
the complete absence of CDK2,4 and 6 expression and production of gelatinase granules. 
Cells also begin to express CXCR2 and start to lose CXCR4 surface expression ready for 
release into the circulation. Mature neutrophils have high levels of CXCR2 and CD10 with 
very low CXCR4 expression. As neutrophils age in circulation, it is thought that CXCR4 
expression begins to increase again allowing homing back to the bone marrow for 
clearance.  
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1.2.1 Activation and transmigration 
Recruitment of neutrophils to tissue is a complex process, tightly regulated by both 
neutrophils and the vascular endothelium. Extensive research has slowly unravelled this 
process at a molecular level and can be described as a cascade broadly split into three stages: 
rolling, firm adhesion, and extravasation or transmigration (Ley et al., 2007). Each of these 
stages has distinct groups of adhesion molecules that govern the interaction of neutrophils 
(and indeed other leukocytes) with the endothelium, including the crawling of neutrophils 
both inside and outside the vascular lumen (Voisin and Nourshargh, 2013). In the absence of 
inflammation, rolling of neutrophils on the endothelium is likely a rare event due to the lack 
of selectins (also referred to as CD62) or selectin receptors expressed at the endothelium 
plasma membrane (Zarbock et al., 2011). However, studies in mice have revealed evidence of 
neutrophil transmigration in the absence of inflammation: fluorescent neutrophils transferred 
into the blood of recipient mice showed these cells were able to enter the lymph nodes via 
high-endothelial venules (Lok et al., 2019) and were also found patrolling in the lungs absence 
of inflammation (Casanova‑Acebes et al., 2018). 
Upon endothelial activation by inflammatory signals, such as histamine or cytokines, or by 
direct detection of lipopolysaccharide (LPS; a bacterial product) (Lorenzon et al., 1998), 
Weibel–Palade bodies (a storage granule) containing intracellular stores of P-selectin (CD62P) 
fuse with the plasma membrane, leading to rapid expression of CD62P  (Berman et al., 1986; 
McEver et al., 1989). E-selectin (CD62E) is also expressed early on in endothelial activation 
from de novo production following transcriptional activation, demonstrated in vitro with 
human umbilical vein endothelial cells (Kansas, 1996). These two selectins can be bound by P-
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selectin glycoprotein ligand-1 (PSGL-1) which, despite its name, can bind all three main 
selectins (CD62P, E and L) and is expressed on the surface of neutrophils (Zarbock et al., 2011). 
CD62L is the only selectin expressed by neutrophils (Alon et al., 1996) and is maintained on 
the plasma membrane (Gómez-Gaviro et al., 2000). Notably, human neutrophils are also able 
to directly bind CD62E with CD62L (Zöllner et al., 1997), demonstrated in vitro in affinity 
binding assays; highlighting the importance of CD62L in neutrophil recruitment to 
inflammatory sites. PSGL-1 is also expressed by activated endothelium (Martins et al., 2007) 
and is, therefore, also capable of binding to CD62L on the surface of the neutrophil. Together, 
the expression of selectins and PSGL-1 results in many interactions between the vascular 
endothelium and neutrophils to mediate rolling – a process that occurs under shear stress in 
the circulation and indeed requires shear stress to function correctly (Marshall et al., 2003). 
Once rolling has been instigated, firm adhesion to the endothelium must occur to halt the 
neutrophil and allow extravasation (Figure 1.2). Integrins function as heterodimers, two of 
which are considered to be vital for neutrophil firm adhesion: lymphocyte function-associated 
antigen 1 (LFA-1) formed from integrin alpha L (CD11a)/β2 (CD18) and macrophage-1 antigen 
(Mac-1) formed from alpha M (CD11b)/CD18 (Ding et al., 1999). Whilst these integrins are 
constitutively expressed by neutrophils, they are upregulated upon activation (Abdel-Salam 
and Ebaid, 2014), leading to the use of CD11b as an activation marker in many studies (Orr et 
al., 2007; Costantini et al., 2010). Whilst expression is important, a conformational change 
increased the affinity of these integrins for their binding partners, leading to firm adhesion 
(Anderson, Hotchin and Nash, 2000). Chemokines, such as CXCL8, produced by endothelial 
cells (Strieter et al., 1989) and fibroblasts (Schröder et al., 1990) are presented on 
glycosaminoglycans on the endothelial surface (Rot and Von Andrian, 2004). Chemokine 
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receptors, especially CXCR2 for neutrophils, then detect these chemokines and trigger integrin 
activation (Luu, Rainger and Nash, 2000; Lefort and Ley, 2012). LFA-1 and Mac-1 then link with 
the corresponding binding partner, Intercellular Adhesion Molecule-1 (ICAM-1, hereon 
referred to as CD54), on the endothelium surface that is similarly constitutively expressed at 
low levels and upregulated upon activation (Yang et al., 2005). The binding of integrins and 
the detection of cytokines also provide signals that induce important changes intracellularly 
in the neutrophil, including cytoskeletal rearrangements, that contribute to cell activation and 
adhesion (Anderson, Hotchin and Nash, 2000), priming of the ROS response (Luo, Carman and 
Springer, 2007) and may also help prepare the nucleus to deform ready for transmigration 
(Manley, Keightley and Lieschke, 2018). 
At the point of firm adhesion and rolling arrest, two processes can occur: crawling along the 
vascular lumen or transmigration into the tissue. Intraluminal crawling has been visualised in 
vivo in mice using intravital microscopy, identifying the reliance on LFA-1 for initial adhesion 
and Mac-1 for efficient crawling (Phillipson et al., 2006). Transmigration (Figure 1.3) 
predominantly occurs paracellularly (between endothelial cell junctions) (Burns et al., 1997), 
however, movement through the endothelial cytoplasm, known as transcellular migration 
(Gane and Stockley, 2012), has also been described in vitro with human endothelial cells and 
isolated neutrophils (Kvietys and Sandig, 2001; Carman and Springer, 2004) and in vivo in mice 
(Woodfin et al., 2011).   
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Figure 1.2: Overview of neutrophil adhesion cascade 
 
At rest, circulating neutrophils express high levels of CD62L and low levels of adhesion 
molecules CD11b and CD66b. They undergo weak binding with the endothelium 
spontaneously through interactions of CD62L and P-selectin glycoprotein ligand-1 (PGSL-
1). Activation in response to damage or chemokine detection causes several changes in 
both neutrophils and the endothelium. Neutrophils increase their surface expression of 
adhesion molecules CD11b and CD66b that increase the chance of firm binding. On the 
endothelium, release of chemokines such as CXC-motif ligand 8 (CXCL8) occurs, along with 
increased vascular permeability and the increase of adhesion molecules including 
intercellular cell adhesion molecule-1 (ICAM-1), E-selectin (CD62E) and vascular adhesion 
molecule-1 (VCAM-1). Tethering between CD62L, CD62E and CD62P slows the rolling of 
neutrophils prior to firm adhesion. Together these induce cytoskeletal changes in 
neutrophils in preparation for extravasation. During this process, neutrophils shed CD62L 
in order to assist migration through the extracellular matrix (ECM). 
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1.2.2 Migration and chemotaxis 
After rolling, firm adhesion to the endothelium, crawling and transmigration, neutrophils are 
now able to enter the next phase in neutrophil migration: moving along chemotactic gradients 
within the tissue. It is important to note, neutrophils can also migrate along non-chemical 
gradients such as hydraulic pressure (Prentice-Mott et al., 2013), but will not be discussed in 
detail here. CD62L is usually shed upon neutrophil activation and transmigration; blocking this 
process using mice expressing a mutant form of CD62L caused neutrophils to be retained in 
the tissue, but did not seem to impede the ability of neutrophils to successfully reach the site 
of inflammation (Venturi et al., 2003). Neutrophils with different levels of CD62L expression 
could, therefore, impact on the clearance of activated neutrophils from the tissue.  
For neutrophils to successfully migrate to the site of inflammation, they must navigate the 
complex milieu of different cytokines and damage-associated signals (Pittman and Kubes, 
2013) and respond to these signals appropriately. A hierarchy of responses was observed 
using a competing migration system in agarose gel (Heit et al., 2002), whereby neutrophils 
responded with lower priority to so-called ‘intermediate’ signals such as CXCL8 compared with 
‘end-stage’ attractants such as N-Formylmethionyl-leucyl-phenylalanine (fMLP), a bacterial 
product (Heit et al., 2002). The same hierarchy was observed in a more complex microfluidic 
system, again with human neutrophils in vitro (Kim and Haynes, 2012). Both studies highlight 
how complex signalling networks allow neutrophils to accurately migrate within the tissue 
microenvironment. Model organisms such as Dictyostelium discoideum that mimic neutrophil 
chemotaxis (Parent, 2004) also revealed migration is highly sensitive, as these cells could 
detect directionality in a gradient as shallow as 1% (Song et al., 2006).  
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Figure 1.3: Overview of neutrophil chemotaxis 
 
Neutrophils move from the blood stream through the extracellular matrix (ECM) before 
reaching the lung epithelium. This can occur by two routes, either paracellularly (p) or 
transcellularly (t). Through this migration, neutrophils cause some tissue damage due to 
release of enzymes that degrade ECM components. Receptors on the surface of the 
neutrophil are able to sense chemical gradients from bacterial products such as N-
Formylmethionyl-leucyl-phenylalanine (fMLP) or inflammatory cytokines such as CXC-
motif Ligand 8 (CXCL8).  
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Two major signalling pathways govern neutrophil chemotaxis: phosphoinositide 3-kinase 
(PI3K) and mitogen-activated protein kinase MAPK (Heit et al., 2002). Responses to 
intermediate chemoattractants are heavily reliant on the dual action of PI3K at the leading 
edge and phosphatase and tensin homolog (PTEN) at the lagging edge (Hirsch et al., 2000; 
Kölsch, Charest and Firtel, 2008) – two enzymes that control the phosphorylation of 
phosphatidylinositol (Figure 1.4). In contrast, p38 MAPK co-ordinates neutrophil chemotaxis 
to end-point chemoattractants (Nick et al., 1997). It is the PI3K pathway that has drawn 
attention in the context of ageing and disease, as there is a gradual decline in accurate 
migration with age that can be partly rescued by PI3K inhibition (Sapey et al., 2014). 
Importantly, these neutrophils did not lack the ability to move, termed chemokinesis, but 
were not able to move as accurately in the model studied. The process of chemokinesis still 
requires cytoskeletal arrangements and may be activated by extracellular ATP (Isfort et al., 
2011). There is, therefore, an important distinction between chemotaxis and chemokinesis: 
chemotaxis is the ability to sense the environment and apply this motion directionally whilst 
chemokinesis demonstrates the correct function of cytoskeletal arrangements to migrate 
(Keller et al., 1978).  
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Figure 1.4: Simplified overview of PI3K and MAPK signalling pathways  
N-Formylmethionyl-leucyl-phenylalanine (fMLP) binds the formyl peptide receptor (FPR), 
leading to activation of the G-protein coupled receptor and dissociation of G-protein 
subunits. Through several intermediaries, p38 mitogen-activated protein kinase is 
activated and results in activation of chemotaxis pathways. In a similar manner, binding of 
CXC-motif (CXC) ligand 8 (CXCL8) to the CXC receptors, such as CXCR2, leads to activation 
of phosphoinositide 3-kinase that catalyses the addition of a phosphate group to 
phosphatidylinositol (PI) 4,5 bisphosphate (PIP2) forming PI 3,4,5 triphosphate (PIP3). This 
leads to cell polarization and activation of chemotaxis pathways. PIP3 can be 
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1.2.3 Phagocytosis 
Upon reaching the site of injury or infection, neutrophils are capable of destroying micro-
organisms by phagocytosis and the production of lethal ROS. These two processes together 
enable micro-organism specific damage, however, ROS production can also be highly 
damaging to local tissue and, therefore, needs to be tightly regulated to minimise collateral 
damage (Dupré-Crochet, Erard and Nüβe, 2013; El-Benna et al., 2016). Bacterial phagocytosis 
begins with the binding of the bacterial surface by specific cell membrane receptors on the 
neutrophil, including those for immunoglobulins bound to opsonised bacteria and non-
specific receptors such as complement receptors (CR)1 and 3 (van Kessel, Bestebroer and van 
Strijp, 2014). However, binding of the bacteria is only the first step and major restructuring of 
the cytoskeleton of the neutrophil is still required to pull the bacteria into the cytoplasm of 
the neutrophil (Herant, Heinrich and Dembo, 2006). Once bacteria are contained within the 
phagosome, fusion with lysosomes containing various cytotoxic compounds and Nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase – the main producer of ROS (Dupré-
Crochet, Erard and Nüβe, 2013) - leads to bacterial killing (Lee, Harrison and Grinstein, 2003).  
1.2.4 Neutrophil granules 
ROS also have a role outside bacterial killing including mediating the release of proteases held 
within several types of neutrophil granules (Faurschou and Borregaard, 2003). A variety of 
proteases are held within neutrophil granules ready for rapid release, allowing neutrophils to 
degrade proteins extracellularly and have powerful antimicrobial effects. They have distinct 
protein content (Falloon and Gallin, 1986), primarily determined by protein expression 
variations during neutrophil development (Figure 1.1) (Faurschou and Borregaard, 2003). 
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Azurophil (primary) granules are produced earliest in neutrophil development and contain 
many enzymes that aid bacterial killing such as neutrophil elastase (NE) and proteinase-3 (PR3) 
(Faurschou and Borregaard, 2003; Segal, 2005; Crisford, Sapey and Stockley, 2018). Both 
specific (secondary) and gelatinase (tertiary) granules are produced from myelocytes onwards 
but have very different protein compositions: specific granules contain multiple antimicrobial 
proteins, whereas gelatinase granules contain enzymes used for digesting the extracellular 
matrix (ECM) during transmigration (Faurschou and Borregaard, 2003). These proteases aid in 
bacterial clearance in the lung (Craig et al., 2009) and are usually held in check by anti-
proteases to prevent damage to healthy lung tissue (Stockley, 1999; Sallenave, 2015). The 
unregulated activity of proteinases are key in the pathogenesis of COPD and will be expanded 
on later. 
1.2.5 Neutrophil Extracellular Traps (NETs)   
The final mechanism neutrophils can deploy is the release of nuclear and mitochondrial DNA 
complexed with proteases to trap and destroy bacteria, viruses, fungi and parasites 
extracellularly (Papayannopoulos, 2017). It is thought that NET formation occurs either in the 
presence of larger microbes or once phagocytic capacity is overwhelmed (Manfredi et al., 
2018). The exact role in vivo is still subject to intense investigation as there is currently no 
consensus on how best to study their formation and function in vivo or in vitro (Boeltz et al., 
2019). It is also emerging that NETs are cytotoxic to the lung epithelium, suggesting that NETs 
within the lung microenvironment may cause more harm than benefit, leading to the 
association of NETs with several lung diseases (Twaddell et al., 2019). 
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1.2.6 Neutrophil senescence and removal from tissues and circulation 
The final stage of the neutrophil life cycle is appropriate apoptosis and removal from either 
the tissue or circulation. It was initially assumed neutrophils that entered tissue were cleared 
exclusively by efferocytosis – phagocytosis by macrophage – after apoptosis and during 
inflammation resolution (Savill and Haslett, 1995). Efferocytosis likely remains the primary 
mechanism of neutrophil clearance following inflammation and is an important mechanism to 
stimulate an anti-inflammatory response by macrophage and neutralises proteases (Fadok et 
al., 2001). However, early studies using radiolabelled neutrophils in rats revealed that 
neutrophils could indeed return to the circulation (Hughes et al., 1997). Nearly 10 years later, 
this process was visualised in zebrafish (Mathias et al., 2006) and from sterile hepatic injury in 
mice (Wang et al., 2017), with a clear reverse transmigration phenotype exhibited in human 
neutrophils involving increased CD54 expression (Buckley et al., 2006). CD54, therefore, has 
emerged as a useful tool for identifying neutrophils that have undergone reverse 
transmigration. 
As not all neutrophils are removed in the tissue, other mechanisms of neutrophil clearance 
exist. Senescence, a term originally coined by Hayflick and Moorhead (Hayflick and Moorhead, 
1961) to describe the limited replicative capacity of cells in culture as they aged, is a process 
that cells go through as they age. There are two key mechanisms described that are associated 
with and identify senescence of individual cells: the change in β-galactosidase activity, termed 
senescence-associated β-galactosidase (SAβG) activity; and the senescence-associated 
secretory phenotype (SASP), a unique pattern of proteins secreted by cells undergoing 
senescence (reviewed in the context of cancer by Coppé et al., 2010). The detection of β-
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galactosidase activity in senescent fibroblasts and not quiescent fibroblasts or terminally 
differentiated keratinocytes (Dimri et al., 1995) led to this biomarker of senescence being 
generally adopted. In vitro studies show an increase in proteins responsible for cell cycle arrest 
in combination with SAβG in human lung fibroblasts exposed to cigarette smoke (Nyunoya et 
al., 2006) and from lung fibroblasts from patients with emphysema (Müller et al., 2006), 
potentially indicating senescence. However, crucially as mature neutrophils do not replicate, 
neutrophil ‘senescence’ requires a more complex interpretation and definition (Klausen et al., 
2004), yet may still occur as a process allowing clearance from the circulation. Studies in mice 
showed that neutrophils increased CXCR4 expression – the receptor that is lost during 
neutrophil maturation – with cellular age, allowing homing of neutrophils back to the bone 
marrow (Martin et al., 2003; Adrover, Nicolás-Ávila and Hidalgo, 2016). There is also evidence 
of this process occurring in human in vitro as neutrophils cultured for 12-18h showed reduced 
CXCR2 expression, increased CXCR4 expression and an increase in migration towards the 
CXCR4 ligand CXCL12 (Yildirim et al., 2005). The use of green fluorescent protein (GFP) 
reporter mice revealed that neutrophils were removed from the circulation at distinct rates in 
different organs including the spleen, liver, lung, bone marrow and skeletal muscle 
(Casanova‑Acebes et al., 2018). In COPD, where significant numbers of neutrophils are found 
in the lung, clearance may also occur by migration into the airways and expectoration of 
sputum (Singh et al., 2010). There appears, therefore, multiple routes for neutrophil clearance 
that maintain a turnover of functional neutrophils. 
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Figure 1.5: Neutrophil functions within the lung 
 
Upon reaching the source of inflammation or infection, neutrophils have multiple effector 
functions that include the release of proteases from granules; phagocytosis of both 
opsonised and non-opsonised bacteria; production and release of reactive oxygen species 
(ROS) and, usually as a last resort, the expelling of nuclear material coated in various 
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1.3 Neutrophil phenotypes in health and ageing 
The concept of phenotype within the context of neutrophils must be considered carefully. It 
does not describe ‘subtypes’ of neutrophils in the same way that distinct types of T cell exist 
(Raphael et al., 2015). Cellular phenotype can be described by any observable characteristic, 
such as gene and protein expression, that contributes to the morphology and function of the 
cell. The surface expression of receptors, integrins and ligands by neutrophils are involved in 
many of the functions discussed, such as activation, chemotaxis and transmigration, and can 
be used to identify the phenotype of the cell. This has a clear advantage – flow cytometry can 
be used to identify surface expression of these markers to gain an insight into the function of 
these neutrophils (Borregaard et al., 1994). However, as neutrophils alter the surface 
expression of proteins to perform different functions, an ongoing debate has questioned if 
neutrophils are just highly plastic heterogeneous cells, or if they do indeed have distinct roles 
(Rosales, 2018). Differences in the functional responses of neutrophils, such as migration 
accuracy and antimicrobial actions can also be measured to add another dimension to the 
neutrophil phenotype that may not necessarily be gained from measuring surface expression 
(Muinonen-Martin et al., 2010). Some of the key phenotypes that can be seen in health will 
now be discussed briefly, including how these may change with healthy ageing and are 
relevant to disease processes. These phenotypes are also linked to COPD and will be expanded 
upon later. 
1.3.1 Maturity and activation 
Multiple changes occur during neutrophil maturation (Section 1.1.1) and studies with 
peripheral blood neutrophils have shown that expression of CD10 reliably identified mature 
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neutrophils (Brandau and Hartl, 2017; Marini et al., 2017). In health, all neutrophils within the 
circulation should be mature and express CD10. However, acute inflammation, such as that 
caused by invasive surgery (Orr et al., 2005), can cause the release of immature neutrophils 
into the circulation that do not express CD10 on their surface. Maturity is likely an important 
feature for correct neutrophil function as immature neutrophils from patients with sepsis 
carried out phagocytosis and ROS production less efficiently than their mature counterparts 
(Drifte et al., 2013). 
Likewise, neutrophil activation results in the increased expression of CD11b, another adhesion 
molecule, CD66b, and the shedding of CD62L (see Section 1.2.1) – leading to these proteins 
being commonly used to identify neutrophil activation (Kinhult et al., 2003; Costantini et al., 
2010; Lakschevitz et al., 2016). Whilst neutrophil activation would not be expected in the 
absence of pathogenic or damage signals, one report suggested an increased proportion of 
activated neutrophils may be present in the circulation after strenuous muscle exercise (Pizza 
et al., 1996), although the intensity of exercise and population group may influence this 
finding, as another study did not find any significant changes in neutrophil activation following 
downhill running in athletes (Peake et al., 2005). 
Increased inflammation observed in an age-dependent manner, so-called inflammaging 
(Franceschi et al., 2000), may also impact on neutrophil activation. Increased circulating 
cytokines, including CXCL8, in elderly individuals demonstrated an increase in activation 
signals for neutrophils (Franceschi and Campisi, 2014). As activation primes neutrophils for a 
functional response, detecting activation gives an insight to the neutrophil activity in health, 
damage and disease.  
Chapter 1  Page | 23 
1.3.2 Chemokine sensing and migration 
Neutrophils also alter the surface expression of chemokine receptors during maturation and 
these play a vital role in controlling neutrophil release and responses to inflammatory stimuli. 
As discussed, CXCR2 and CXCR4 are thought to govern neutrophil release from the bone 
marrow and return during senescence (Section 1.1.2 and 1.2.6). In the circulation, therefore, 
neutrophils expressing CXCR2, but lacking CXCR4, indicates mature functional neutrophils (De 
Filippo and Rankin, 2018). As CXCR2 is a major chemokine sensing receptor on neutrophils, 
expression is vital for the ability of neutrophils to migrate towards sites of inflammation and 
links closely to functional neutrophil responses.  
Several previous studies have suggested that neutrophil migration is not substantially altered 
with age (Butcher, Chahel and Lord, 2000). However, whilst the overall speed that neutrophils 
can travel might not be altered, neutrophils isolated from elderly individuals did not travel as 
accurately towards chemokines compared with neutrophils from younger individuals (Sapey 
et al., 2014). Murine models have also revealed aspects of age-related changes in chemotaxis. 
Fewer neutrophils in older mice (18-20 months, equivalent to humans in their 60s; Dutta and 
Sengupta, 2016) were recruited in vivo into tissue injected with the murine homologue of 
CXCL8 compared to younger mice (3-4 months, equivalent to humans in their mid-20s; 
Brubaker et al., 2013). The same trend was observed by the same group using a cutaneous 
wound model combined with Staphylococcus aureus infection (Brubaker et al., 2013). 
However, a model using 26-28-month-old mice compared to 8-10-month-old mice (equivalent 
to 70+ years vs 40-50 years in human) found that in vitro neutrophils showed no difference in 
their response to fMLP, but neutrophils from older mice actually responded in greater 
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numbers to a common respiratory bacterium, Streptococcus pneumoniae (Esposito, Poirier 
and Clark, 1990).  
There are, however, important differences between these human and murine studies. Both 
murine studies looked at numbers of neutrophils responding to stimuli rather than the 
accuracy of the response. In addition, aged mice do not directly represent older humans, as 
environmental exposure to infection and harm is usually tightly controlled in murine models. 
Nevertheless, together these data suggest neutrophils may respond in greater numbers and 
less accurately with increased age. 
1.3.3 Senescence, apoptosis and cell death 
It is important to understand that two distinct ageing processes exist: the ageing of the host 
and the ageing of an individual cell. When studied in vitro, human neutrophils upregulated 
CXCR4 during the ageing process, detected in both mRNA and surface expression (Weisel et 
al., 2009). CD62L expression is also reported to be reduced as CXCR4 levels increase on the 
surface of ageing neutrophils in mice (Casanova-Acebes et al., 2013). Further to these, a 
murine study reported that aged neutrophils, determined by detection of neutrophil 
precursors labelled 48 hours before experimental procedures, responded faster to 
intraperitoneally injected LPS than non-aged neutrophils (Uhl et al., 2016). 
However, homing of neutrophils expressing CXCR4 back to the bone marrow has only really 
been shown in mice (Martin et al., 2003; De Filippo and Rankin, 2018) with data on the process 
in humans lacking and reliant on artificial in vitro ageing methodology (Nagase et al., 2002). 
Caution must also be taken in translating murine studies on CXCR4 into human, as whilst 
functional CXCR4 (that responds to CXCL12) can be expressed on human neutrophils, CXCR4 
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was not involved in sequestering neutrophils in the human lung in contrast to murine studies 
(Pillay et al., 2018). Whilst detection of CXCR4 neutrophils in the circulation could indicate an 
increase in senescent neutrophils, it is necessary to place this in the context of a functional 
alteration if it is to be of use clinically. 
Apoptosis is also an important process to allow the clearance of neutrophils by efferocytosis 
and facilitate the rapid turnover of neutrophil number in health (McCracken and Allen, 2014). 
Importantly, neutrophil apoptosis is associated with functional decline and, whilst a 
completely healthy process, it is vital apoptotic neutrophils are removed to maintain 
homeostasis of functional neutrophils in the body (Whyte et al., 1993; Kebir and Filep, 2013). 
There is not a wealth of evidence about how host ageing impacts on neutrophil apoptosis, 
maybe in part due to the lack of changes observed in published data. Neutrophils from older 
individuals showed no difference in apoptosis over a 24 hour period in vitro compared to 
younger individuals, nor was it found that expression of receptors allowing cells to respond to 
pro-apoptotic signals was changed in older individuals (Tortorella et al., 1998). However, in 
response to inflammatory challenge, subtle changes were noted as apoptosis in neutrophils 
from older individuals was not prevented to the same degree when exposed to common 
stimulants such as LPS (Fülöp et al., 1997). Determining levels of cellular apoptosis may give 
an insight into the function of neutrophils and the rate of clearance from the body and provide 
a disease-related signature. 
Understanding the normal behaviour of neutrophils and the variety of functions and 
phenotypes that neutrophils have is vital to identify any aberrant behaviour within disease 
settings. Neutrophils do, therefore, have multiple phenotypes that alter depending on 
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developmental stage and contribute to their function, and how they may be altered in the 
context of disease will be expanded upon later. 
1.4 Chronic Obstructive Pulmonary Disease 
One of the major chronic respiratory diseases is Chronic Obstructive Pulmonary Disease 
(COPD), defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as “a 
common, preventable and treatable disease that is characterised by persistent respiratory 
symptoms and airflow limitation” (GOLD, 2021). COPD tends to present later in life and is 
commonly described as an age-related disease (Cosio, Cazzuffi and Saetta, 2014), with the 
exception of a specific genetic deficiency in alpha-1 anti-trypsin (AAT) that predisposes to the 
development of COPD at a younger age (R. A. Stockley, 2015). COPD ranks in the top five 
causes of mortality worldwide (Lozano et al., 2012) and remains the most prevalent chronic 
respiratory disease worldwide (Soriano et al., 2020), thus presenting a substantial 
socioeconomic burden on society.  
1.4.1 Diagnosis  
The clinical diagnosis of COPD is based on the presence of symptoms (e.g. shortness of breath 
or a cough) and fixed airflow obstruction, determined by the ratio of the post-bronchodilator 
forced expiratory volume in 1 second (FEV1) to the forced vital capacity (FVC) being less than 
0.7 (GOLD, 2021). Many patients with these symptoms and airflow obstruction will also 
present with emphysema - the destruction of the alveoli leading to a reduction of oxygen 
transfer into the bloodstream (Turino, 2006) - small airways abnormalities and mucus 
hypersecretion (Barnes, Shapiro and Pauwels, 2003). However, these features are interlinked 
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with the underlying biology (O’Donnell et al., 2004) and provide a landscape for a highly 
heterogeneous disease that will be explored in more detail in the following sections. 
1.4.2 Associated risk factors and susceptibility 
Whilst the exact pathogenesis of COPD is still under investigation, it is likely to be multifactorial 
and involve both inflammation and environmental exposures (MacNee, 2005). In western 
countries, the largest risk factor for developing COPD remains smoking and exposure to 
cigarette smoke (CS) plays a key role in introducing ROS into the lung, causing damage and an 
inflammatory response known to be implicated in the development of COPD (McGuinness and 
Sapey, 2017). However, even if patients do not continue to smoke,  patients with COPD have 
persistent lung inflammation (Barnes, 2008a) and a large influx of neutrophils (Hogg, 2004) 
and monocytes (Traves et al., 2004) into the lung tissue. It is also true that not all smokers 
develop COPD that may, in part, be explained by differential cellular responses to smoke 
exposure in healthy individuals (Franciosi et al., 2014) leading to different levels of damage 
caused in the lungs by smoking (Cosio Piqueras and Cosio, 2001).  
A clear genetic-associated risk factor comes from people with alpha-1 antitrypsin deficiency 
(AATD), where mutations in the AAT gene prevent the release, or complete absence, of this 
key anti-proteinase (Stockley, 2016). Several genome-wide association studies have been 
performed in large cohorts of both patients and generally people with a substantial smoking 
history (Pillai et al., 2009; Cho et al., 2010; W. Chen et al., 2015), but results reveal very few 
gene associations with variation based on factors such as the ethnicity of population group 
used. Several other factors are also in play in determining if individuals will develop COPD. The 
role of immune cells, such as neutrophils and macrophage, as well as epithelial cells, are 
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known to play a role in established COPD (Barnes, Shapiro and Pauwels, 2003), so dysfunction 
in any of these cell types may make the development of COPD more likely. There is also 
increasing evidence that healthy early childhood lung development plays a crucial role in 
preventing lung disease in later life (Stocks and Sonnappa, 2013). Changes in the lung 
microbiome, including colonisation with pathogenic bacteria (Dickson et al., 2016), may play 
a role in determining the extent of lung damage caused in COPD (Wang et al., 2019).  
1.4.3 Disease severity and clinical phenotypes 
The categorisation of COPD is routinely used to inform what therapies are offered to patients 
(Montuschi, 2006), but also has important considerations when studying COPD (Chung and 
Adcock, 2008). Previously, GOLD COPD stages (I-IV) were used to classify patients based on 
the FEV1 percent predicted (GOLD, 2017). However, as this approach only reflects an aspect 
of the disease and more recent global guidelines now include an assessment of the patient’s 
exacerbation history and a symptom score to determine a grade and group (Table 1.1). 
However, in this thesis, as it was not always possible to conduct or access results from an 
exacerbation history and symptom score. Therefore, only GOLD Grades, equivalent to the 
National Institute for Health and Care Excellence (NICE) stage (NICE, 2019) was used to classify 
COPD severity (Table 1.1).  
Smoking also has a profound impact on both disease pathology and immune cell function, and 
is an important factor to consider when investigating COPD. Smoking history is routinely 
recorded as a pack-year, where one pack-year is equivalent to smoking 20 cigarettes (one 
pack) a day for a year (NIH, 2020). This measure allows a comparison of total smoking 
Chapter 1  Page | 29 
exposure, as a person who has smoked 10 cigarettes (half a pack) a day for 10 years will have 
the same history as someone who has smoked 20 cigarettes for 5 years.  
In addition to these measures of severity, it is now well established that there are many clinical 
phenotypes of COPD formed by differing contributions of the underlying pathology that have 
been referred to as ‘treatable traits’ (Agusti et al., 2016). These traits include pulmonary 
features of COPD such as emphysema and airway smooth muscle contraction, but also other 
factors such as the presence of obesity, persistent systemic inflammation and lifestyle factors 
(Agusti et al., 2016). Together, these traits lead to other phenotypes such as frequent 
exacerbators (patients that routinely have more than 2 exacerbations a year), COPD-asthma 
overlap where patients have some reversible airflow obstruction (Miravitlles, Calle and Soler-
Cataluña, 2012) and those who see a rapid decline in FEV1 (Lange et al., 2016). Patients with 
COPD that do not experience exacerbations and have fairly stable lung function are likely to 
have very different underlying cellular mechanisms to those experiencing frequent 
exacerbations and rapid decline in FEV1. Whilst it is not always possible to ascertain these 
aspects of COPD for every patient in a study, it is important to understand heterogeneity 
within COPD – an aspect that directly links to the clinical care of patients and has potentially 
limited therapeutic development. 
1.4.4 Current therapeutics 
Unfortunately, current therapies for COPD are limited to elevating symptoms and slowing 
disease progression rather than reversing or repairing lung damage. A review in 2005 
highlighted several therapies currently available for COPD, including smoking cessation, the 
use of several inhaled drugs such as long-acting β2-agonists that enable bronchodilation, 
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inhaled steroids and pulmonary rehabilitation (Barnes and Stockley, 2005) – all of which 
primarily elevate symptoms to varying degrees of success. Limited progress has been made 
since, with therapeutics aiming to tackle the underlying biology of COPD, even if showing 
promise in vitro or in animal models, showing limited benefit in patients. Examples include 
anti-TNFα therapies showing no benefit (Rennard et al., 2007) and antioxidant therapeutics 
aiming to increase antioxidant genes that worked in murine models (Rangasamy et al., 2004) 
showed no effect in patient groups (Wise et al., 2016). 
Even repeated promising data showing CXCR2 (and in some cases both CXCR2 and CXCR1) 
inhibition reduced neutrophil influx to the lungs and reduced inflammation in animal models 
(Lomas-Neira et al., 2004; Gordon, 2005; Stevenson et al., 2005; Mattos et al., 2020) have 
failed to provide benefits to patients with acceptable safety profiles (Rennard et al., 2015; 
Lazaar et al., 2020). These have created a somewhat graveyard for failed COPD therapies, 
potentially caused by lack of understanding of the underlying biology or the heterogeneity of 
COPD where benefits may be seen on a more discrete cohort of patients. Repurposing existing 
therapeutics to help reduce the lung decline seen in COPD have showed some positive results 
(Walton et al., 2016) but are yet to be proven in larger-scale clinical trials. 
Together, these provide a strong need to further understand COPD to guide and improve the 
development of effective therapies for these patients. 
1.4.5 Acute exacerbations of COPD 
As well as heterogeneity within stable disease, exacerbations represent another element of 
COPD. At the simplest level, an acute exacerbation of COPD (AECOPD) is defined as “an acute 
worsening of respiratory symptoms that results in additional therapy” (GOLD, 2021). 
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However, it has been highlighted that no biomarkers exist to determine a COPD-specific 
exacerbation and that heterogeneity in both clinical aspects and underlying biological 
processes exist in AECOPD (Celli, 2017; Sapey et al., 2019). Studies of cohorts of hospitalised 
(or previously hospitalised) patients with COPD have identified Serum Amyloid A (SAA; 
Bozinovski et al., 2008) and C-reactive protein (CRP; Hurst, Donaldson, et al., 2006) to be 
potential markers of COPD exacerbations, however, these were not able to predict the 
severity of the exacerbation. In addition, there is likely a large selection bias in both these and 
many other studies (including this thesis) investigating AECOPD, as patients presenting at 
hospital are likely to be those experiencing the most severe AECOPD – balanced by the fact 
these patients are the ones most at risk from the most adverse health outcomes and require 
the most help (Antoniu and Carone, 2013). 
There is often a strong inflammatory component to AECOPD (Sapey and Stockley, 2006) and 
patients with AECOPD were found to have higher levels of CXCL8, IL-6 and CRP in serum, 
sputum and nasal washes (Hurst, Perera, et al., 2006) compared with those with stable COPD 
– indicating systemic inflammation as well as localised airway inflammation. Patients with 
AECOPD are also far more likely to have cardiovascular complications, including ischemic heart 
disease (Malo de Molina et al., 2018), pulmonary hypertension, and heart failure (El-Shabrawy 
and Eldamanhory, 2017), leading to a significant healthcare burden, morbidity and mortality. 
Heterogeneity also exists within exacerbations and a key study following patients over a year 
measuring biomarkers in both sputum and serum identified four distinct phenotypes of 
exacerbation (Bafadhel et al., 2011) – these are summarised in Table 1.2.  
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Table 1.1: GOLD assessment of patients with COPD based on spirometry, exacerbation 
history and symptoms  
GOLD Grade FEV1 % predicted NICE Stage  
1 ≥80 1 – Mild  
2 50-79 2 – Moderate  
3 30-49 3 – Severe  
4 < 30 4 – Very Severe  
GOLD Group Exacerbations (past year) mMRC score CAT score 
A 0 or 1 (not hospitalised) 0-1 <10 
B 0 or 1 (not hospitalised) ≥2 ≥10 
C ≥2 or ≥1 hospitalised 0-1 <10 
D ≥2 or ≥1 hospitalised ≥2 ≥10 
Legend: Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade and National 
Institute for Health and Care Excellence (NICE) stage assigned based on the percent 
predicted forced expiratory volume in one second (FEV1). GOLD group assigned based on 
both the number and type of exacerbations in the previous year followed by either the 
modified Medical Research Council (mMRC) score or COPD Assessment Test (CAT) score. 
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Table 1.2: Phenotypes of AECOPD  
Phenotype Features 
Bacterial-dominant Associated with positive bacterial pathogen sputum cultures, 
raised neutrophil counts in both blood and sputum and high 
levels of sputum IL-1β and TNFRII  
Viral-dominant Associated with viral infection (commonly rhinovirus) and 
serum CXCL10. Also showed the greatest decline in FEV1  
Eosinophilic-dominant Associated with high numbers of blood eosinophils 
Pauciinflammatory Generally low levels of sputum mediators with no clear 
dominant cause, with a mixture of the other three phenotypes 
Legend: A summary of exacerbation phenotypes identified using cluster analysis of multiple 
sputum and serum biomarkers (Bafadhel et al., 2011).  
IL-1β, interleukin 1-beta; TNFRII, tumour necrosis factor receptor II; CXCL10, C-X-C 
containing ligand 10; FEV1, forced expiratory volume in 1 second. 
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1.4.6 Multimorbidity 
Several other chronic diseases occur in patients with COPD more commonly than the general 
population, including type-2 diabetes mellitus (T2D) and cardiovascular diseases (CVD); even 
after accounting for common risk factors such as smoking and poor diet (Lee et al., 2013; 
Mullerova et al., 2013; Martín-Timón et al., 2014). The presence of multiple chronic diseases 
in a single person is referred to as multimorbidity and has a significant impact on mortality 
and healthcare costs (Barnett et al., 2012; Sambamoorthi, Tan and Deb, 2015), affecting 
around 30% of individuals in the UK, rising to over 50% in over 65 year-olds (Cassell et al., 
2018). Not only does this place importance in understanding multimorbidity, but also on the 
potential of unified underlying mechanisms linking COPD, T2D and CVD (Hughes, McGettrick 
and Sapey, 2020b).  
There is great interest in understanding why multi-morbidities cluster in individuals (Ording 
and Sørensen, 2013) and there are several common threads that might link these diseases 
together, including inflammation, age and changes in neutrophil function (Hughes, McGettrick 
and Sapey, 2020b). It is increasingly recognised that inflammation is both caused by and drives 
many chronic non-communicable diseases.  Furthermore, there are increased levels of acute-
phase proteins and inflammatory cytokines in the bloodstream of multi-morbid patients 
compared with those with a single disease or healthy volunteers (Martín-Timón et al., 2014; 
Wei et al., 2015; Min et al., 2017), suggesting a potentially cumulative inflammatory effect 
with increasing numbers of diseases.  
Atherosclerosis (AS) is often a precursor to cardiovascular disease and the use of 
atherosclerosis-prone apolipoprotein E-deficient (ApoE-/-) mice has provided evidence to 
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support the inflammatory basis of AS (Demer, 2002; Lo Sasso et al., 2016). Equally, T2D has an 
important inflammatory component. Raised levels of soluble TNF-α in patients with T2D has 
been linked with insulin resistance (Nilsson et al., 1998; Moller, 2000) as well as being a 
potential mediator of murine pancreatic β-cell destruction in insulin-dependent diabetes 
mellitus in vitro (Stephens et al., 1999).  
It is also important to recognise that multimorbidity itself may be a source of heterogeneity 
among patients with COPD. Heterogeneity within COPD has implications for both the clinical 
management of the disease (Barrecheguren and Miravitlles, 2016) and research that underlies 
clinical trials to provide treatment options for these patients as it is likely one size does not fit 
all (Sidhaye, Nishida and Martinez, 2018). Whilst many trials separate patients with COPD 
based on clinical characteristics such as FEV1 and annual exacerbation frequency (De Soyza 
and Calverley, 2015), multimorbidity and more subtle underlying neutrophil biology may be 
equally as important. 
1.4.7 Inflammatory mechanisms in COPD 
Several inflammatory processes are known to be implicated in COPD, contributing to disease 
progression and pathogenesis (King, 2015). Macrophages present in the lung are markedly 
increased in COPD and they also associate with regions of emphysema (Retamales et al., 
2001). Macrophages are also capable of producing cytokines that recruit more immune cells 
to the lung and perpetuate the inflammatory response (Barnes, Shapiro and Pauwels, 2003). 
In addition, defective clearance of bacteria and apoptotic neutrophils by macrophages in 
COPD may further shift the balance to increased damage in the lungs (Belchamber et al., 
2019). Other cell types are also linked with COPD such as T cells, as the number of T cells in 
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the lung and circulation increases in COPD and has been correlated with increased alveolar 
destruction (Majo, Ghezzo and Cosio, 2001).   
Neutrophils are the most abundant immune cells found in the lungs of patients diagnosed 
with COPD, and elevated levels of CXCL8, a potent neutrophil chemoattractant, in the lungs of 
patients with COPD perpetuates this response (Hollander et al., 2007). The chronic presence 
of neutrophils is also likely to be direct a contributor to the symptoms seen in COPD such as 
increased mucus production and tissue destruction through the release of neutrophil elastase 
(Nadel, 2000). The role of neutrophils, and their potential dysfunction, in the pathogenesis of 
COPD will now be discussed in more detail. 
1.5 The neutrophil in COPD and multimorbidity 
Multiple facets of neutrophil biology have been linked to COPD (Jasper et al., 2019) and it is 
well-established neutrophils are present in large numbers in the lungs of patients with COPD 
(Tregay et al., 2019). A decline in lung function (Stǎnescu et al., 1996), development of 
emphysema (Shapiro et al., 2003) the severity of COPD (Singh et al., 2010) and association of 
small airways disease and exacerbation frequency (Day et al., 2020) have all been linked to 
neutrophil products or numbers, cementing the role for neutrophils in the pathogenesis of 
COPD. The persistence of neutrophils in the lung of patients with COPD also makes them prime 
candidates for causing collateral damage in the lung (Stockley, 2002). However, attempts to 
block neutrophil recruitment to the lungs using CXCR2 antagonists did not universally lead to 
clinical benefits to patients with COPD and led to increased susceptibility to infection (Rennard 
et al., 2015) – indicating it is not simply about the number, but also the function of neutrophils 
in COPD. 
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1.5.1 Neutrophil proteinases 
Neutrophils in COPD are thought to disrupt the balance between proteinases and anti-
proteinases in the lung. This proteinase/anti-proteinase imbalance has long been suspected 
(Stockley, 1999) and is especially important in AATD where levels of natural anti-proteinases 
are lower. Neutrophils, when active, release large quantities of proteases (Shamamian et al., 
2001) that can also be bound on the cell surface of neutrophils (Csernok et al., 1994). Some of 
the key proteinases, collectively known as neutrophil serine proteinases, including neutrophil 
elastase (NE) and proteinase 3 (PR3), and the role they play in lung damage are summarised 
in Table 1.3. Local injection of NE and PR3 in hamsters, or mice deficient in AAT, resulted in 
the development of emphysema (Kao et al., 1988; Borel et al., 2018) – supporting the role of 
the proteinase/anti-proteinase balance in maintaining healthy lung tissue. NE activity in both 
human and murine models has also been linked with insulin resistance and an NE inhibitor 
(GW311616A) reversed insulin resistance and body weight gain in mice (Mansuy-Aubert et al., 
2013), indicating roles for neutrophil proteinases in the development of T2D. 
1.5.2 The role of systemic inflammation and neutrophil retention by the lung 
Systemic inflammation - the presence of inflammatory markers within the blood that can lead 
to inflammation in multiple organs (Jaffer, Wade and Gourlay, 2010) - has been linked to COPD 
in various studies (Garcia-Rio et al., 2010; Singh et al., 2018) and provides a potential link 
between COPD and other chronic inflammatory conditions (Hughes, McGettrick and Sapey, 
2020b). A study looking at both smokers and ex-smokers with and without COPD found 
current smokers had increased levels of systemic TNF-α compared to ex-smokers with COPD 
(Tanni et al., 2010). Higher levels of IL-6 and CRP were found systemically in patients with 
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COPD  compared to both smokers and non-smokers without COPD, suggesting systemic 
inflammation is not only due to smoking status (Tanni et al., 2010). However, another study 
of 50 patients with COPD observed poor correlations between systemic levels of CXCL8 and 
IL-6 disease severity in ex-smokers. It is, therefore, complex to separate the cause and effect 
relationship between systemic inflammation and smoking in the context of chronic 
inflammation observed in COPD. 
The presence of systemic inflammatory cytokines, such as IL-1β and CXCL8, has several 
implications for neutrophils in patients with COPD. Some studies have suggested that 
neutrophil retention in the lung capillaries is increased with systemic inflammation – a 
phenomenon that could partly explain the influx of neutrophils in patients with COPD  
(Wozniak et al., 1993; Summers et al., 2014; Tregay et al., 2019). Neutrophils are required to 
deform to pass through capillaries, including the lung capillaries (Doerschuk et al., 1993), but 
despite this, in vivo studies whereby healthy volunteers were infused with autologous 
radiolabelled neutrophils have shown that in health, human neutrophils pass through the 
pulmonary capillaries only marginally slower than red blood cells (Summers et al., 2014). 
Studies using radiolabelled neutrophils injected into patients with COPD showed increased 
retention of neutrophils in the lung, similar to that of healthy volunteers that inhaled LPS as a 
priming agent (Tregay et al., 2019). The ex vivo priming of radio-labelled neutrophils with 
either granulocyte-macrophage colony-stimulating factor (GM-CSF) or platelet-activating 
factor (PAF) before injection into the right jugular vein of healthy volunteers demonstrated 
the retention of neutrophils by the lung was steadily lost, recorded by external imaging of the 
thorax, suggesting these cells are either cleared from the body or are deprimed (Summers et 
al., 2014). Of note, the retention time in the lung vasculature was dependant on the priming 
Chapter 1  Page | 39 
agent, as GM-CSF had a greater effect on neutrophil retention compared with PAF (Summers 
et al., 2014). Forced mechanical deformation ex vivo of neutrophils has been shown to 
deprime neutrophils (Ekpenyong et al., 2017). It has been suggested that the lungs may form 
an important site where neutrophils, primed through exposure to circulating inflammatory 
mediators, may return to the quiescent state because of mechanical modulation in the tight 
pulmonary capillaries (Ekpenyong et al., 2017). The narrow pulmonary vasculature might 
therefore have important functions for immunomodulation in systemic inflammation 
(Summers et al., 2014).  
In patients with COPD, increased systemic inflammation in combination with inflammatory 
signals in the lung may explain the sustained influx in neutrophils. It has also been shown that 
persistent systemic inflammation leaves patients with COPD at a higher risk of developing CVD 
and diabetes (Agusti et al., 2012). Furthermore, there appears to be an additive effect of 
multiple chronic diseases in a single patient: the ECLIPSE study with over 2000 patients with 
COPD demonstrated higher circulating IL-6 and CXCL8 levels in patients with both COPD and 
heart disease; higher CRP levels in patients with COPD and diabetes and both were associated 
with poorer clinical outcomes (Miller et al., 2013). 
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Table 1.3: Overview of key neutrophil proteinases and their main inhibitors along with 
their potential role in lung damage 
Proteinase Anti-
proteinase 
Role in lung damage Reference 
Neutrophil elastase α1-antitrypsin Degradation of elastin and 
development of emphysema. 
Also evidence it can cause 




Guyot et al., 
2014) 





Linked with development of 
emphysema, impaired mucus 
clearance and amplifying 
inflammation by attenuating 
cytokine activation states. 
(Owen, 2008; 




Cathepsins Cystatins Contributes to elastin 
degradation and alveolar 
enlargement, but also can 
cause epithelial apoptosis. 
(Owen, 2008; 
Guyot et al., 
2014; Brown et 
al., 2020) 
Legend: A brief overview of proteinases associated with lung damage in COPD, including 
their major inhibitors. 
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1.5.3 Defective chemotaxis 
Accurate chemotaxis is an important attribute of neutrophil function, enabling neutrophils to 
reach a site of infection or injury (Iglesias and Devreotes, 2008; White et al., 2018). Multiple 
factors can affect neutrophil chemotaxis, including the type of chemoattractant and the age 
of the neutrophil (McDonald et al., 2010; Uhl et al., 2016). CS, whilst altering the expression 
of adhesion molecules by endothelial cells (Scott and Palmer, 2003), has also been shown to 
alter migratory dynamics as neutrophils exposed to CS extract (CSE) showed a reduction in the 
speed and accuracy of chemotaxis (White et al., 2018). However, neutrophils are still present 
in large numbers within the lungs of smokers (Higuchi et al., 2016), demonstrating neutrophils 
are still recruited to the lungs, even if they move through the tissue less accurately. In addition, 
isolated neutrophils exposed to CSE also produced more CXCL8, further enhancing 
recruitment to the lungs (Mortaz et al., 2010). 
Neutrophil chemotaxis is also impaired in patients with COPD. Isolated blood neutrophils from 
patients with COPD demonstrated a significant reduction in accuracy in vitro to both individual 
chemoattractants, such as fMLP and CXCL8 (Sapey et al., 2011), as well as sputum from 
patients with COPD (Yoshikawa et al., 2007). These studies expanded on earlier work 
suggesting isolated neutrophils from patients with emphysema digested larger amounts of 
fibronectin, a component of the ECM (Burnett et al., 1987). Together these studies build a 
picture of altered function in COPD: active neutrophils that are responsive to 
chemoattractants but move less accurately in the tissue leading to enhanced tissue 
destruction.  
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Both a reduction in accuracy and a reduced number of pseudopodia being extruded from 
migrating COPD neutrophils have been described in vitro (Sapey et al., 2011). In this study, 
PI3K inhibitors were able to restore migratory accuracy of these cells to that of neutrophils 
from healthy volunteers, demonstrating a role for PI3K in controlling neutrophil chemotaxis 
(Sapey et al., 2011). A reduction in neutrophil migratory accuracy has also been described 
using the same experimental technique in peripheral neutrophils taken from patients with 
severe acute infections such as pneumonia in aged but not younger adults (Sapey et al., 2017), 
suggesting COPD changes might reflect, in part, an accelerated ageing phenotype. 
In COPD, the impact of smoking, lung damage and age must all be considered. There is a 
difference between an aged cell and cells taken from an aged host (who will contain 
neutrophils of different ages). This concept is particularly important in the context of 
accelerated ageing and understanding the loss of function that occurs with cellular senescence 
and with advancing age of the host. 
1.5.4 Accelerated ageing as a theory of COPD 
There are many parallels between age and chronic disease, giving rise to the theme of COPD 
being a disease of accelerated ageing that has been reviewed multiple times in the literature 
(Ito and Barnes, 2009; MacNee, 2009; Mercado, Ito and Barnes, 2015; Hughes, McGettrick and 
Sapey, 2020b). One aspect is based on the hallmarks of ageing, including areas such as 
senescence, genetic instability and alteration, mitochondrial dysfunction and the loss of 
proteostasis (López-Otín et al., 2013) that may be accelerated in COPD. Features such as DNA 
instability (Samara et al., 2010; Palazzo et al., 2011; Cervelli et al., 2012), epigenetic 
modifications (Barnes, 2008b; Kong et al., 2009; Noh et al., 2009) and the loss of proteostasis 
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and autophagy (Mukherjee et al., 2015; Bodas et al., 2017; Hofmann, Katus and Doroudgar, 
2019) have all been linked with COPD, CVD and T2D.  
In addition, lung function declines even in healthy ageing (Janssens, Pache and Nicod, 1999) 
and some people will develop emphysema in old age (Lamb, Gillooly and Farrow, 1991), 
further leading to the concept that COPD may represent an acceleration of the processes that 
occur with ageing – although this observation alone does not identify if the mechanisms 
underlying the ageing lung are similar.  
Molecular mechanisms such as expression of sirtuins (SIRT), so-called anti-ageing histone-
deacetylases (Chun, 2015), and release of cytokines by senescent cells, known as the 
senescence-associated secretory phenotype (SASP), have also been implicated in COPD 
(Rajendrasozhan et al., 2008; Baker, Donnelly and Barnes, 2020) – although not directly with 
neutrophils. Decreased SIRT1 expression by lung tissue was identified in patients with COPD 
compared to non-COPD controls (Rajendrasozhan et al., 2008). The SASP also contains 
multiple chemokines that attract neutrophils, linking senescence in the lungs with an 
increased influx of neutrophils (Prata et al., 2018) 
Parallels between COPD and ageing are also observed in neutrophil function. As mentioned in 
Section 1.3.2, both human and murine studies have suggested an age-related decline in the 
accuracy of neutrophil chemotaxis (Sapey et al., 2014). Indeed, reduced neutrophil migratory 
accuracy is a feature that appears to be exaggerated in patients with COPD beyond that of 
age-matched volunteers without COPD (Sapey et al., 2011). Reduced neutrophil migratory is 
linked with increased tissue damage through migration associated release of proteases and 
ROS (Naccache and Lefebvre, 2014; Sapey et al., 2014). In turn, this leads to the accelerated 
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development of emphysema (Barnes, Shapiro and Pauwels, 2003) and further observations of 
an accelerated ageing effect. Therefore, migratory inaccuracy in COPD may represent an 
exaggeration of the ageing process.  
Oxidative stress and ROS production are also linked to inflammation, ageing and senescence 
as described by the free radical theory of ageing originally proposed by Professor Denham 
Harmen (Harman, 1956, 2006). Whilst only one aspect of the damage-induced ageing 
hypothesis (Gladyshev, 2014),  damage from increased ROS responses provides a potential 
link between the neutrophil and accelerated ageing in COPD. Successful bacterial killing in 
neutrophils relies on the ability to mount an appropriate ROS response (Nguyen, Green and 
Mecsas, 2017), but the generation and extracellular release of ROS by neutrophils can also 
contribute to collateral lung tissue damage (McGuinness and Sapey, 2017). Furthermore, 
mouse models have demonstrated that oxidising environmental agents (such as ozone) cause 
neutrophilia and airway damage, leading to emphysema (Williams et al., 2007; Wiegman et 
al., 2014). Evidence of oxidative stress has been identified in both the sputum and plasma of 
patients with COPD, related to both the increased ROS challenge and decreased anti-oxidant 
activity (Zeng et al., 2013).  
1.5.5 Neutrophils in AECOPD 
Increases in neutrophil chemoattractants in the lungs during exacerbation causes an increased 
number of neutrophils within the lung (Crooks et al., 2000). The influx of neutrophils further 
increases the presence of neutrophil proteinases, tipping the balance towards increased lung 
damage. Recent cohorts of patients with AECOPD have identified that exacerbations with a 
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neutrophilic phenotype were more severe and may impact on mortality (Kandemir et al., 
2020). 
In addition, multiple aspects of neutrophil function are also thought to be altered during an 
exacerbation of COPD. Peripheral blood neutrophils isolated from patients hospitalised with 
AECOPD showed reduced chemotaxis towards CXCL8 and fMLP compared with neutrophils 
from stable COPD – a phenomenon that was sustained at 56-day follow up (McIver et al., 
2019). In a small cohort of patients with AECOPD, neutrophils also demonstrated reduced 
phagocytosis of Staphylococcus Aureus bacteria in vitro (Lavinskiene et al., 2011). However, it 
is difficult to determine if changes in neutrophil behaviour predispose to AECOPD or are as a 
result of the respiratory insult. Further investigation of neutrophil phenotypes may shed light 
on the increased disease burden in these patients. 
1.5.6 Other functional defects 
Other key neutrophil functions discussed in Section 1.2, including phagocytosis, ROS and NET 
production are also implicated in COPD, CVD and T2D. 
Neutrophils exposed to CSE in vitro were capable of releasing more ROS compared with 
unexposed cells in a TNF-α-dependant manner (Friedrichs et al., 2014), especially important 
given raised TNF-α levels in the lungs of patients with COPD. In addition, TNF-α increases 
endothelium susceptibility to ROS (Ishii et al., 1992), presenting another mechanism of 
enhanced lung damage in patients with COPD. There is also evidence of systemic ROS activity 
in patients with COPD, potentially predisposing to events seen in the pathogenesis of AS and 
T2D (Rahman et al., 1996; Zeng et al., 2013). ApoE-/- mice with an absence of functional NADPH 
Oxidase (NOX)1/2, modelling a reduction in ROS production, showed reduced lesion size and 
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reduced ROS production by smooth muscle cells in vitro (Barry-Lane et al., 2001; Madamanchi, 
Vendrov and Runge, 2005). ROS production can also contribute to pancreatic β-cell 
destruction – as these cells are particularly sensitive to ROS-induced apoptosis (Lenzen, 2008). 
However, comparisons of ROS production between mice and humans are complicated by the 
fact that TNF-α serves as an important priming agent for the oxidative burst in neutrophils in 
humans, but this mechanism does not exist in mice or rats (El-Benna et al., 2016). These 
studies suggest how ROS could be a mechanism linking COPD, CVD and T2D; one that 
increased ROS production by neutrophils may play an important role. 
Studies of neutrophils from patients with COPD have demonstrated these neutrophils 
maintain the molecular mechanisms to carry out phagocytosis as neutrophils were able to 
phagocytose fluorescently-labelled polystyrene beads (Thomas, Barnes and Donnelly, 2012). 
However, the uptake of Candida, Haemophilus influenzae and Streptococcus pneumoniae by 
neutrophils from patients with COPD was reduced compared to neutrophils from both healthy 
smoker and non-smoker controls – indicating changes in the ability to sense bacteria and fungi 
(Thomas, Barnes and Donnelly, 2012; Shanmugam et al., 2015). Not all studies, however, 
agree with these findings as neutrophils isolated from a small cohort of 10 patients with COPD 
found no difference in phagocytosis compared to healthy age-matched controls (Walton et 
al., 2014).  Potential confounders, such as alcohol consumption, that may also reduce 
phagocytic capacity by neutrophils (Chiu et al., 2018) could skew these results. 
A putative role for NETs in chronic disease is beginning to emerge, with in vitro evidence of a 
transiently reduced ability of circulating neutrophils to produce NETs in patients with COPD 
(Pullan et al., 2015), but increased NET production identified in the sputum (Dicker et al., 2018) 
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that may link to collateral lung damage (Trivedi et al., 2021). Despite this potential location-
dependent difference, both studies postulate that altered NET function is linked to a reduction 
in effective bacterial clearance and a mechanism of damage in COPD. Induction of NETosis in 
the lungs of mice using ovalbumin sensitisation and exposure showed a reduction in ROS and 
oxidative stress in the lung after treatment with DNase (that breaks down extracellular DNA, 
the primary structural component of NETs), demonstrating not only a potential detrimental 
role of NETs in the lung but also a potential therapeutic option and a link between oxidative 
stress and extracellular DNA (da Cunha et al., 2016). These studies suggest an involvement of 
NETs in lung disease, but the variability in the way NETs are measured both in vitro and in vivo 
(Boeltz et al., 2019) presents a challenge in interpreting these data.  
All the factors discussed in this section influence disease progression and neutrophil function: 
bacterial infection or colonisation, smoking status, age and lung damage. Investigating the 
phenotype of neutrophils based on the surface expression of receptors and adhesion 
molecules has begun to change the way neutrophils are viewed in the context of health and 
disease, especially as these may link to the aforementioned functions. The next section will 
address the topic of neutrophil phenotypes and subtypes, and the key molecules that have 
been linked to key neutrophil functions within a disease setting. 
1.6 Neutrophil phenotypes in disease 
The many functions of neutrophils that have been discussed may have important implications 
in chronic lung disease. The question remains regarding the multi-faceted nature of neutrophil 
function: does this reflect a highly plastic population with adaptive responses which are 
environment-dependent or reflect distinct subtypes of cells each with a specific role? 
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The balance of evidence currently suggests that neutrophils change in response to signals such 
as cytokines, physical pressure or bacterial products, resulting in different functional 
phenotypes, supported by neutrophil heterogeneity observed in vitro in pro-inflammatory 
culture conditions (Chakravarti et al., 2009; Takashima and Yao, 2015; Evrard et al., 2018). 
These changes can be subtle and may relate to the immediate cellular environment. To further 
complicate investigations of neutrophil phenotypes, experimental methods may inadvertently 
alter the neutrophil phenotype (Pallister et al., 2006). Examining conditions and diseases 
where neutrophils have a different phenotype may help identify differences between 
individuals that are healthy, or with COPD and the associated co-morbidities. An overview of 
these key phenotypes, and the markers used to identify them will now be discussed and are 
summarised in Figure 1.6. 
1.6.1 Activation and adhesion 
1.6.1.1 CD11b 
Activation markers may play an important part in identifying potentially aberrant neutrophil 
responses. CD11b epitomises the fine balance that exists in neutrophil responses: patients 
constitutively lacking CD11b have neutrophils with a severely hampered phagocytic response 
(Arnaout, 1990) and neutrophils from patients with COPD with higher expression of CD11b 
that may be linked to airflow limitation (Yamagata et al., 2007). The latter study does, 
however, make a leap from CD11b overexpression to the causative role in airflow limitation 
(Yamagata et al., 2007), yet warranting further investigation. Trauma and sterile injury have 
also been linked with increased neutrophil activation, with one study demonstrating 
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neutrophil activation in trauma patients with a systemic inflammatory response syndrome 
(Hazeldine et al., 2015). 
1.6.1.2 CD62L 
CD62L expression is also in a fine balance, requiring temporal expression and shedding for 
normal neutrophil function.  A study utilising mice with a mutant CD62L molecule resistant to 
cleavage revealed blocking CD62L cleavage resulted in an increased number and prolonged 
presence of neutrophils migrating into inflamed peritoneum compared to wild-type mice 
(Venturi et al., 2003). The same study also showed, however, neutrophils lacking cleavable 
CD62L were less capable of migrating large distances (>50µm) from post-capillary venules 
compared to wild-type following stimulation with the murine CXCL8 homologue (Venturi et 
al., 2003), demonstrating stimuli-dependant differences in neutrophil migration following 
CD62L cleavage. In addition, another murine model utilising a mutant CD62L molecule with 
enhanced catch-bond lifetime and engagement resulted in increased sensitivity of neutrophils 
to activation signals (Z. Liu et al., 2017), suggesting increased CD62L expression may confer a 
similar outcome.  
Turning attention to CD62L expression from neutrophils in humans, a study demonstrated, 
both in vitro and in vivo, the use nonsteroidal anti-inflammatory drugs (NSAIDs) resulted in 
enhanced CD62L shedding and that maintaining CD62L expression was an energy-dependant 
process, suggesting common drugs can alter neutrophil behaviour (Gómez-Gaviro et al., 
2000). Indeed, blood neutrophils from long-term smokers and patients with COPD have been 
linked with lower CD62L expression compared with healthy non-smokers (Stockfelt et al., 
2020). This phenotype of reduced CD62L expression has also been demonstrated in blood 
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neutrophils from patients with COPD compared with asthmatics and healthy volunteers 
(Lokwani, Wark, Baines, Fricker, et al., 2019) and linked with reduced lung function (Lokwani, 
Wark, Baines, Barker, et al., 2019). Preceding these observations, it has been suggested lower 
CD62L expression denotes hypersegmented neutrophils, so named because of the increased 
in nuclear lobes (Pillay et al., 2012; Tak et al., 2017). Whilst the exact function, or dysfunction, 
of hypersegmented neutrophils remains unknown, they do not typically exist in the circulation 
of healthy individuals (van Grinsven et al., 2019), do not exhibit altered migratory function 
(van Grinsven et al., 2019), are less able to adhere to endothelial cells (Kamp et al., 2012) and 
can be seen in the circulation following systemic LPS challenge in humans (Pillay et al., 2012; 
van Grinsven et al., 2019) – although the reduction in endothelial adhesion may be purely due 
to the role CD62L plays in initial endothelial attachment (see Section 1.2.1). 
1.6.2 Chemokine sensing and migration 
As discussed (Sections 1.2.2 and 1.3.2), the ability to detect and migrate accurately to chemical 
signals is vital to the role neutrophils play in the immune response. Several receptors and 
surface proteins co-ordinate this response and may provide insight into the dysfunction 
observed within disease. Neutrophils express a wide range of chemokine receptors that 
enable responses to lipid mediators (such as leukotriene B4), complement proteins (such as 
C5a), formyl peptides (such as fMLP) and a variety of CXC and CC containing ligands, leading 
to some redundancy between receptors, but also with nuanced roles for neutrophil activation 
and migration (Metzemaekers, Gouwy and Proost, 2020), As mentioned, CXCR2 is one such 
receptor expressed by neutrophils that is able to bind to CXCL1-3 and CXCL5-8 (Bachelerie et 
al., 2014) with overlapping function with CXCR1 that also binds CXCL6 and CXCL8 (Bachelerie 
Chapter 1  Page | 51 
et al., 2014). Given the importance of CXCR2 in binding the most potent chemoattractant 
CXCL8, ongoing trials for pharmacological blockade in therapies and the role in controlling 
neutrophil release from the bone marrow, CXCR2 was chosen as a chemokine receptor to 
investigate further. 
1.6.2.1 CXCR2 
In mice, a model of severe sepsis demonstrated both a reduction in the number of neutrophils 
in the peritoneal cavity (the source of the bacterial insult) and a reduction in CXCR2 expression 
compared to non-severe sepsis (Rios-Santos et al., 2007). Furthermore, blockade of CXCR2 
recapitulated the neutrophil phenotype observed in severe sepsis mice in those with non-
severe sepsis (Rios-Santos et al., 2007). Reduction in CXCR2 expression and impaired 
migration has also been linked with anti-neutrophil cytoplasmic autoantibody (ANCA)-
associated vasculitides (Hu et al., 2011). The same study also revealed that pharmacological 
blockade of CXCR1 and CXCR2 exhibited altered migration (Hu et al., 2011).  
The complexities of neutrophil CXCR2 expression are highlighted in COPD, as neutrophils 
isolated from the sputum had reduced CXCR2 expression and increased CD11b expression 
compared with peripheral neutrophils, both of which were reduced compared to peripheral 
neutrophils from healthy individuals (Pignatti et al., 2005). It is important to note, however, 
that a reduction in CXCR2 expression is also observed after bacterial phagocytosis, a potential 
confounder in experiments where phagocytosis is possible but not measured (Doroshenko et 
al., 2002).  
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These studies demonstrate that CXCR2 expression and migration accuracy are key neutrophil 
phenotypes, but also raise the potential that modulation of CXCR2 may be a therapeutic 
avenue to reduce neutrophil infiltration to inflamed tissue (Konrad and Reutershan, 2012). 
1.6.2.2 CXCR4 
As CXCR4 has also been linked with neutrophil senescence, the role of CXCR4 will be discussed 
in Section 1.6.3. 
1.6.2.3 CD54 
As highlighted with CXCR2, different phenotypes of neutrophils may be somewhat restricted 
by the microenvironment, especially regarding neutrophils within the lung compared with 
those in the circulation. However, human neutrophils can reverse migrate, demonstrated in 
vitro with neutrophils moving through endothelium monolayers, modelling movement back 
into the circulation (Buckley et al., 2006). These neutrophils maintained a pro-inflammatory 
and apoptotic-resistant phenotype, as well as upregulating CD54 expression (Buckley et al., 
2006). If neutrophils are capable of migrating from the lung tissue back into the circulation, 
this could provide a link between chronic inflammation and systemic damage in COPD, AS and 
T2D, especially as increased numbers of circulating CD54+ neutrophils were found in patients 
with AS (Buckley et al., 2006).  
Other scenarios where neutrophils display increased CD54 expression also exist. 
Hypersegmented neutrophils, in the same study that identified these neutrophils displaying a 
CD62Ldim phenotype, also upregulated CD54 in response to LPS injection in vivo with human 
volunteers (Pillay et al., 2012). The authors also note that this phenotype could not be 
recapitulated in vitro, highlighting both limitations of in vitro models, but also that other cells 
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and processes are involved in regulating neutrophil phenotypes. The same group also 
identified that increased CD54 expression, along with an increase in CD11b and reduction of 
CD62L, occurs when neutrophils enter the lung tissue irrespective of disease (Fortunati et al., 
2009). Together, these studies highlight that CD54 provides a useful tool to identify 
transmigrated neutrophils. 
1.6.3 Senescence and apoptosis 
In both inflammation and chronic lung conditions such as COPD, the lifespan of neutrophils is 
prolonged due to resistance to apoptosis (Uddin et al., 2010; Geering et al., 2013), but is this 
response helpful or harmful in the context of chronic inflammation?  
1.6.3.1 CXCR4 
CXCR4 is the major receptor for CXCL12 and a potential marker of neutrophil senescence as 
discussed (Section 1.2.6). CXCR4 functionality in health is partly revealed by a genetic 
condition whereby CXCR4 signalling is enhanced, leading to neutrophil retention in the bone 
marrow and peripheral neutropenia (Hernandez et al., 2003). It might also be expected that 
reductions or enhancements of CXCR4 in peripheral neutrophils would also impact their ability 
to migrate effectively.  
Neutrophils taken from the lungs of patients with fungal colonisation and cystic fibrosis 
(Carevic et al., 2015), and from mice with LPS-induced lung injury (Yamada et al., 2011), had 
increased CXCR4 expression – indicating lung damage may increase neutrophil CXCR4 
expression. Peripheral damage may also increase CXCR4 expression as blood neutrophils 
isolated from patients with ischemic stroke revealed higher CD11b expression and lower 
CD62L expression in conjunction with raised CXCR4 expression – a phenotype termed 
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‘overactive senescent’ (Weisenburger-Lile et al., 2019). CXCR4 expression has also been linked 
with a pro-angiogenic phenotype in both mice and human (Massena et al., 2015), but this 
phenotype may be more dependent on Vascular Endothelial Growth Factor Receptor 1 
(VEGFR1) expression than CXCR4. Together these data highlight scenarios where neutrophils 
express higher levels of CXCR4, however, the disparate nature of these conditions still leaves 
many questions around neutrophil CXCR4 expression and regulation unanswered. 
It is important to also note that CXCL12 is present outside the bone marrow with 
concentrations in healthy humans reported anywhere between 0.2ng/mL (Yang et al., 2020) 
to 40ng/mL (Soriano et al., 2002). Patients with COPD who were current or ex-smokers have 
been reported to have raised serum levels of CXCL12 compared to people without COPD 
(Kuźnar-Kamińska et al., 2016). Elevated CXCL12 levels have also been linked to the 
pathogenesis of T2D as diet-induced obese mice showed raised CXCL12 levels in the adipose 
tissue and blocking CXCR4 pharmacologically improved insulin sensitivity (Kim et al., 2014). It 
is unclear, however, if raised CXCL12 levels interfere with the return, or indeed the release, of 
neutrophils to or from the bone marrow. These data indicate CXCR4 can be altered by chronic 
inflammation, but the exact role and functional impact requires further investigation. 
1.6.3.2 Phosphatidylserine and annexin V 
It has long been known that phosphatidylserine, a membrane phospholipid that is usually 
contained to the inner plasma membrane, is exposed on the outer plasma membrane during 
cellular apoptosis and can be readily detected by the binding of annexin V (Darzynkiewicz et 
al., 1997; Wlodkowic, Skommer and Darzynkiewicz, 2009). Apoptosis of neutrophils is not only 
a normal physiological process but also aids the resolution of inflammation – particularly after 
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phagocytosis of bacteria (Greenlee-Wacker, 2016). Neutrophils, like other cells, have a variety 
of mechanisms that trigger apoptosis and have been well documented (Simon, 2003; Geering 
and Simon, 2011). An extensive review has drawn together how neutrophil apoptosis is 
influenced by various bacterial pathogens (DeLeo, 2004) – of note, a common respiratory 
bacteria S. pneumoniae accelerated neutrophil apoptosis when cultured with isolated 
neutrophils in vitro (Zysk et al., 2000), a process that was not altered by co-incubation with 
GM-CSF (Engelich, White and Hartshorn, 2001). In combination with a study suggesting 
neutrophils from patients with ARDS showed increased apoptotic resistance (Matute-bello et 
al., 1997), partially due to increased G-CSF and GM-CSF, neutrophil apoptosis appears fine-
tuned by the microenvironment. 
It is possible, therefore, fine-tuning of apoptosis could provide benefits in either neutrophil 
clearance or inflammation resolution. Sputum neutrophils from patients with COPD were 
shown to be no more resistant to apoptosis than sputum neutrophils from healthy smokers 
and non-smokers (Rytilä et al., 2006), suggesting neutrophilia seen in the lungs of patients 
with COPD may be linked with prolonged survival. It is important to note, however, that 
neutrophils are not generally present at any large numbers in healthy lungs, making direct 
comparisons between COPD and healthy sputum challenging. A small study suggested that 
blood neutrophils from patients with COPD exhibited increased activation during apoptosis, 
although the rate of apoptosis itself was not altered (Noguera et al., 2004), however, this may 
represent an increased sensitivity to activation during isolation – especially relevant with in 
vitro experimental procedures.  
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Altered apoptosis, either accelerated or inhibited is likely to impact on both neutrophil 
function and the resolution of inflammation, but it is unclear the exact role this may play in 
COPD. In diabetes, again, neutrophils isolated from patients with T1D demonstrated normal 
spontaneous apoptosis but were unable to delay apoptosis in response to LPS, in contrast with 
neutrophils from healthy volunteers (Tennenberg, Finkenauer and Dwivedi, 1999). Neutrophil 
apoptosis has been reported to be altered in a variety of other inflammatory diseases, 
including inflammatory bowel disease (Brannigan et al., 2000) and cystic fibrosis (Gray et al., 




As discussed, CD10 is a useful marker to identify neutrophil maturation status (Section 1.1.1 
and 1.3.1), however, it may also reveal important information about other neutrophil 
functions. CD10 is an endopeptidase and incubation of human neutrophils with fMLP resulted 
in the degradation of fMLP that was blocked with a CD10 inhibitor, phosphoramidon (Painter 
et al., 1988). Importantly, a study using monoclonal antibodies to CD10 reported inhibition of 
neutrophil chemotaxis towards fMLP with no impact on chemokinesis (McCormack, Nelson 
and LeBien, 1986). Conversely, two other studies report the use of CD10 inhibitors (thiorphan 
(Shipp et al., 1991) and thiorphan/phosphoramidon (Hofman et al., 1998)) resulted in 
enhanced chemotaxis across an acellular membrane towards fMLP. The first of these studies 
also highlighted that stimulation of neutrophils with PMA resulted in decreased CD10 activity, 
whereas activation with TNF-α increased CD10 activity (Shipp et al., 1991). Together these 
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results suggest CD10 not only has enzymatic activity but may also participate in intracellular 
signalling events involved in regulating chemotaxis. Indeed, a prostate cancer cell line capable 
of performing cellular migration revealed CD10 engagement was capable of directly blocking 
migration via focal adhesion kinase (Sumitomo et al., 2000) – suggesting an explanation for 
the reduced chemotaxis response observed with antibody blocking of CD10 (McCormack, 
Nelson and LeBien, 1986). CD10 expression, therefore, may be an important marker of both 
maturity and neutrophil bacterial responses in patients. 
1.6.5 Inflammatory phenotypes 
Potentially pro-inflammatory and anti-inflammatory phenotypes of neutrophils have also 
been reported in the literature. Aside from surface marker expression, regulatory or ‘anti-
inflammatory’ neutrophils have been reported in patients with melanoma and from wild-type 
mice based on production of the anti-inflammatory cytokine IL-10 (De Santo et al., 2010). 
However, another study has suggested that the IL-10 locus is epigenetically inactive in human 
neutrophils and, therefore, these results might arise from contaminating monocytes in human 
neutrophil preparations (Tamassia et al., 2013).  
The divergence between pro- and anti-inflammatory neutrophils is also demonstrated in 
patients receiving peripheral blood stem cell therapy in conjunction with G-CSF infusions  
(Marini et al., 2017). In this patient population, two neutrophil phenotypes were observed:  
CD66b+CD10+ neutrophils – mature neutrophils that inhibited T cell responses and 
CD66b+CD10- neutrophils with an immature morphology and the promotion of T cell function 
(Marini et al., 2017). However, the functional difference was only observed in low-density 
granulocytes – a specific subset of granulocytes that exist in primarily inflammatory conditions 
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(Hacbarth and Kajdacsy‐Balla, 1986; Hassani et al., 2020), are of interest in their own right, 
but will not be covered in detail here. Yet, these observations set the premise for pro- and 
anti-inflammatory phenotypes of neutrophils.  
1.6.5.1 CD11c 
CD11c, or integrin alpha X, is one of the four α-subunits expressed on the surface of 
neutrophils that pairs with CD18 and has over 50% homology with CD11b (Frick et al., 2005). 
CD11c binds fibrinogen; demonstrated by blocking the binding of stimulated neutrophils with 
TNF-α in vitro to fibrinogen with anti-CD11c antibodies (Loike et al., 1991). Neutrophils 
expressing higher levels of CD11c in vivo has been linked to an immunosuppressive 
phenotype, as volunteers injected intravenously with LPS resulted in neutrophils with higher 
CD11c expression that in vitro suppressed T cell activation (Pillay et al., 2012). Neutrophils 
with higher CD11c expression have also been found in the circulation of patients with sepsis, 
of note without the loss CD62L or increase in CD11b expression (Lewis et al., 2015). Another 
study reported increases in neutrophil expression of both CD11b and CD11c in patients with 
sepsis (Muller Kobold et al., 2000) – the differences in isolation procedures may be responsible 
for the discrepancy in CD11b expression. 
Peripheral blood neutrophils from patients with T2D have also been reported to have 
increased surface expression of CD11c (Caimi et al., 2002), including a blunted upregulation 
of CD11b expression in response to fMLP, adding to the notion that CD11c expression may 
indicate an immunosuppressive phenotype. 
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1.6.5.2 PD-L1 
Programmed-death receptor 1 (PD-1) is predominantly expressed on T cells and engagement 
of PD-1 inhibits T cell proliferation and activation, maintaining immune tolerance in health 
(Keir et al., 2008; Wei et al., 2013). The PD-1 receptor has two natural ligands, PD-L1 and PD-
L2. PD-L1 has gained attention because of its role in cancer, as expression by tumour cells 
inhibits T cell-mediated killing through engagement of PD-1, and there is an evolving clinical 
programme to block PD-L1 as a therapeutic (Dong, Sun and Zhang, 2015; Huang et al., 2015; 
J. Chen et al., 2016; Hahn et al., 2017). 
Neutrophils can also express PD-L1 and this is implicated in a variety of disease settings. 
Neutrophils isolated from patients with systemic lupus erythematosus (SLE) showed an 
increased proportion of PD-L1 expressing neutrophils in the circulation that correlated with 
disease severity (Luo et al., 2016). Another study also found increased PD-L1 expression on 
peripheral blood neutrophils isolated from patients with active tuberculosis infection 
compared to healthy volunteers (McNab et al., 2011). Human neutrophils exposed in vitro to 
cancer-associated fibroblast conditioned media also up-regulated PD-L1 leading to inhibition 
of T cell proliferation, and reduced neutrophil apoptosis (Cheng et al., 2018). It is yet unclear 
if these represent advantageous compensatory changes or pathogenic changes in neutrophil 
function. 
The PD-1/PD-L1 axis also has links to COPD as CD8+ T cells isolated from lung sections of 
patients with COPD have increased PD-1 expression that has been linked with reduced anti-
viral responses (McKendry et al., 2016). However, the impact of altering the PD-1/PD-L1 axis 
in patients with COPD is not yet well understood (Stoll, Virchow and Lommatzsch, 2016). 
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These studies suggest that neutrophil expression of PD-L1 may indicate an 
immunosuppressive function, one that may be of future therapeutic benefit. 
1.6.5.3 HLA-DR 
A third surface molecule linked with neutrophil inflammation is Human Leukocyte Antigen 
(HLA)-DR, a molecule that presents antigen to the T Cell Receptor (Jendro, Goronzy and 
Weyand, 1991). HLA-DR is a class II Major Histocompatibility Complex (MHC) molecule more 
commonly linked to functions of dendritic cells, macrophage and B cells (Ting and Trowsdale, 
2002) rather than neutrophils (Lin and Loré, 2017).  
HLA-DR expression may be linked to neutrophil activation: in vitro stimulation of synovial 
neutrophils with LPS and fMLP, among others, induced HLA-DR surface expression (Sandilands 
et al., 2006), a finding supported by the expression of HLA-DR by synovial neutrophils in 
patients with RA (Cross et al., 2003). Is this feature limited in vivo, therefore, to synovial 
neutrophils? A growing body of evidence suggests that peripheral blood neutrophils can 
express HLA-DR, at least in vitro, as isolated neutrophils from healthy volunteers could present 
antigen via HLA-DR, but importantly required antigen-specific or activated T cells as co-
stimulation (Vono et al., 2017). Another study demonstrated that neutrophils can indeed 
express HLA-DR by incubating isolated neutrophils with IgG-opsonised erythrocytes 
(Meinderts et al., 2019). Furthermore, this study indicated these neutrophils could indeed 
present antigen and induce T cell proliferation (Meinderts et al., 2019), albeit in an artificial in 
vitro system. 
The role HLA-DR expression on human neutrophils in the context of COPD, T2D and CVD still 
requires further investigation. An abstract submitted for the European Respiratory Society 
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conference suggested circulating neutrophils from patients with COPD showed increased HLA-
DR expression (Scrimini et al., 2013), however, the full data was not published. 
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Figure 1.6: Overview of several described neutrophil phenotypes in health and disease 
 
Several phenotypes of neutrophils have been described in health and disease and may 
potentially be altered in COPD. Neutrophils constitutively express CD16 and CD66b and are 
commonly used to identify human neutrophils. During activation, expression of CD11b and 
CD66b increase and can be accompanied by shedding of CD62L. Neutrophils may acquire 
expression of HLA-DR or PD-L1, potentially with pro- or anti-inflammatory effects 
respectively. Neutrophil senescence has previously been described by the increase of 
CXCR4 and decline of CXCR2 expression, potentially with the loss of CD62L expression. 
Neutrophil transmigration causes an increase in CD54 expression and, therefore, CD54 
expression in the circulation is an indicator of reverse transmigration. Neutrophils increase 




Chapter 1  Page | 63 
1.7 Aims and Hypothesis 
COPD is a disease with a considerable healthcare burden and substantial morbidity and 
mortality both in the UK and worldwide (World Health Organisation, 2018). Among others, 
the neutrophil plays a wide-ranging role in the pathogenesis of COPD, and changes in the 
phenotype and function of neutrophils may improve our understanding of both the 
mechanism of disease progression and heterogeneity in COPD linked with multi-morbidity.  
It was hypothesised that altered functions of neutrophils in COPD would be revealed by 
changes in surface expression and gene expression, consistent with an activated, pro-
inflammatory and senescent phenotype, with changes due to healthy ageing, accelerated in 
patients with COPD. These changes would be exaggerated in patients with multimorbidity and 
further increased during AECOPD.  
Therefore, the main aims of this thesis are as follows: 
1. To validate a novel panel of antibodies in order to investigate potentially important 
phenotypes of circulating neutrophils (Chapter 3 and 4). 
2. To assess the phenotype of neutrophils from healthy young and old volunteers, 
patients with COPD, including the impact that multimorbidity may have on causing 
changes in the neutrophil phenotype, specifically T2D and CVD (Chapter 5). 
3. To assess changes in the circulating neutrophil phenotype during AECOPD compared 
with stable disease (Chapter 6). 
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4. To determine the potential for neutrophils from healthy volunteers to be altered with 
pooled plasma from patients with COPD (Chapter 7).  
5. The gene expression profile of neutrophils from healthy volunteers, patients with 
COPD and AECOPD will be investigated to further support the identification of 
phenotypes by surface expression (Chapter 5 and 6). 
6. The ability of neutrophils to accurately migrate to chemokines both from patients and 
healthy volunteers will be investigated, including the response to CXCL12 and how 
chemotaxis may be altered when neutrophils from healthy elderly volunteers are 
incubated with plasma from patients with COPD (Chapter 7).   
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2 CHAPTER 2: 
MATERIALS AND METHODS 
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2.1 Ethical Approval 
All participants provided informed written consent before biological samples were obtained 
and used in this study. The study was sponsored by the University of Birmingham and 
approved by University Hospitals Birmingham (UHB) NHS Trust under approval from the West 
Midlands – Solihull Research Ethics Committee (REC 18/WM/0097). Research was conducted 
following Good Clinical Laboratory Practice and in accordance with the Declaration of Helsinki 
with Research and Development support from UHB NHS Trust.  
2.2 Participant Recruitment 
2.2.1 Healthy volunteers 
Healthy volunteers were recruited from the Centre for Translational Inflammation Research 
or from the Birmingham 1000 Elders cohort. All participants were seen at the Queen Elizabeth 
Hospital Birmingham (QEHB; Birmingham, UK) where a clinical assessment was performed and 
a blood sample obtained. Volunteers must have been over 18, with no significant respiratory 
symptoms and no previous diagnosis of COPD, asthma, interstitial lung disease, 
bronchiectasis, lung cancer or previous lung resection. 
2.2.2 Stable COPD  
Patients with a clinical diagnosis of COPD, defined as an FEV1/FVC ratio <0.7 (GOLD, 2019), 
were recruited from the Chronic Disease Resource Centre COPD cohort and from routine 
respiratory clinic outpatient appointments, both at the QEHB. Briefly, patients must have had 
at least a 10 pack-year smoking history, be over 40, be able to provide informed consent, not 
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have a diagnosis of asthma, interstitial lung disease or lung cancer and be free from 
exacerbation in the past 42 days. 
2.2.3 Exacerbations of COPD  
Patients hospitalised with an acute exacerbation of COPD (AECOPD), determined by a 
worsening of respiratory symptoms with an existing diagnosis of COPD (GOLD, 2019), were 
recruited from the Acute Medical Unit at QEHB. Briefly, patients must have had at least a 10 
pack-year smoking history, be over 40, be able to provide informed consent, the first blood 
sample taken within 48 hours of admission with AECOPD being the primary reason for 
admission, and not have a diagnosis of asthma, interstitial lung disease or lung cancer. 
The full inclusion and exclusion criteria for each group can be found in Appendix 1. 
2.3 Isolation of human neutrophils from whole blood 
All centrifugation steps were carried out at room temperature (RT) with acceleration and 
brake unless otherwise specified. Human blood was collected via venepuncture using the 
vacutainer system (BD Biosciences, UK) into 6 mL lithium heparin-containing (17 international 
units/mL) tubes. Neutrophils were isolated as previously described (Jepsen and Skottun, 
1982). Briefly, the red blood cells were sedimented 6:1 whole blood to dextran sulphate (2% 
w/v; Sigma-Aldrich, Poole, UK) in saline (0.154 M; Sigma-Aldrich) for 30 minutes. Isotonic 
Percoll was made using 9:1 v/v Percoll (GE Healthcare) to sterile NaCl (1.54 M). This isotonic 
Percoll was further diluted with sterile NaCl (0.154 M) in a 4:1 ratio to make 80% or 1.27:1 to 
make 56%. A discontinuous density gradient was made in a 15 mL centrifuge tube by layering 
2.5 mL of 80% Percoll underneath 5 mL of 56% Percoll. The remaining cellular fraction (buffy 
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coat) was then layered on top of the 56% Percoll (Figure 2.1) and centrifuged at 470 g with 
acceleration of 1 and no brake for 20 minutes. The top plasma and peripheral blood 
mononuclear cell (PBMC) layer were removed and discarded, and then the lower granulocyte 
band obtained and diluted to 15 mL in phosphate-buffered saline (PBS; Sigma-Aldrich) and 
centrifuged at 300 g for 5 minutes. The pellet was resuspended in RT double-plus media (RPMI 
1640 containing 2 mM L-glutamine supplemented with Penicillin/Streptomycin (1% w/w; all 
Sigma-Aldrich)). Cells were counted with a haemocytometer and diluted to required 
concentration in double-plus media. 
2.3.1 Assessment of neutrophil purity 
Neutrophil purity was assessed by adding 100 μL of neutrophils at 1x106 cells/mL to a cytospin 
chamber attached to a frosted glass slide (ThermoFisher Scientific, Loughborough, UK) and 
centrifuged in a cytospin (ThermoFisher Scientific) at 300 revolutions per minute (RPM) for 5 
minutes (Figure 2.2). The glass slide was then removed and stained using a Quick-Diff staining 
kit (Reagena, Finland) by dipping in methanol for 10 seconds, solution I for 30 seconds and 
solution II for 30 seconds followed by rinsing in distilled water. Slides were imaged using a 
light microscope (Wilovert, Germany). The number of cells and neutrophils were counted in 
the field of view at x20 magnification, and the percentage of neutrophils calculated. A purity 
of >95% was typically observed.  
2.4 Isolation of PBMCs from whole blood 
Human blood was collected using the vacutainer system into 6 mL lithium heparin containing 
tubes. In a 15 mL centrifuge tube, 2.5 mL of Histopaque 1077 (Sigma-Aldrich) was layered on 
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top of 2.5 mL of Histopaque 1119 (Sigma-Aldrich) as previously described (Munir et al., 2015). 
Whole blood was then layered on top and centrifuged at 800 g for 30 minutes with 
acceleration 1 and brake 0 at RT. The top layer of cells containing the PBMCs was then pipetted 
into a fresh 15 mL centrifuge tube and diluted in double-plus media. Cells were centrifuged at 
300 g for 5 minutes with acceleration and brake of 9 at RT. The supernatant was discarded; 
the pellet was resuspended in double-plus media and counted with a haemocytometer before 
diluting further in double-plus media as required. 
2.5 Collection of serum and plasma from blood 
Human blood was collected using the vacutainer system (BD Biosciences) into either 
Potassium-Ethylenediaminetetraacetic acid (K2EDTA)-containing, for plasma, or silica clot 
activator serum clotting containing, for serum, tubes. The vacutainer was centrifuged at 1000 
g for 10 minutes and the plasma or serum pipetted off the top into 500 μL aliquots that were 
frozen at -20oC for up to two months before long-term storage at -80oC.  
2.5.1 Pooling of serum and plasma samples 
Serum pools were made by thawing stored serum from randomly selected donors (healthy 
young (HY), COPD and AECOPD) or selected age-matched healthy elderly (HE) donors and 
combining 300 μL of each sample together before re-aliquoting into 110 μL aliquots and 
storing at -20oC until required. In all cases, each pooled aliquot was thawed immediately 
before use and any remainder discarded. 
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Figure 2.1: Diagram of the setup of the neutrophil isolation  
Percoll and the buffy coat were layered as shown prior to centrifugation at 470 g with 
acceleration of 1 and no brake for 20 minutes. After centrifugation, remaining red blood 
cells (RBCs) pellet at the bottom, the granulocytes form a band at the interface between 
80% and 56% Percoll, and the remaining peripheral blood mononuclear cells (PBMCs) form 
a layer on top of the 56% Percoll. 
 
 
Figure 2.2: Diagram of the cytospin setup 
All four sections were clamped together in the order shown prior to the addition of cells 
into the top of the chamber. This was then loaded into a cytospin centrifuge. 
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2.6 Phenotyping of isolated neutrophils by flow cytometry 
The antibodies used for flow cytometry are summarised in Table 2.1. The stated dilutions were 
used in all experiments unless specifically expressed otherwise. 
2.6.1 Validating antibodies for flow cytometry 
Neutrophils at 1x106 cells/mL in double-plus media were added to 12x75 mm polystyrene 
tubes (BD Biosciences, USA; total of 1x105 cells) and incubated with 5 μL (1:20), 2.5 μL (1:40) 
or 1 μL (1:100) of the relevant antibody and corresponding concentration of the isotype 
control for 20 minutes on ice in the dark. Cells were washed twice with 100 μL of BSA (2% w/v 
in PBS; Sigma-Aldrich) and centrifugation at 300 g for 5 minutes. Samples were resuspended 
in 200 μL of 2% BSA in PBS and then analysed by flow cytometry using a 4-laser Fortessa X20 
flow cytometer (BD Biosciences, UK) or a 2-laser Accuri C6 flow cytometer (BD Biosciences, 
UK) as described in Section 2.6.3. For each sample, a staining index was calculated using 
median fluorescence intensity (MFI) as previously described  (Maecker et al., 2004)  using the 
following equation: 
𝑆𝑡𝑎𝑖𝑛𝑖𝑛𝑔 𝐼𝑛𝑑𝑒𝑥 =  
(𝑀𝐹𝐼 𝑎𝑛𝑡𝑖𝑏𝑜𝑑𝑦 − 𝑀𝐹𝐼 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
2 × 𝑟𝑜𝑏𝑢𝑠𝑡 𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑖𝑠𝑜𝑡𝑦𝑝𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
 
In further experiments, the identified optimal antibody concentration was used during the 
incubation step (Table 2.1). 
2.6.2 Sample preparation and staining 
Neutrophils at 1x106 cells/mL in double-plus media at 100 μL/well were added to wells of a 
polyvinyl chloride 96-well U-bottomed plate (Costar, Loughborough, UK) and incubated with 
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relevant antibodies (Table 2.1) for 20 minutes on ice in the dark. Cells were washed with 
100 μL of BSA (2% v/v in PBS), centrifuged at 300 g for 5 minutes with acceleration and brake 
of 9 at RT. Pellets were resuspended in 100 μL of annexin V Staining Buffer (BioLegend, 
London, UK) before centrifugation at 300 g for 5 minutes with acceleration and brake of 9 at 
RT before cell pellets were resuspended in either 100 µL of annexin V Staining Buffer 
(BioLegend) or 100 μL of PE-conjugated annexin V (1:40 in annexin V Staining Buffer; both 
BioLegend based on (Rieger et al., 2011)). Cells were then incubated for 15 minutes at RT in 
the dark and then washed in 100 µL of annexin V Staining Buffer at 300 g for 5 minutes. Cell 
pellets were resuspended in either 100 µL annexin V Staining Buffer or 100 μL of 7-
Aminoactinomycin D (7AAD; diluted 1:20 in annexin V Staining Buffer; all BioLegend, UK). 
Samples were transferred to 12x75mm polystyrene tubes (BD Biosciences, UK) containing 
130 μL of annexin V Staining Buffer before running on a 4-laser Fortessa X20 flow cytometer 
(BD Biosciences, UK) or a 2-laser Accuri C6 flow cytometer (BD Biosciences, UK) as described 
in Section 2.6.3. 
2.6.2.1 Addition of pooled serum and plasma 
For experiments using pooled plasma, neutrophils at 1x106 cells/mL in double-plus media at 
100 μL/well were added to wells of a polyvinyl chloride 96-well U-bottomed plate (Costar, 
Loughborough, UK) and incubated with 100 µL of either double-plus media, autologous 
plasma (AP), pooled plasma from HE donors or pooled plasma from stable COPD donors for 
30 minutes at room temperature. Cells were centrifuged at 300 g for 5 minutes and washed 
twice with double-plus media prior to antibody staining as detailed in Section 2.6.2. 
 
Chapter 2  Page | 73 
2.6.3 Analysis of flow cytometry data 
Gates were set up in FACSDiva (Version 7; BD Biosciences, USA) or BD Accuri C6 Software 
(Version 1; BD Biosciences, USA) to exclude doublets, gate for granulocytes and, where 
viability dyes were included, live cells as shown in Figure 2.3. Samples were run at medium 
speed (default settings on both flow cytometers). Data were exported from FACSDiva or BD 
Accuri C6 Software as Flow Cytometry Standard (FCS) files and analysed using FlowJo (Version 
10.6, BD Biosciences, USA). The standard gating strategy used is shown in Figure 2.3 to exclude 
doublets, gate for granulocytes using both forward (FSC) and side scatter (SSC) and neutrophil 
markers and, where viability dyes were included, live cells. For each channel, the raw median 
fluorescence intensity (MFI) and the percentage positive and negative was exported into a 
table. MFI values of the samples were adjusted by 𝑀𝐹𝐼𝑠𝑎𝑚𝑝𝑙𝑒 − 𝑀𝐹𝐼𝑖𝑠𝑜𝑡𝑦𝑝𝑒. For further 
analysis of neutrophil populations, only live neutrophils (indicated in Figure 2.3) were analysed 
to identify overactive senescent neutrophils (Figure 2.4a), segmentation status (Figure 2.4b) 
senescence (Figure 2.4c), or activation (Figure 2.4d). 
Computational analysis of high-dimensional data was also used to analyse neutrophil 
phenotypes. Live neutrophils (Figure 2.4) were exported as FCS files for each sample and 
clustered using the Rphenograph clustering method (Levine et al., 2015) and t-Distributed 
Stochastic Neighbor Embedding (t-SNE) visualisation (Van Der Maaten and Hinton, 2008) 
within the cytofkit package (H. Chen et al., 2016) to identify neutrophil phenotypes without 
traditional manual gating strategies. The output of this analysis was used to generate heat-
map profiles and investigate the expression profiles of each cluster according to the markers 
detailed in Table 2.1.
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Table 2.1: Neutrophil phenotyping antibody panel.  
Target Alternative 
names 
Clone Conjugate Manufacturer LOT# Concentration 
(μg/mL) 
Dilution Assay 
CD16 FcγRIII eBioCB16 FITC eBiosciences E13735-104 25 1:100 V 
CD16 FcγRIII 3G8 AF700 BioLegend B205739 500 1:100 V 
CD16 FcγRIII 3G8 AF700 Invitrogen 1218921C 100 1:20 V 
CD16 FcγRIII B73.1 AF700 BioLegend B201272 300 N/A V 
CD16 FcγRIII VEP-13 FITC Miltenyi Biotec 5130805659 N/A 1:100 V 
CD10 Neprilysin, 
CALLA 
HI10a BV510 BioLegend B253991 
B248239 
100 1:20 V, NP, PP 
CD11b Mac-1, CR3 ICRF44 BV786 BioLegend B245198 100 1:40 V, NP, PP 
CD11c CR4 S-HCL-3 FITC BioLegend B231151 200 1:40 V, NP 
CD16 FcγRIII eBioCB16 AF700 eBiosciences 4348114 25 1:100 V, NP, PP 
CD54 ICAM-1 HCD54 APC BioLegend B215798 200 1:100 V, NP 
CD62L L-selectin DREG-56 BV605 BioLegend B213455 100 1:100 V, NP, PP 
CD66b CEACAM8 G10F5 APC BioLegend B245473 200 1:100 V, NP, PP 
CD66b CEACAM8  AF700 BioLegend    V 
CD182 CXCR2 5E8/CXCR2 FITC BioLegend B225522 500 1:40 V, NP, PP 
CD184 CXCR4 12G5 BV421 BioLegend B232492 100 1:20 V, NP 
HLA-DR MHCII L243 BV421 BioLegend B236256 100 1:40 V, NP 
CD274 PD-L1, B7-H1 29E.2A3 BV605 BioLegend B239150 100 1:100 V, NP 
CD274 PD-L1, B7-H1 130021 APC R&D Systems ABKW0214101 10 1:100 V 
Legend: The concentration is the stock concentration the antibody was supplied at and the dilution is the standard dilution the antibody 
was used in the staining procedure unless otherwise stated in the results section. The assays each antibody appears in are listed as  
V: validation experiments; NP: neutrophil phenotyping; PP: pooled plasma experiments. 
 




Figure 2.3: Initial flow cytometry gating strategy for neutrophil phenotyping experiments 
 
Firstly, doublets were excluded based on cell circularity, followed by identification of 
granular cells (neutrophils). Cells positive for CD16 (Panel 1, P1) or CD66b (Panel 2, P2) 
were selected and viability assessed using 7AAD and Annexin V to identify live (double 
negative), apoptotic (Annexin V single positive), dead (double positive) or cells dead 
through a cellular process other than apoptosis, such as necrosis (7AAD single positive). 
Live and apoptotic cells were then assessed for the surface expression of each subsequent 
marker by median fluorescence intensity (MFI) and percentage positive (%+). 




Figure 2.4: Extended flow cytometry gating strategy for neutrophil phenotyping 
experiments 
 
Live neutrophils (as identified in Figure 2.3) were further analysed based on a) CD62L and 
CXCR4 expression, b) CD62L and CD16 expression, c) CXCR4 and CXCR2 expression or d) 
CD66b and CD11b expression. Live neutrophils were also used as the input for t-Stochastic 
Neighbor Embedding (t-SNE) analysis performed using Rphenograph. 
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2.7 Chemotaxis 
Chemotaxis was assessed using Insall chambers (Weber Scientific, Teddington, UK) as 
previously described (Sapey et al., 2014) and shown in Figure 2.5. BSA (1.125% v/v; Sigma-
Aldrich) was added to neutrophils at 2x106 cells/mL isolated as described in Section 2.3. 
Square 22x22 mm glass coverslips (Leica, UK) were sterilised in H2SO4 (0.4M; Sigma-Aldrich) 
and rinsed in double distilled (dd) H2O before allowing to dry on filter paper under a petri dish 
lid (Corning, USA). Once dry, 400 µL of 7.5% BSA (Sigma-Aldrich) was added to the coverslip 
ensuring it covered the entire surface before tipping off and leaving to dry for 30 seconds 
under a petri dish lid. Then, 400 μL of neutrophils prepared as in Section 2.3 were then added 
to the coverslip and incubated at room temperature for 20 minutes. The Insall chamber was 
rinsed with double-plus media, filled level with double-plus media and then the coverslip 
inverted over the chamber once the excess neutrophils had been discarded. The remaining 
liquid in the chemoattractant well was then removed using filter paper and filled with 70 μL 
of one of the following chemoattractants: CXCL8 (100nM; Bio-techne), fMLP (10nM; Sigma-
Aldrich), CXCL12 (1.25μM; Tonbo Biosciences), or fresh double-plus media. A gradient was 
allowed to form for 1 minute before imaging using a Leica DM 6000 with Leica Application 
Suite X software (Leica Microsystems, Version 3.3.0.16799) set to record a brightfield image 
at 20x magnification every 20 seconds for 12 minutes. The resulting data was exported as a 
combined Tagged Image File Format (TIFF) image for later analysis. 
2.7.1 Inhibition of CD10 
A CD10 inhibitor, phosphoramidon, was used to block CD10 prior to assessment of neutrophil 
chemotaxis. Isolated neutrophils were incubated with either double plus media, 0.5 µM, 1 µM, 
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10 µM or 50 µM of phosphoramidon, covering the concentration range of previously 
published data, for 30 minutes prior to chemotaxis (Hofman et al., 1998; Stuardo et al., 2004).  
2.7.2 Analysis of neutrophil chemotaxis 
Combined TIFF images were opened using ImageJ (Version 1.52i; National Institutes of Health, 
USA). Ten cells were randomly selected and then tracked using the included “Manual 
Tracking” plugin as previously described (Sapey et al., 2014) and validated within the group 
where this sample size gave a representative result of the population. Cells were excluded if 
their path during the recording was substantially altered by collision with another cell. Analysis 
generated pixel positions for each frame for every cell tracked that was further analysed by 
calculating the following parameters to describe the movement of the cell divided into two 
types, per frame and whole time-lapse (Figure 2.6): 
Per frame: 
• Speed: the distance travelled by the cell divided by time, calculated as pixels per frame 
and converted to μm/minute using the frame length and distance per pixel; 
• Velocity: the speed travelled towards (or away from) the chemoattractant, calculated 
from the movement in the y-direction only; 
• Chemotaxis index: a measure of movement towards the chemoattractant, calculated 
from the sine transformation of the angle in radians between the cell movement and 
the x-axis (θ); 
• Persistence: a measure of the change in the angle of movement of the cell, calculated 






  , where x is the change of the angle in radians. 
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Whole time-lapse: 
• Displacement: the distance between the start point and endpoint of the track. This 
was independent of direction by removing the sign as follows √(𝑥)2; 
• Cumulative distance: the total distance travelled by the cell during the track, 
calculated at each frame. This was independent of direction by removing the sign as 
follows √(𝑥)2; 
• Directness: a measure of straightness of the path taken by the cell, calculated by 
displacement/cumulative distance; 
• Centre of mass (COM): the coordinates of the endpoint of the cell measured from a 
starting position of 0,0.  
Each of these parameters was then averaged to provide a result for each condition formed 
from ten individual cells. 
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Figure 2.5: Schematic of an Insall chamber and tracking of neutrophils 
 
a) Isolated neutrophils were adhered to a coverslip before inversion onto the Insall 
chamber. RPMI (as a negative control) or chemoattractant (such as CXCL8) was loaded into 
the outer well. b) a typical brightfield image of neutrophils adhered to the coverslip with 
c) an example of ten tracked cells using the ImageJ “manual tracking” plugin overlaid with 
the cell path. 
 




Figure 2.6: Schematic of neutrophil chemotaxis analysis 
 
Conversion from light microscopy image and image trace to plotted points allowed the 
analysis of parameters for a single tracked cell. The black arrow, forming the angle (θ) and 
distance (𝑥) show parameters calculated over the whole time-lapse. Parameters calculated 
per frame are indicated by the red arrow and symbols. 
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2.8 Quantification of CXCL12 using enzyme-linked immunosorbent assay 
(ELISA) 
CXCL12 levels in platelet-poor human plasma samples were quantified using the Quantikine 
CXCL12 ELISA Kit (Bio-techne) according to manufacturer’s guidelines. Briefly, all supplied 
reagents and frozen plasma samples were thawed to room temperature. Platelet removal was 
achieved by spinning plasma samples at 10000 g for 10 minutes at 4oC in a microcentrifuge 
(Prism R; Labnet, NJ, USA). Lyophilised CXCL12 was reconstituted in distilled water and diluted 
to 10000 pg/mL in supplied diluent to obtain the top CXCL12 standard. A serial 1:2 dilution in 
the supplied diluent was subsequently performed down to a final concentration of 156 pg/mL, 
including a diluent blank as the 0 pg/mL control. To each well of the supplied capture-antibody 
coated 96-well plate, 100 μL of assay diluent was added, followed by 100 μL of each standard 
or sample in duplicate. The plate was incubated for 2 hours on an orbital plate shaker 
(ThermoFisher Scientific, UK) at 500 RPM. The plate was then washed 4 times using supplied 
wash buffer ensuring all liquid from the plate was removed by blotting on clean absorbent 
paper. To each well, 100 μL of supplied detection antibody was added and incubated for 2 
hours on a shaker as previously described. Again, the plate was washed as described and 200 
μL of a 1:1 solution of supplied reagent A and reagent B was added to each well. The plate was 
incubated for 30 minutes in the dark, followed by addition of 50 μL of supplied stop solution 
to each well. The plate was then read on an absorbance plate reader (BioTek Synergy HT; 
NorthStar Scientific, VT, USA) at 450 nm and 540 nm. The final absorbance value was obtained 
as follows: 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 𝐴𝑏𝑠450 − 𝐴𝑏𝑠540 − 𝐴𝑏𝑠𝑏𝑙𝑎𝑛𝑘 
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The concentration of CXCL12 was obtained from direct interpolation of the standard curve 
fitted using a 4-parameter sigmoidal least-squares fit. Assay range was 156 -10000 pg/mL with 
a sensitivity of 47 pg/mL. 
2.9 Extraction of RNA 
Cellular RNA was stabilised by pelleting isolated neutrophils (Section 2.3), discarding the 
supernatant and resuspending in 1 mL of RNALater (ThermoFisher Scientific, UK) and storing 
at -20oC for up to 1 week before transferring to long-term storage at -80oC. The total number 
of cells stored was recorded for each sample. 
RNA was isolated using the RNEasy Mini Kit (QIAGEN, Manchester, UK) with QIAshredder and 
RNase-free DNase (both QIAGEN, UK) according to the manufacturer’s guidelines. Briefly, 
neutrophils in RNALater were thawed on ice and up to 1x107 neutrophils were removed into 
a fresh 1.5 mL microcentrifuge tube and diluted up to 1.5 mL in ice-cold PBS. Cells were 
centrifuged at 500 g for 5 minutes and the supernatant discarded. Cells were disrupted using 
350 µL of supplied RLT buffer before transferring to a supplied QIAshredder tube. Tubes were 
centrifuged at 10000 g for 2 minutes and 350uL of 70% ethanol added to each collection tube. 
Samples were then transferred to a supplied RNeasy spin column and centrifuged at 9000 g 
for 30 seconds. The flow-through was discarded, 350 µL of supplied RW1 added to the column 
and centrifuged at 9000 g for 30 seconds. The flow through was discarded and 80 µL of DNase 
mix (1:7 mix of supplied DNase I stock to Buffer RDD) added to each column. Columns were 
incubated at RT for 15 minutes before adding 350 µL of RW1 and centrifuged at 9000 g for 30 
seconds. The flow-through was discarded and 500 µL of supplied Buffer RPE working solution 
was added and centrifuged at 9000 g for 30 seconds. The flow-through was discarded and 500 
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µL of Buffer RPE was added and centrifuged at 9000 g for 2 minutes. Each column was placed 
in a fresh collection tube and centrifuged at 9000 g for 1 minute. Each column was then 
transferred to a supplied 1.5 mL collection tube and 30 µL of supplied nuclease-free water was 
added to the column and centrifuged at 9000 g for 1 minute. Samples were immediately 
placed on ice and tested using 1 µL of sample on a Nanodrop 2000 (ThermoFisher Scientific, 
UK) where ratios (260nm to 280nm and 260nm to 230nm) above 2.0 indicated good sample 
purity, between 2.0 and 1.8 indicated adequate purity and below 1.8 indicated poor purity. 
Further quality control was carried out by University of Birmingham Genomics Service 
(Birmingham, UK) including fluorescence quantification using Qubit (ThermoFisher Scientific) 
and RNA integrity score (RIN) using a Tapestation (Agilent, CA, USA) where a RIN score of 8 or 
higher is considered good, between 7 and 8 adequate and below 7 as poor. RNA was stored 
immediately at -80oC. 
2.10 RNA sequencing and analysis 
Isolated RNA was thawed and diluted to 11.6 ng/mL in 30uL of nuclease-free water and placed 
into a skirted 96-well PCR plate and sealed with a PCR adhesive plate seal (both ThermoFisher 
Scientific, UK). Samples were shipped on dry ice to the Oxford Genomics Centre for 
sequencing: poly-A mRNA selection; cDNA generation; 150 base pair paired-end sequencing 
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2.10.1 Analysis workflow 
An overview of the analysis pipeline is shown in Figure 2.7. Sequence data in .fastq format was 
uploaded to the Galaxy web platform at usegalaxy.eu (Afgan et al., 2016) using FileZilla (Tim 
Kosse; Version 3.46.0). The human genome GRCh38.p13.genome and annotations 
gencode.v33.annotation were obtained from GENCODE (Frankish et al., 2019) and were also 
uploaded to Galaxy. Each paired read was aligned using RNA STAR (Dobin et al., 2013), gene 
counts calculated with FeatureCounts (Liao, Smyth and Shi, 2014) and gene abundance 
calculated using StringTie2 (Kovaka et al., 2019). Differential expression analysis was 
performed using DESeq2 (Love, Huber and Anders, 2014). The Galaxy server that was used for 
these calculations is in part funded by Collaborative Research Centre 992 Medical Epigenetics 
(DFG grant SFB 992/1 2012) and German Federal Ministry of Education and Research (BMBF 
grants 031 A538A/A538C RBC, 031L0101B/031L0101C de.NBI-epi, 031L0106 de.STAIR 
(de.NBI)). The full workflow can be seen in Figure 2.7 and freely accessible at 
https://usegalaxy.eu/u/mxh619/w/rnaseq-primary-analysis-mh; 
https://usegalaxy.eu/u/mxh619/w/downstream-rna-analysis. 
Gene ontology (GO) analyses were performed using a combination of ShinyGO (Ge, Jung and 
Yao, 2019) and ClueGO (Bindea et al., 2009). Heatmaps were generated using Shinyheatmap 
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2.11 Figures and graphics 
All graphs were generated using Graphpad Prism (Version 8.4.3 for Windows, GraphPad 
Software, San Diego, California USA). Where appropriate, figures and diagrams are original 
and generated using Inkscape (Version 0.92, Inkscape.org). Other third-party software is 
referenced in the specific sections where they were used (Sections 2.6.3 and 2.7.2). 
2.12 Statistical analysis and power calculations 
Data were assessed for a normal distribution using the Shapiro-Wilk test, where a  
p-value>0.05 was considered normally distributed. Pilot data from previous work indicated 
14-20 samples gave an 80% power to detect a 20% difference in both chemotaxis and receptor 
marker expression. 
For normally distributed data, parametric tests were used. A paired t-test was used for data 
between two treatment groups on the same participants. For non-related samples (e.g. 
healthy vs. COPD), an unpaired t-test was used. For analysis between more than two 
independent groups where all groups were normally distributed, a one-way ANOVA was 
performed. Multiple comparisons were then carried out using either Tukey’s multiple 
comparisons (comparing all groups to each other) or Dunnett’s multiple comparisons 
(comparing data to a control group). Pearson’s correlation coefficients were used to 
determine associations between two variables. Analysis was performed by Graphpad Prism 
(Version 8.4.3 for Windows, GraphPad Software, San Diego, California USA). 
For non-normally distributed data, or where at least one comparison group was non-normally 
distributed, non-parametric tests were used. Wilcoxon matched-paired signed-rank test was 
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used for analysing two treatment groups on the same participants. For non-related samples 
(e.g. healthy vs. COPD) a Mann-Whitney test was used. For analysis between more than two 
independent groups, Kruskal-Wallis analysis was performed. Multiple comparisons were then 
carried out using Dunn’s multiple comparisons. Spearman’s rank correlation coefficients were 
used to determine associations between two variables. Analysis was performed by Graphpad 
Prism (Version 8.4.3 for Windows, GraphPad Software, San Diego, California USA). 
For demographic data where information was categorical, the Fishers Exact test was used. 
Analysis was performed using the fisher.test command within R (Version 4.0.0 for Windows, 
R Core Team, 2018) 
In all cases, a p-value<0.05 was considered to be statistically significant.  
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Figure 2.7: Simplified workflow for RNASeq analysis in Galaxy 
 
a) Sequenced FASTA files (forward, 1; reverse, 2), including annotated gene information 
(guide file) and the complete human genome were uploaded to the Galaxy server. FastQC 
analysis was performed on each FASTA file and merged into a single file using MultiQC. 
Both FASTA files, the guide file and genome file were used to map the sequence to the 
genome. Gene expression and quantification was performed using StringTie and 
FeatureCounts before sorting based on total expression of identified genes. b) Normalised 
gene counts from FeatureCounts, grouped based on participant group, were used as the 
input for differential gene expression. The counts and p-value from this output was merged 
with genes of interest based on the flow cytometry phenotyping panel (Table 2.1), and all 
other genes with a p-value <0.05 were filtered before plotting on a heatmap of gene 
expression. 
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3 CHAPTER 3: 
VALIDATING THE USE OF MULTI-
COLOUR FLOW CYTOMETRY TO 
PHENOTYPE NEUTROPHILS 
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3.1 Brief introduction 
Flow cytometry is a common technique used in an increasing array of applications including 
measuring effector functions (for example phagocytosis; Miksa et al., 2009), cell viability and 
intracellular markers (Adan et al., 2017). Whilst being a staple in both clinical (Bakke, 2000) 
and research settings, variations in reagents and flow cytometers leads to poorly comparable 
results between experiments and studies and, therefore, rigorous validation of reagents and 
standardisation of methodology is required (Maecker, McCoy and Nussenblatt, 2012).  
The analysis of flow cytometry data also poses a challenge for the reproducibility of data. A 
variety of methods can be employed to analyse flow cytometry data (Bashashati and 
Brinkman, 2009), many of which require time and an in-depth understanding of the data to 
avoid erroneous placing of gates and reporting of incorrect or misleading statistics.  
Here we establish two antibody panels to assess the phenotype of isolated human neutrophils 
from peripheral blood. Appropriate fluorophores and dyes that could be used as part of a 
multi-parameter flow cytometry panel to quantify surface expression of markers and cell 
viability were identified. A robust gating strategy was developed to identify neutrophil viability 
and phenotypes based on surface expression of key functional markers. Standardisation beads 
were validated for use to ensure cytometer performance between experiments based on 
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3.2 Results 
3.2.1 Target selection 
In order to investigate the phenotype of neutrophils based on their surface expression, a flow 
cytometry panel was designed to target various of receptors and adhesion molecules linked 
to neutrophil activation, senescence, pro-inflammatory and anti-inflammatory phenotypes (as 
introduced in Section 1.6) and are summarised in Table 3.1. In total, 13 targets were identified 
and, given the limitation to simultaneously detect these markers using the flow cytometers 
available, split between two panels as indicated in Table 3.1. 
3.2.2 Fluorophore selection 
A spectral viewer (Figure 3.1a) was used to identify 8 fluorophores that had minimal spectral 
overlap, were readily commercially available as antibody conjugates and compatible with 
7AAD - the chosen DNA dye for these experiments due to its low cost and previously validated 
use (Schmid et al., 1992). Due to the spatial separation of the excitation lasers, each laser path 
could be considered individually (Figure 3.1b-e). Each fluorophore was then matched with a 
target depending on three characteristics: relative fluorophore brightness; predicted target 
abundance and antibody availability. Lower abundance targets were matched with a relatively 
brighter fluorophore to enable better detection and, conversely, high abundance targets with 
dimmer fluorophores to avoid saturation of the signal and increasing spectral overspill. These 
results are summarised in Table 3.2.
Chapter 3  Page | 92 
Table 3.1: Target selection, functional relevance and panel distribution 
Target Alternative 
names 
Function Panel References 
Activation 
CD11b Mac-1, CR3 Found in combination with CD18 to form complement receptor 3 (CR3), it 
contributes to several neutrophil functions including adhesion, migration and 
degranulation. It is also rapidly recruited to the plasma membrane upon neutrophil 
activation.  
1,2 (Arnaout MA, 
1990; Van Spriel 
et al., 2001) 
CD66b CEACAM8 CD66b a cellular adhesion molecule and is also exclusively expressed by neutrophils 
and can therefore be used to identify neutrophils in mixed cell populations. 
Expression of CD66b increases upon neutrophil stimulation.  
2 (Lakschevitz et al., 
2016) 
CD62L L-selectin The only selectin expressed on neutrophils and mediates rolling along the 
endothelium. L-selectin is also shed upon neutrophil activation and extravasation. 
1 (Stadtmann et al., 
2013) 
Senescence 
CD182 CXCR2 C-X-C receptor 2 is the chemokine receptor for IL-8 (CXCL8) and is expressed on 
mature neutrophils. It has been implicated in the neutrophil senescence, as aged 
neutrophils show reduced CXCR2 expression. 
1 (Eash et al., 2010; 
Stadtmann and 
Zarbock, 2012) 
CD184 CXCR4 C-X-C receptor 4 is the chemokine receptor for stromal-derived factor 1 (SDF-1 or 
CXCL12). It is highly expressed during neutrophil maturation and surface expression 
is lost before release into the bloodstream. Re-expression of CXCR4 is thought to 
occur during senescence; allowing homing back to the bone marrow. 
1 (Eash et al., 2010) 
Pro-inflammatory 
HLA-DR MHC-II A potential role has been identified for neutrophils to express HLA-DR and cross-
present antigen to CD4+ T cells, thereby promoting T cell proliferation. 
 
2 (Vono et al., 2017) 
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Target Alternative 
names 
Function Panel References 
Anti-inflammatory 
PD-L1 CD274 Programmed-death ligand 1 is a ligand for programmed-death receptor 1 (PD-1) and 
ligation is known to inhibit T cell activation. Some evidence suggests a role in cancer-
associated neutrophils in immunosuppression. 





 Binds phosphatidylserine, displayed on the outer leaflet of the plasma membrane as 
cells undergo apoptosis. 
1,2 (Fadok et al., 
1998; Schutte et 
al., 1998) 
7AAD  A DNA-binding dye that can only penetrate a permeabilised plasma membrane, a 
process that occurs during cell death.  
1,2 (Schmid et al., 
1992) 
Other 
CD54 ICAM-1 Reverse endothelial migration causes increased expression of CD54 on the surface 
of neutrophils.  
1 (Buckley et al., 
2006) 
CD11c CR4 An integrin that forms part of complement receptor 4 and has been shown to be 
increased on neutrophils from sepsis patients, indicative of systemic inflammation 
and inhibit T cell responses. 
2 (Pillay et al., 2012; 
Lewis et al., 2015) 
CD10 Neprilysin, 
CALLA 
An enzyme that hydrolysis fMLP, however, is not expressed on immature neutrophils 
and expressed on maturation and release into the bloodstream. 
1,2 (Marini et al., 
2017) 
CD16 FcγRIII An Fc gamma receptor constitutively expressed by human neutrophils that is 
functionally involved in the detection of immune complexes. 
1 (Fossati et al., 
2002a) 
Legend: Each target and common alternative names listed with an overview of function alongside the panel the marker is included in. 
Chapter 3  Page | 94 
  
 
Figure 3.1: Emission spectra of conjugates for a 9-colour flow cytometry panel 
Schematic representation of relative intensity (%) of a) each fluorophore combined and 
then separated by excitation laser: b) 405nm, c) 488nm, d) 561nm, e) 640nm as denoted 
by vertical line. 
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Table 3.2: Relative fluorophore brightness and target abundance. 
Fluorophore Relative brightness Matched target Predicted 
abundance 




PE Very bright Annexin V Variable 
PE/Cy7 Bright CD16 High 
BV605 Bright PD-L1 Low/unknown 
CD62L High 
BV786 Bright CD11b High 
APC Bright CD54 Low 
CD66b Moderate 
FITC Moderate CXCR2 High 
CD11c Moderate 
BV510 Moderate CD10 Moderate 
Legend: Relative brightness listed were obtained from BD Biosciences online 
supplement (BD Biosciences, 2014). Predicted target abundance determined from 
existing literature as discussed in Section 1.6. 
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3.2.3 Titration of antibodies 
To obtain the optimal concentrations of each antibody, a titration was carried out using 
isolated neutrophils (Figure 3.2, Figure 3.3 and Figure 3.4) or, where expression by neutrophils 
was unknown, PBMCs (Figure 3.5 and Figure 3.6) from healthy volunteers incubated with the 
antibody (starting with the manufacturer recommended 1:20 dilution) or matched isotype 
control (Table 3.3). In each case, the median fluorescence intensity (MFI) was recorded, and a 
staining index calculated (Section 2.6.3) and summarised in Table 3.4.  
Optimal antibody concentrations were determined by clear distinctions between the stained 
population and isotype control population on histograms and, where necessary, informed by 
the staining index. For clarity, these analyses have been split into activation markers (CD11b 
and CD66b), markers that are highly or moderately expressed on neutrophils (CD62L, CD11c, 
CD10, CD16 and CXCR2) and markers that have low expression on neutrophils (PD-L1, HLA-DR, 
CXCR4 and CD54). The staining index for all antibodies in Sections 3.2.3.1 - 3.2.3.3 and the 
selected antibody concentrations for all future experiments are summarised in Table 3.4. 
3.2.3.1 CD11b and CD66b 
Stimulation of isolated neutrophils with 10μM fMLP increased the MFI of CD11b (Figure 3.2a) 
and, to a lesser extent, CD66b (Figure 3.2b) compared with unstimulated neutrophils as 
expected (Abdel-Salam and Ebaid, 2014; Krogh Nielsen et al., 2017). Reducing the 
concentration of anti-CD11b reduced the staining index between unstained and unstimulated 
neutrophils, however, increased the staining index between unstimulated and stimulated 
neutrophils (Table 3.4). Therefore, a concentration of 1:40 was selected to achieve the best 
balance between separating both activated and unactivated cells from CD11b negative cells. 
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In contrast, reducing the concentration of anti-CD66b had little effect on either staining 
indexes (Figure 3.2b and Table 3.4) and therefore the lowest concentration of 1:100 was 
selected for future experiments.  
3.2.3.2 CD62L, CD11c, CD10, CD16 and CXCR2 
For anti-CD62L (Figure 3.2c), CD10 (Figure 3.3b) and CD16 (Figure 3.3c), reducing the 
concentration of the antibody reduced the MFI and also reduced the staining index (Table 
3.4). As both CD62L and CD16 are highly expressed and good separation was observed 
between positive and negative peaks (Figure 3.2c and Figure 3.3c respectively), the lowest 
antibody concentration was selected despite lower staining indexes.  
Reducing the antibody concentration of anti-CD11c (Figure 3.3a) and anti-CXCR2 (Figure 3.4) 
reduced the MFI but also reduced staining by the isotype control, therefore increasing the 
staining index between 5uL and 2.5uL (Table 3.4). Based on this, a concentration of 1:40 was 
chosen for both antibodies to provide the best resolution between positive and negative 
peaks. 
As there was poor separation between the unstained and anti-CD10 stained population 
(Figure 3.3b) and a reduction in the staining index with reducing antibody concentration, the 
highest concentration (1:20) was selected for anti-CD10.  
3.2.3.3 PD-L1, HLA-DR, CXCR4 and CD54 
For anti-PD-L1 (Figure 3.5), HLA-DR (Figure 3.6a), and CXCR4 (Figure 3.6b), reducing the 
concentration of the antibody reduced the MFI and also reduced the staining index (Table 
3.4). However, good separation between the positive and negative peak was observed with 
anti-PD-L1 (Figure 3.5) and, therefore, the lowest antibody concentration (1:100) was 
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selected. Poor separation was observed with anti-CXCR4 and so the highest concentration 
(1:20) was selected. 
In contrast to all other antibodies, reducing the antibody concentration of CD54 (Figure 3.6c) 
increased the staining index between 1:20 and 1:40, and again to 1:100 (Table 3.4). Good 
separation between peaks was also observed and therefore, the lowest concentration (1:20) 
was selected.  
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Figure 3.2: Titration of anti-CD11b, anti-CD66b and anti-CD62L 
Isolated neutrophils from a healthy donor (n=1) were untreated (red trace) or treated with 
10μM fMLP (blue trace) for 20 minutes. Neutrophils were then incubated with the 
concentration of antibody shown above each plot and the fluorescence intensity of a) anti-
CD11b, b) anti-CD66b or c) anti-CD62L (red trace) or corresponding isotype control (grey 
trace) were measured by flow cytometry. 
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Figure 3.3: Titration of anti-CD11c, anti-CD10, anti-CD16 
Isolated neutrophils from a healthy donor (n=1) were incubated with the concentration of 
antibody shown above each plot. The fluorescence intensity of a) anti-CD11c, b) anti-CD10 
or c) anti-CD16 (red trace) or corresponding isotype control (grey trace) were measured by 
flow cytometry. Dilution denoted above each plot. 
 
 





Figure 3.5: Titration of anti-PD-L1 
Isolated PBMCs from a healthy donor (n=1) were incubated with 10ng/mL 
phytohaemagglutinin for 3 days prior to antibody incubation at the stated dilution above 
each plot. The fluorescence intensity of anti-PD-L1 (red trace) or corresponding isotype 
control (grey trace) measured by flow cytometry. 
 
 
Figure 3.4: Titration of anti-CXCR2 
Isolated neutrophils from a healthy donor (n=1) were incubated with the concentration of 
antibody shown above each plot. The fluorescence intensity of anti-CXCR2 (red trace) or 
corresponding isotype control (grey trace) were measured by flow cytometry. 
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Figure 3.6: Titration of anti-HLA-DR, anti-CXCR4 and anti-CD54 
Isolated PBMCs from a healthy donor (n=1) were incubated with the concentration of 
antibody shown above each plot. The fluorescence intensity of a) anti-HLA-DR, b) anti-
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CD11b 100 IgG1, κ 100 1:20 1:20 
CD66b 200 IgM, κ 200 1:20 1:20 
CD62L 50 IgG1, κ 100 1:20 1:40 
CD11c 100 IgG2b, κ 200 1:20 1:40 
CD10 100 IgG1, κ 100 1:20 1:20 
CD16 200 IgG1, k 200 1:20 1:20 
CXCR2 400 IgG1, κ 500 1:20 1:25 
PD-L1 150 IgG2b, κ 100 1:20 3:40 
HLA-DR 50 IgG2a, κ 100 1:20 1:40 
CXCR4 100 IgG2a, κ 100 1:20 1:20 
CD54 100 IgG1, κ 200 1:20 1:40 
Legend: Each primary antibody, concentration and immunoglobin (Ig) type is listed followed 
by the corresponding isotype control concentration and top dilution. 
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Staining Index Selected 
dilution 1:20 1:40 1:100 
CD11b 
(unstimulated) 
100 7.6 3.8 2.3 1:40 
CD11b 
(stimulated) 
100 0.8 1.7 2.4 
CD66b 
(unstimulated) 
200 12.6 12.8 11.7 1:100 
CD66b 
(stimulated) 
200 1.6 1.6 1.8 
CD62L 50 60.2 34.4 22.8 1:100 
CD11c 100 7.9 8.3 7.5 1:40 
CD10 100 9.1 8.0 5.6 1:20 
CD16 200 229.8 216.2 178.6 1:100 
CXCR2 400 17.7 20.1 8.3 1:40 
PD-L1 150 15.6 14.2 11.2 1:100 
HLA-DR 50 6.6 4.2 2.5 1:40 
CXCR4 100 6.5 6.0 5.0 1:20 
CD54 100 17.2 21.8 27.0 1:100 
Legend: Each primary antibody and stock concentration is listed followed by the calculated 
staining index for each dilution. Where applicable, stimulated designates pre-incubation 
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3.2.4 Validation of combined antibody panel 
After determining optimal concentrations, antibodies were combined in smaller groups to 
assess spectral compatibility and initially identify antibody cross-reactivity. Neutrophils from 
healthy young (<40 years old; HY) participants were stained with different antibody 
combinations with or without viability dyes and the MFI of each marker recorded (Table 3.5). 
In combinations P1 and P1a, ‘arching’ (where cell populations curve on a dot plot, indicative 
of uncompensated data or spectral overlap) was observed in the annexin V vs 7AAD plots 
compared to P1b (Figure 3.7a). The same observation was observed in combinations P2 and 
P2a compared to P1b (Figure 3.7b). Importantly, both P1a and P2a do not contain annexin V 
and, therefore, should have no annexin V positive events. In the absence of both annexin V 
and 7AAD, but with all other antibodies (viability fluorescence minus one, FMO), annexin V 
positive events were recorded (Figure 3.7a). From these data, it was likely another fluorophore 
was spilling over into the annexin V detection channel. Quantification of these data highlight 
the increased detection of apoptotic and dead cell events in P1, P1a, P2, P2a when compared 
to conditions P1b and P2b (Figure 3.7c). These combinations were used to identify a potential 
antibody that could spill into the annexin V channel. 
Based on the above analysis, and the PE-Cy7 conjugate, anti-CD16 was identified as a potential 
candidate for spectral overlap. In order to investigate the role of anti-CD16 in producing 
annexin V positive events, neutrophils from an elderly participant without COPD (HE, Figure 
3.8a) and with COPD (Figure 3.8b) were stained with all P1 or P2 antibodies with and without 
anti-CD16 (conjugated to PE/Cy7). Neutrophils from either donor demonstrated an increase 
in the proportion of detected apoptotic cells with anti-CD16 compared to without anti-CD16 
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staining (Figure 3.8). Furthermore, neutrophils stained with all P1 or P2 antibodies without 
anti-CD16 or viability dyes (Sub-panel c, Table 3.5) did not show any annexin V or 7AAD 
positive events as expected (Figure 3.9), suggesting PE/Cy7-conjugated anti-CD16 was altering 
the detection of annexin V positive events. Therefore, an alternative fluorophore of anti-CD16 
was obtained to mitigate this effect. 
AlexaFluor™700 (AF700), was identified as a suitable fit in the existing panel and commercially 
available conjugate for anti-CD16 and is reflected in the spectral analysis (Figure 3.10). To 
determine the optimal concentration, neutrophils from a HY volunteer were stained with 
different concentrations of AF700-conjugated anti-CD16 (BioLegend, clone 3G8, Figure 3.11). 
A staining index could not be calculated for this sample as the isotype control had a reported 
fluorescence of zero, however, a clear separation was observed between peaks (Figure 3.11) 
and, therefore, the lowest concentration (1:100) was selected. Further validation of anti-CD16 
within both antibody panels is described separately in Chapter 4.  
  




Table 3.5: Antibody combinations used in initial panel validation.  
Fluorophore Target P1 P1a P1b P1c AnV / 
7AAD 
FMO  
Target P2 P2a P2b P2c 
BV421 CXCR4      HLA-DR     
BV510 CD10      CD10     
BV605 CD62L      PD-L1     
BV785 CD11b      CD11b     
FITC CXCR2      CD11c     
PE AnV      AnV     
PE/Cy7 CD16      CD16     
APC CD54      CD66b     
7AAD DNA      DNA     
Legend: Each fluorophore and corresponding target for Panel 1 (P1) and Panel 2 (P2) are 
shown. Grey highlighted cells indicate the inclusion of that antibody in the group. Viability 
dyes [Annexin V (AnV)/7-aminoactinomycin (7AAD)] were excluded from P1 using a 
fluorescence minus one (FMO) group as shown. 
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Figure 3.7: Viability flow plots using different antibody combinations 
 
Neutrophils from a healthy young participant (n=1) were isolated and stained with 
different antibody combinations (Table 3.5) and viability was assessed using annexin V and 
7AAD. a,b) Flow cytometry plots show 7AAD and annexin V fluorescence intensity. c) 
Quantification of each condition in (a) and (b) in stacked histograms, divided into the 
percentage of neutrophils that were live (white), apoptotic (light grey), necrotic (dark grey) 
or dead (black). Data are for n=1 donor. 
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Figure 3.8: Viability of neutrophils stained with and without PE/Cy7-conjugated anti-
CD16 
 
Neutrophils from a) healthy young (n=1) and b) a patient with COPD (n=1) were isolated 
and treated as shown (full panel shown in Table 3.5). Stacked histograms show the 
percentage of total neutrophils that are live (empty), apoptotic (light grey), necrotic (dark 
grey) or dead (black) for each staining condition. 




Figure 3.9: Viability of neutrophils stained without PE/Cy7-conjugated anti-CD16 or 
viability dyes 
 
Neutrophils from healthy young participants (n=2) were isolated and stained with panel 
P1c or P2c (Table 3.5). a) Representative viability flow cytometry plot of isolated 
neutrophils stained with panel P1c. b) Stacked histograms show median percentage of 
neutrophils that are live (empty), apoptotic (light grey), necrotic (dark grey) or dead (black) 
for each staining condition. Error bars (red) indicate the range for n=2 participants. 
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Figure 3.10: Spectral view of conjugates for a 9-colour flow cytometry panel replacing 
PE/Cy7 for AF700 
 
Schematic representation of relative intensity (%) of a) each fluorophore combined and 
then separated by excitation laser: b) 405nm, c) 488nm, d) 561nm, e) 640nm as denoted 
by vertical line. 
 




Figure 3.11: Titration of AF700-conjugated anti-CD16 
 
Isolated neutrophils from a healthy donor (n=1) were incubated with anti-CD16 at the 
dilutions indicated above each plot. The fluorescence intensity of anti-CD16 (red trace) or 
corresponding isotype control (grey trace) were measured by flow cytometry. 
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3.2.5 Single-stain analysis 
In order to determine the impact of spectral overlap on the entire panel, neutrophils from HY 
participants were stained individually with each antibody and compared to the entire panel. 
Changes between the single stain controls and the entire panel were then used to determine 
if the detection of the given marker was influenced by other antibodies in the panel.  
An increase in the MFI between unstained cells and single-stained samples was observed for 
anti-CD16, CD62L, CXCR2 and CD11b (Figure 3.12) and anti-CD66b, CD10, CD11c and CD54 
(Figure 3.13), indicating basal expression of these markers. Little or no difference was 
observed between unstained and single-stained samples for anti-CXCR4, HLA-DR and PD-L1, 
indicating little or no basal expression of these markers. 
For anti-CD16, CD62L, CXCR2 and CD11b antibodies (Figure 3.12), a decrease in the MFI was 
observed between the single stain control and the whole panel, and thus indicated a reduction 
in the sensitivity of these channels. 
In contrast, anti-CD66b, CD10, CD11c and CD54 (Figure 3.13) and anti-CXCR4, HLA-DR and PD-
L1 (Figure 3.14) showed no change in the MFI was observed between the single stain control 
and the whole panel. These data indicated no reduction in sensitivity in these channels.  
  





























































































































Figure 3.12: Median fluorescence intensity of neutrophils stained individually with anti-
CD16, anti-CD62L, anti-CXCR2, anti-CD11b or in combination with all panel antibodies  
 
Neutrophils from healthy young participants (n=2) were isolated and left unstained or 
stained individually with a) anti-CD16, b) CD62L, c) CXCR2, d) CD11b or with all relevant 
antibodies (All, as shown in AnV / 7AAD FMO in Table 3.5) and the median fluorescence 
intensity (MFI) recorded. The MFI is plotted for each participant. 
 
 

























































































































Figure 3.13: Median fluorescence intensity of neutrophils stained individually with anti-
CD66b. anti-CD10, anti-CD11c, anti-CD54 or in combination with all panel antibodies  
 
Neutrophils from healthy young participants (n=2) were isolated and stained individually 
with a) anti-CD66b, b) CD10L, c) CD11c, d) CD54 or with all relevant antibodies (All, as 
shown in AnV / 7AAD FMO in Table 3.5) and the median fluorescence intensity (MFI) 
recorded. The MFI is plotted for each participant. 
 




























































































Figure 3.14: Median fluorescence intensity of neutrophils stained individually with anti-
CXCR4, anti-HLA-DR, anti-PD-L1 or in combination with all panel antibodies 
 
Neutrophils from healthy young participants (n=2) were isolated and stained individually 
with a) anti-CXCR4, b) HLA-DR, c) PD-L1 or with all relevant antibodies (All, as shown in 
AnV / 7AAD FMO in Table 3.5) and the median fluorescence intensity (MFI) recorded. The 
MFI is plotted for each participant. 
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3.2.6 Use of fluorescence minus one controls 
In order to assist with setting gates, FMO controls were used. Based on the initial validation 
information, it was identified that CXCR4, HLA-DR and viability markers most required these 
controls to accurately discriminate between positive and negative cells. Therefore, controls 
that contained staining for every other marker in the panel excluding each of these were used 
to inform the gate placement (Figure 3.15). As shown, gates were drawn around the FMO 
population to allow accurate gating of any positive events where it was not possible to clearly 
distinguish the positive and negative populations. In all other cases, isotype controls were 
used to perform a similar function where the positive population was separated from the 
negative population. 
3.2.7 Neutrophil dim and bright gating calculations 
Identifying bright and dim populations using flow cytometry is usually poorly described or 
based only on the visual appearance of the flow cytometry plot. To ensure a more robust 
gating strategy, neutrophils from HY participants were isolated and stained with panel 1 or 
panel 2 antibodies (Table 3.5). The fluorescence intensity value at the 10th percentile, for 
determining dim populations, or 90th percentile for bright populations was determined for 
each sample and the median value used as the threshold (Figure 3.16a-d). The exact values 
calculated are shown in Table 3.6. 
In order to ensure this method enabled identification of activated neutrophils, neutrophils 
from HY participants were incubated with 10 μM fMLP and expression of anti-CD11b and 
CD66b measured. Addition of fMLP resulted in an increase in both CD11b and CD66b and a 
respective increase in the percentage of CD11bbrightCD66bbright neutrophils (Figure 3.16e). 
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3.2.8 Use of Sphero Calibration Particles to maintain comparable laser performance 
As this project relies heavily on comparing the expression of surface proteins using the MFI of 
each sample, a method of ensuring accurate reporting of fluorescence between samples was 
required. Sphero Calibration Particles (or SpheroBeads; Fisher Scientific) were used to 
generate fluorescence intensity values that would act as target values for each individual 
sample. Eight fluorescent peaks are detected in each channel and a peak in the upper range 
of the detector without being saturated was selected to provide accurate target values (Figure 
3.17). The first run generated the target values shown in Table 3.7 and a 10% tolerance was 
set for subsequent experiments. Data were only collected once the flow cytometer was within 
these target ranges.  
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Figure 3.15: Fluorescence intensity of neutrophils stained with all panel antibodies or in 
fluorescent minus one controls 
 
Healthy young neutrophils (n=1) were stained with all P1 antibodies (Full, as shown in Table 
3.5) or without a) viability dyes or b) anti-CD184 (fluorescence minus one, FMO).  
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Figure 3.16: Mathematical calculation of gate cut-off values and activation marker 
validation 
 
Neutrophils were isolated from healthy young donors (n=15) and stained with all panel 1 
or panel 2 antibodies (Table 3.5). The fluorescence intensity for a) CD62L, b) CD11, c) 
CD66b, and d) CD16 were measured and the fluorescence value at either the 10th 
percentile (a and d) or 90th percentile (b and c) was recorded. The mean value across all 
samples was then used to determine ‘dim’ or ‘bright’ respectively. e) Neutrophils from 
healthy young individuals (n=2) were incubated with either RPMI (untreated) or 10 µM N-
Formylmethionyl-leucyl-phenylalanine (fMLP) for 20 minutes prior to antibody staining. 
The percentage of neutrophils above the 10% threshold for both CD11b and CD66b 
(section 2.x) were recorded, where error bars show interquartile range. 
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Table 3.6: Fluorecence thresholds for dim and bright gates 
Gate Channel MFI 
CD11bbright BV768 3021 
CD66bbright APC 1164 
CD16dim AF700 831 
CD62Ldim BV605 4490 
Legend: Gate threshold values for determining dim and bright populations 
  









Figure 3.17: SpheroBeads shown on FITC and APC channels  
 
One drop of SpheroBeads was added to 500uL of water and 4000 bead events collected. 
a) Beads were gated using FITC and APC as 8 clear populations can be visualized. Each of 
the 8 peaks were plotted for each channel and b) FITC and c) 7AAD are represented. 
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Table 3.7: Target MFI values from SpheroBeads.  
Fluorophore Bead Target MFI Upper limit Lower limit 
BV421 6 22500 24750 20250 
BV510 7 36020 39622 32418 
BV605 7 3270 3597 2943 
BV785 7 113674 125041 102307 
FITC 7 73805 81186 66425 
PE 7 47530 52283 42777 
AF700 7 3300 3630 2970 
APC 7 51876 57064 46688 
7AAD 7 61000 67100 54900 
Legend: Each fluorophore and corresponding target value is shown, along with upper and 
lower limits for a 10% tolerance. 
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3.3 Discussion 
Flow cytometry is a widely used technology routinely used in both research and diagnostic 
capacities (Davidson et al., 2012). At the time of writing, BioLegend (a major supplier of 
antibodies for use in flow cytometry) listed over 15000 primary antibodies designed for use in 
flow cytometry (BioLegend, 2021). There are now many commercially available fluorophores 
and advances in synthetic biology have led to many different options available to researchers 
(Martynov et al., 2016). These advances provide the opportunity to collect large amounts of 
information on an individual cell by using multiple antibodies conjugated to different 
fluorophores, but also increase the complexity in deciding what fluorophores to use. A report 
highlighted the lack of standardisation in antibody production and use (Bradbury and 
Plückthun, 2015), combined with only around half of 6000 tested antibodies recognising only 
their reported target (Berglund et al., 2008). Whilst many antibody suppliers have robust 
validation procedures, they cannot account for each individual experiment and antibody 
combination and, therefore, researchers must carry out their own validation. In this chapter, 
each antibody was individually titrated and optimised for use in two multiparameter panels 
with PE/Cy7-conjugated anti-CD16 being identified as incompatible and was replaced with an 
AF700-conjugated anti-CD16 antibody. 
3.3.1 Importance of panel design 
The selection of antibody conjugates is the first step in designing a successful multiparameter 
flow cytometry panel. The fluorophores in this panel were chosen to minimise the spectral 
spill-over from one channel to another. This ensured that individual antibodies were detected 
and is considered a fundamental principle underpinning multiparameter flow cytometry 
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(Nguyen et al., 2013). Another important reason for minimising overlap in fluorophore 
selection was to reduce the compensation required as compensation negatively impacts the 
sensitivity of detection and limits the range of the detector (Maecker et al., 2004). 
Compensation is, however, necessary in all multi-colour flow cytometry experiments and 
involves the subtraction of any fluorescence originating from a different fluorophore to the 
one being detected (Bagwell and Adams, 1993). The importance of correct compensation has 
also been highlighted in phenotyping panels and can be predicted from the fluorophores used 
(Njemini et al., 2014). Using well-separated fluorophores in this panel, therefore, increased 
the ability to accurately detect changes in surface protein expression. With larger panels, a 
reduction in sensitivity is inevitable due to the broad emission spectra seen with all 
fluorophores. To improve detection between antibodies, each fluorophore was matched to a 
target based on the fluorophore brightness and target abundance. Fluorophore brightness 
indexes are produced by multiple manufacturers and are readily available online (BioLegend, 
no date). Targets highly expressed on neutrophils, such as CXCR2, were matched with 
relatively dimmer fluorophores and low expressed targets, such as CXCR4, were matched with 
relatively bright fluorophores. The loss of sensitivity observed in 4 markers reduced the ability 
to detect small differences in these markers, but the validation steps carried out minimises 
the impact of this on downstream data analysis.  
3.3.2 Validation of specificity and antibody concentration 
Nearly all commercially available antibodies are already validated for their specificity for a 
given target and multiple processes have been described for achieving this (Marcon et al., 
2015). In this panel, the optimal concentration of each antibody was determined using a 
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titration on a cell type known to express the target. Whilst not a direct measure of antibody 
specificity, it was able to show that the target could be visualised using flow cytometry and 
enabled calculation of a staining index. The staining index is a relative measure of the ability 
to discriminate a positive population and a negative population in flow cytometry and can aid 
in selecting appropriate dilutions of antibody (Maecker et al., 2004) and a basic version using 
a three-step titration was implemented here. For the majority of antibodies tested in this 
chapter, the staining index reduced as the concentration of antibody was decreased. 
However, reduction in the spread of non-specific binding (measured using an isotype-control) 
increased this index in some cases and informed selection of a lower antibody concentration. 
As demonstrated by the data presented in this chapter, a higher concentration of antibody 
does not always increase the separation between the positive and negative population as 
higher antibody concentrations can increase non-specific binding. However, lower staining 
indexes don’t necessarily mean poor separation as they are only one tool used, and where 
clear separation is observed, lower antibody concentrations that provide a cost benefit are 
preferred. Titration of antibodies is common practice in flow cytometry experiments and is 
usually described in guides or blogs (UCFlow, 2009), but is very poorly reported in the 
literature, with many papers simply stating that it was carried out (e.g. Tanaka et al., 2004) or 
not reporting at all (e.g. Schlub et al., 2010). This may, however, be as a result of publishers 
not requiring or allowing the publication of validation data and instead assume it has been 
carried out correctly. 
So far, these two sections deal with each specific antibody and how, in theory, they will 
interact together. It is important however to experimentally validate the compatibility of 
every antibody in the panel together. 
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3.3.3 Validation of spectral overlap and antibody compatibility 
Validation of each antibody has been carried out to ensure reliable results from surface 
expression on human neutrophils is obtained. Initially, spectral overlap was suspected 
between the PE/Cy7 conjugated anti-CD16 and the detection of PE-conjugated annexin V due 
to a high percentage of annexin V positive events in a sample containing PE/Cy7-conjugated 
anti-CD16 but no annexin V. Whilst PE and PE/Cy7 fluorophores have been used together in 
many flow cytometry panels, it has been shown that PE/Cy7 shows one of the highest 
degradation rates of PE tandem dyes (Hulspas, Dombkowski, et al., 2009) and substantial spill 
over into the PE channel is reported for some antibody manufacturers (Johansson and Macey, 
2014). Particular caution with PE/Cy conjugates was also recommended from a published 
workshop on multiparameter flow cytometry as the decay time after illumination may lead to 
overlap between lasers (Bayer et al., 2007). Spectral overlap, or poorly compensated data, 
presents with a characteristic ‘arching’ of the cell population when viewed on a two-
dimensional plot (Roederer, 2001). This was observed in the PE channel in samples containing 
the PE/Cy7 tandem conjugated anti-CD16 antibody and was absent when anti-CD16 was 
excluded. Therefore, an alternative fluorophore was sought to negate spectral overlap 
between the PE fluorophore and the PE/Cy7 tandem.  
After changing PE/Cy7 for AF700-conjugated anti-CD16, further spectral compatibility was 
assessed using single-stained samples compared to staining with the whole antibody panel. 
Any increases in MFI between the single-stain and whole panel could indicate further spectral 
overlap, however, this was not observed. This step also tests the compatibility of each 
antibody in the whole panel – highlighting any potential antibody-antibody interactions. 
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Antibody cross-reactivity usually refers to the ability of an antibody to bind a specific antigen 
across different species (Moreira et al., 2015) and very little attention is given to the ability of 
antibodies to interact with each other. Apart from secondary antibodies that are specifically 
designed to bind the Fc portion of antibodies (Min et al., 2016), the literature does not report 
any antibody-antibody interactions. The European Journal for Immunology extensively 
reviewed flow cytometry practice and ensuring antibody-antibody did not exist was not 
mentioned and may also indicate how rare these events may be (Cossarizza et al., 2017). 
Chapter 4 of this thesis details the potential pitfalls if this step is omitted and therefore 
comparisons of single-stained cells against the whole panel as shown in this chapter provides 
two key benefits: recording the expected baseline expression of that particular marker and 
detecting any antibody-antibody incompatibilities.  
3.3.4 Importance of correct controls 
There has been much debate on the number and type of controls that flow cytometry 
experiments should include. As part of this validation work, isotype controls were used for 
each antibody as a means of correcting for background staining and to match many published 
papers that still report using isotype-corrected data as a relatively low-cost control. Isotype 
controls are widely used and commonly reported (Hulspas, O’Gorman, et al., 2009), but it is 
important the correct isotype is used as they can vary considerably (Maecker and Trotter, 
2006). They also have limitations and do not specifically aid the placing of gates during 
analysis. There have been many calls to move away from reliance on isotype controls, instead 
using a cell population that does not express the marker of interest (O’Gorman and Thomas, 
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1999). This is a challenge in some experimental models and may require the use of cell lines if 
there are no similar primary cells that fit this criterion.  
The move towards using FMO controls is generally a positive move, however, FMO controls 
do not serve the same purpose as isotype controls and instead aid placement of gates 
(Baumgarth and Roederer, 2000; Bayer et al., 2007). FMO controls do not provide any 
information on background staining from a particular antibody (Hulspas, O’Gorman, et al., 
2009). It is also important to distinguish between two key questions: the level of expression 
on a particular cell, determined by MFI and the percentage of cells expressing a given marker, 
identified by either a ‘positive’ or ‘negative’ cell. Isotype controls will not help discriminate 
positivity (Bayer et al., 2007) and will require an FMO control. However, distinct bi-modal 
expression as observed in CD4+ and CD8+ T cells are unlikely to require an FMO control as 
clear distinctions will exist. In a 9-colour panel, to have an FMO for each marker would require 
9 separate controls, resulting in each antibody being used 9 times – once each in other FMO 
controls, absent from its own FMO but included in the full panel of antibodies. Clearly, there 
is a large cost implication to using an FMO for each marker and therefore based on the single-
stain validation data, CXCR4 and HLA-DR, along with the viability dyes would have an FMO to 
aid with gating for positive samples. Unlike isotype controls, there is little report of them being 
used in published papers, yet are vital to ensure accurate discrimination between positive and 
negative events (Cossarizza et al., 2017).  
Again, journals may not require researchers to disclose the controls that were used in the 
experiments and papers where FMO controls are vital, for example measuring the change in 
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receptor expression in different populations (Zhang et al., 2015), do not mention the use of 
these controls. 
In this thesis, SpheroBeads are used to ensure the fluorescence intensity recorded by the flow 
cytometer between each experiment is consistent. This approach was developed by EuroFlow 
(a consortium comprised of 20 diagnostic research groups) that uses this technique to allow 
multi-centre flow cytometry of leukocytes to generate directly comparable data (Theunissen 
et al., 2017). Generating tables of MFI values, as has been done in this thesis, allows the 
replication of data on a comparable machine as each laser can be configured to give the same 
fluorescence output. Publication of these data for any flow cytometry experiment would 
greatly improve transparency and reproducibility in published work.  
3.3.5 Determining phenotypes from surface expression 
As neutrophils constitutively express markers such as CD16, CD11b and CD66b, it is not 
accurate to describe changes in these markers by the percentage of positive cells as all 
neutrophils will inherently be ‘positive’ for these markers, but instead by measuring the 
absolute fluorescence intensity. Exceptions do exist in specific genetic diseases such as 
leukocyte adhesion deficiency (LAD), where leukocytes lack surface expression of CD11 and 
CD18 (Hogg et al., 1999; Jasani, Nanavati and Kabra, 2014), but generally measuring changes 
in constitutively expressed markers must be done by fluorescence intensity. This does have 
issues, especially as the fluorescence intensity can vary with cytometer laser voltage and 
between instruments (Ashhurst and Smith, no date), putting importance on being able to 
ensure this is comparable between runs as described in the use of SpheroBeads. Ensuring a 
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stringent control on the output of the cytometer collecting the data greatly reduces sample-
to-sample variation due to technical setup.  
Some previous studies and groups have attempted to identify cell phenotypes based on either 
bright or dim expression for particular markers, including categorisation of activated 
neutrophils as being ‘bright’ for CD11b, CD66b and ‘dim’ for CD62L (Fortunati et al., 2009), or 
hypersegmented neutrophils as being CD16bright and CD62Ldim (Tak et al., 2017). Highlighting 
these populations allows the splitting of potentially functionally distinct neutrophil 
populations, however, relies on manual selection of the population that does not usually have 
a distinct separation. Considerable ambiguity can occur with this gating method and many 
publications do not show how these gates were determined, but also have different gating 
positions even within the same dataset (Zhang et al., 2015). Here, the use of MFI allows for 
determination of surface expression, whilst gating for subpopulations is performed in line with 
previously published studies, where appropriate, to supplement these data. 
3.3.6 Conclusion 
This chapter provides a detailed analysis of the construction and validation of two multi-
parameter flow cytometry panels to enable immunophenotyping of human neutrophil 
populations. Using an evidence-based and methodical approach, these experiments ensure 
that these panels have good sensitivity to detect the selected markers on the cell surface, the 
correct controls for downstream data analysis and robust measures to ensure quality control 
between samples. It also highlights potential pitfalls that could be made if this process is not 
carried out, and the shortcomings in published data that prevent transparency and 
reproducibility of data.
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4 CHAPTER 4: 
EXTENDED VALIDATION: ANTI-PD-L1 
ANTIBODY BINDS THE ALEXAFLUOR™ 
700 FLUOROCHROME 
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4.1 Brief introduction 
Programmed Death receptor protein 1 (PD-1) has been the focus of multiple cancer 
immunotherapies (Rotte, 2019) and is recognised as an important immune checkpoint 
(Dermani et al., 2019).  PD-1 is predominantly expressed on T cells and engagement of PD-1 
inhibits T cell proliferation and activation, maintaining immune tolerance in health (Keir et al., 
2008; Wei et al., 2013), and has been implicated in evasion of immune-mediated clearance of 
cancer cells (Dong, Sun and Zhang, 2015). Programmed death receptor ligand 1 (PD-L1) is the 
major ligand of PD-1 and is expressed on multiple cell types, including dendritic cells (Karwacz 
et al., 2011) and macrophages (Liu et al., 2019). PD-L1 is also expressed by certain cancers, 
where it inhibits T cell-mediated killing of the tumour cells (J. Chen et al., 2016). There is an 
evolving clinical programme to block the action of PD-L1 on T cell inhibition as a therapeutic 
in cancer therapy (Huang et al., 2015; Hahn et al., 2017). It is clear that the PD-1 axis has a role 
in the suppression of T cell function and is involved in the progression of some cancers, but 
the importance of this axis may extend to other disease areas and cell types. 
Far less is known about the expression of PD-L1 on neutrophils and its importance in 
neutrophil function in health and disease. Neutrophil PD-L1 may be of interest in inflammatory 
diseases, such as COPD, where neutrophils are abundant, but bacterial clearance appears 
reduced (Hodge and Reynolds, 2012). Moreover, it has been postulated that PD-L1 expression 
is reduced on macrophage and dendritic cells in COPD, rather than increased as in cancer 
(Stoll, Virchow and Lommatzsch, 2016). Neutrophil PD-L1 expression has also been implicated 
in other inflammatory conditions: for example, an increased proportion of PD-L1-expressing 
neutrophils have been detected in the blood of patients with SLE, and this increase positively 
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correlated with disease severity (Luo et al., 2016). Moreover, human neutrophils up-regulated 
PD-L1 expression when exposed to conditioned media from cancer-associated fibroblasts, 
leading to a reduction in T cell proliferation and increased neutrophil survival in vitro (Cheng 
et al., 2018). Furthermore, isolated blood neutrophils from patients with active tuberculosis 
infection have been reported to have elevated levels of PD-L1 surface expression compared 
to neutrophils isolated from healthy volunteers (McNab et al., 2011). Thus, current evidence 
suggests that neutrophils can express PD-L1 during infection and in chronic inflammatory 
diseases and that this heightened expression may play a role in disease pathogenesis. 
Importantly, the impact of altering the PD-1/PD-L1 axis in chronic inflammatory lung disease 
is not yet fully understood. Due to the role of PD-L1 in immunosuppression, it is possible that 
increased expression of PD-L1 on neutrophils from patients with COPD may contribute to 
reduced efficiency of bacterial clearance, or be a beneficial compensatory response to 
inflammation in these patients. However, expression by neutrophils from healthy volunteers 
and patients with COPD is largely unknown. 
4.1.1 Hypothesis and aims 
We hypothesised that PD-L1 expression could be measured in combination with other 
antibodies using flow cytometry without any changes occurring due to this procedure and that 
expression would be raised in patients with COPD. We aimed to investigate the expression 
profile of PD-L1 on neutrophils from these groups and ensure the compatibility of anti-PD-L1 
antibodies with other antibodies widely used to identify the phenotype of human neutrophils.  
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4.2 Results 
As discussed in Section 3.2.4, due to incompatibilities with PE/Cy7-conjugated anti-CD16 and 
other fluorophores in the antibody panels, identification of a suitable alternative fluorophore 
was carried out theoretically from spectral analysis. AlexaFluor™700 (AF700) was identified as 
a suitable and commercially available conjugate for anti-CD16. The AF700-conjugated anti-
CD16 (BioLegend, clone 3G8) was titrated as shown in Figure 3.11 and a dilution of 1:100 was 
selected as an appropriate concentration for antibody staining.  
4.2.1 Validation of AF700-conjugated anti-CD16  
In all experiments, the gating strategy shown in Figure 4.1 was used to identify neutrophils 
and assess viability. To validate AF700-conjugated anti-CD16 in the existing antibody panels, 
neutrophils from an elderly participant with or without COPD (see Section 2.2 for cohort 
definitions) was stained with two different but overlapping antibody panels (P1 and P2; Table 
4.1) and viability dyes in the presence or absence of the AF700-conjugated anti-CD16 
antibody. All neutrophils were detected as live when viability dyes were absent (Figure 4.2). A 
reduction in the proportion of live cells was observed in both participants when neutrophils 
were stained with AF700-conjugated anti-CD16 in addition to P1 and P2 antibody panels 
compared to neutrophils not stained with AF700-conjugated anti-CD16 (Figure 4.2). 
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4.2.2 Investigating neutrophil viability with anti-CD16 
In order to further investigate neutrophil survival when incubated with AF700-conjugated 
anti-CD16 antibody, neutrophils were isolated from HY donors and incubated with viability 
dyes with or without anti-CD16 (Figure 4.3a). There was no significant reduction in the 
percentage of live neutrophils in the presence of the viability dye and anti-CD16 antibody 
compared to those stained with the viability dyes alone. In order to mitigate an age or disease 
bias, neutrophils from HE participants (Figure 4.3b) and patients with COPD (Figure 4.3c) were 
isolated and, as with the young cohort, incubated with viability dyes with or without anti-
CD16. Again, no significant differences in the percentage of live neutrophils were observed, 
indicating antibody incubation did not significantly impact on cell viability. 
4.2.3 Investigating changes in BV605 fluorescence with anti-CD16 
Whilst no impact on cell viability was seen, it was important to ensure there were no changes 
in marker surface expression within the panel. Isolated neutrophils from an elderly individual 
without COPD (HE, Figure 4.4a) and with COPD (Figure 4.4b) incubated with AF700-conjugated 
anti-CD16 antibody led to an increase in the detected level of PD-L1 expression (BV605-
conjugated PD-L1 in P2, Figure 4.4). However, incubation with anti-CD16 did not alter the 
detected expression of CD62L (BV605-conjugated anti-CD62L in P1, Figure 4.4). In order to 
investigate whether these findings were due to spectral overlap between AF700 and BV605, 
isolated neutrophils from HY individuals were incubated with either AF700-conjugated anti-
CD16 or BV605-conjugated anti-PD-L1 antibodies alone, and the fluorescence detected in the 
AF700 and BV605 channel measured. As expected, an increase in the MFI of AF700 was 
detected when neutrophils were incubated with anti-CD16, but there was no increase in the 
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MFI of BV605 (Figure 4.5a). There was also no increase in the MFI of AF700 or BV605 when 
neutrophils were incubated with anti-PD-L1 (Figure 4.5b). These data indicated that AF700-
conjugated anti-CD16 was not spilling into the BV605 detector and that under these 
conditions, isolated neutrophils do not express detectable levels of PD-L1.   
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Figure 4.1: Representative flow cytometry plots showing gating of neutrophils and 
classification of live, apoptotic, necrotic and dead cells 
  
Isolated neutrophils are gated based on forward scatter (FSC) and side scatter (SSC) to 
remove any remaining contaminating cells. Neutrophil viability was assessed by staining 
for annexin V and 7AAD and reported as live (double negative), apoptotic (annexin V 
positive), necrotic (7AAD positive) or dead (double positive).  
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 Table 4.1: Antibodies and dyes included in each panel for validation 
of anti-CD16 
Target Fluorophore Panel 
CXCR4 BV421 1 
CD62L BV605 1 
CXCR2 FITC 1 
CD54 APC 1 
CD10 BV510 1,2 
CD11b BV786 1,2 
AnV PE 1,2 
DNA 7AAD 1,2 
HLA-DR BV421 2 
PD-L1 BV605 2 
CD11c FITC 2 
CD66b APC 2 
Legend: Each antibody or dye target is listed alongside the respective 
fluorophore and which panel it is included in as validated in Chapter 
3. 
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Figure 4.2: Viability of neutrophils with and without AF700-conjugated anti-CD16 
 
Isolated neutrophils from a) a healthy elderly (HE, n=1) and b) a patient with COPD (n=1) 
were stained with either panel 1 (P1) or panel 2 (P2) antibodies (Table 4.1) with or without 
AF700-conjugated anti-CD16 antibody and viability dyes. Stacked histograms show 
percentage of total neutrophils that are live (annexin V and 7AAD negative), apoptotic 
(annexin V positive), necrotic (7AAD positive) or dead (annexin V and 7AAD positive). 




















































































Figure 4.3: Percentage of live neutrophils from healthy young donors following staining 
with and without AF700-conjugated anti-CD16 antibody 
 
Neutrophils were isolated from a) healthy young (HY, n=6), b) healthy elderly participants 
without COPD (HE, n=4) and c) participants with COPD (n=6) and stained with viability dyes 
with or without AF700-conjugated anti-CD16. Paired data are shown for the percentage of 
live neutrophils (negative for both annexin V and 7AAD). Statistical analysis performed 
using Wilcoxon matched-pairs signed rank test. 
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Figure 4.4: BV605 median fluorescence intensity detected on neutrophils from elderly 
donors with and without COPD following incubation with and without AF700-conjugated 
anti-CD16 antibody 
  
Isolated neutrophils from a) elderly participants without COPD (HE, n=1) and b) 
participants with COPD (n=1) stained with panel 1 (P1) or panel 2 (P2) antibodies (Table 
4.1) with or without AF700-conjugated anti-CD16 and viability dyes. Median fluorescence 
intensity (MFI) shown for 5000 neutrophil events on a log(10) scale.  
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Figure 4.5: Median fluorescence intensity of AF700 and BV605 of isolated neutrophils 
stained with AF700-conjugated anti-CD16 or BV605-conjugated anti-PD-L1  
 
a and b) Representative histogram plots of (left) AF700 and (right) BV605 fluorescence of 
isolated neutrophils from healthy young (HY, n=6) unstained (US) or stained with either a) 
AF700-conjugated anti-CD16 or b) BV605-conjugated anti-PD-L1. c and d) Quantification 
of the median fluorescence intensity (MFI) of AF700 and BV605 for c) anti-CD16 or d) anti-
PD-L1. Each point represents one independent donor (total n=6 paired results) with the 
median shown. Statistical analysis performed using Wilcoxon signed-rank paired test. 
Chapter 4  Page | 144  
4.2.4 Changes detected PD-L1 expression are due to anti-CD16 
In order to assess if PD-L1 expression was influenced by anti-CD16, neutrophils from HY 
donors were incubated with AF700-conjugated anti-CD16 or BV605-conjugated anti-PD-L1 
alone or in combination and the fluorescent signal from both detection channels measured 
(Figure 4.6). Co-incubation of neutrophils with these two antibodies led to an increase in the 
MFI of AF700 (Figure 4.6b), indicating CD16 staining. Under these conditions, the MFI of BV605 
was significantly higher compared to staining with anti-PD-L1 alone (Figure 4.6c: without anti-
CD16 median MFI=193, with median MFI=4888, p=0.03). Therefore, the detected expression 
of PD-L1 was dependant on incubation with AF700-anti-CD16 antibody. 
4.2.5 Identification of alternative anti-CD16 antibodies 
Given that AF700-conjugated anti-CD16 altered the amount of PD-L1 detected on the surface 
of neutrophils, alternative clones and conjugates of commercially available anti-CD16 
antibodies (Table 4.2) were used to determine if antibody incubation altered cell viability and 
PD-L1 expression. Neutrophils from HY participants were incubated with each anti-CD16 
antibody in combination with BV605-conjugated anti-PD-L1. There was no significant 
difference in the viability of neutrophils following staining with any of the anti-CD16 
antibodies tested (Figure 4.7).  
Antibodies from eBiosciences (clone eBio-CB16, Figure 4.8a) and Invitrogen (clone 3G8, Figure 
4.8b) showed a similar increase in the detected expression of PD-L1 as with BioLegend’s anti-
CD16 (clone 3G8). In contrast, the anti-CD16 antibody from Miltenyi (clone VEP-13) did not 
demonstrate an increase in the MFI of PD-L1 (Figure 4.8c). Therefore, not all anti-CD16 
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antibodies resulted in an increase in the detected expression of PD-L1 and the underlying 
cause required further investigation.  
4.2.6 Changes in PD-L1 expression are conserved in COPD 
In order to investigate if the changes in PD-L1 expression were recapitulated by neutrophils 
from patients with COPD, isolated neutrophils from both elderly participants with and without 
COPD were incubated with different anti-CD16 antibodies as described above and the BV605-
conjugated anti-PD-L1 antibody (Figure 4.9). Similar to the healthy participant group, an 
increase in detectable expression of PD-L1 was observed when neutrophils were stained with 
the anti-CD16 antibodies from with BioLegend 3G8, eBiosciences eBioCB16 and Invitrogen 
3G8 (Figure 4.9). Whilst the same trend was observed with HE participants without COPD 
(Figure 4.9a-c), the sample number prevented this reaching statistical significance. Once again, 
there was no increase in detectable PD-L1 expression when incubated with Miltenyi VEP-13 
anti-CD16 in either participant group (Figure 4.9d,h). These data point to the possibility that 
the increase in detected PD-L1 expression was age and antibody clone independent, but 
fluorophore dependent. 
4.2.7 Changes in PD-L1 expression depend on the AF700 fluorophore 
In order to identify if the detected increase in PD-L1 was dependent on AF700, a direct 
comparison of anti-CD16 (clone eBio-CB16) conjugated to either AF700 or FITC was carried 
out. A significant increase in the detectable PD-L1 expression was observed on neutrophils 
isolated from HY donors following incubation with AF700 conjugated (Figure 4.10a), but not 
FITC-conjugated anti-CD16 antibody (Figure 4.10b), suggesting that AF700 was a key factor in 
this phenomenon. 
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4.2.8 Neutrophils do not directly engage with AF700 
To further investigate if neutrophils directly interact with AF700, neutrophils from HY 
participants were incubated with a non-specific mouse anti-human IgG1 (isotype control) 
conjugated to AF700. Incubation with anti-IgG1 demonstrated a comparable MFI of PD-L1 
(Figure 4.11 median MFI [IQR] = 178.7 [95.5-202.8]) to previous incubation with anti-PD-L1 
alone (Figure 4.6 median MFI [IQR] = 193 [182.9-203.8]). However, incubation with AF700-
conjugated anti-CD16 still resulted in an increase in the MFI of PD-L1 (Figure 4.11). These data 
highlight that AF700 alone was not responsible for the increase in PD-L1 expression and that 
neutrophils are not directly binding AF700 to give a false-positive signal.
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Figure 4.6: Median fluorescence intensity of AF700 and BV605 of isolated neutrophils 
stained with BV605-conjugated anti-PD-L1 with or without AF700-conjugated anti-CD16 
 
a) Representative histogram plots of (left) AF700 and (right) BV605 fluorescence of isolated 
neutrophils from healthy young (HY, n=6) unstained (grey), stained with BV605-conjugated 
anti-PD-L1 alone (purple trace) or in combination with AF700-conjugated anti-CD16 (green 
trace). b and c) Quantification of the median fluorescence intensity (MFI) of (b) AF700 and 
(c) BV605 on a log(10) scale. Each point represents one independent donor (total n=6 
paired results). Statistical analysis performed using Wilcoxon signed-rank paired test. 
 
 






Table 4.2: Alternative anti-CD16 antibodies 
Manufacturer Clone Fluorophore 
eBiosciences eBioCB16 AF700 
Invitrogen 3G8 AF700 
Miltenyi VEP-13 FITC 
Legend: Each anti-CD16 antibody is listed by manufacturer alongside 
the respective clone and fluorophore. 
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Figure 4.7: Viability of neutrophils incubated with different clones and suppliers of anti-
CD16 
 
Isolated neutrophils from healthy young participants (n=6) were assessed for viability using 
annexin V and 7AAD following antibody incubation. Median percentage live neutrophils 
without antibody incubation indicated by dotted grey line. Data are shown as median with 
interquartile range for n=6 individual donors. ANOVA analysis showed no significant effect 
of staining condition or manufacturer on neutrophil viability.  
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Figure 4.8: Median fluorescence intensity of BV605 with neutrophils from healthy young 
incubated with both BV605-conjugated anti-PD-L1 and anti-CD16 
  
Isolated neutrophils from healthy young participants (n=6) were incubated with anti-PD-
L1 with or without a) eBiosciences eBio-CB16, b) Invitrogen 3G8 or c) Miltenyi VEP-13 anti-
CD16. Median fluorescence intensity (MFI) of BV605 shown on a log(10) scale. * = P<0.05 
determined using Wilcoxon signed-rank paired test. 
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Figure 4.9: Median fluorescence intensity of BV605 with neutrophils from healthy elderly 
and COPD participants incubated with both BV605-conjugated anti-PD-L1 and anti-CD16  
 
Isolated neutrophils from a-d) elderly participants without COPD (n=5) or e-h) with COPD 
(n=6) were incubated with anti-PD-L1 with or without a,e) BioLegend 3G8, b,f) eBiosciences 
eBio-CB16, c,g) Invitrogen 3G8 or d,h) Miltenyi VEP-13 anti-CD16. Median fluorescence 
intensity (MFI) of BV605 shown on a log scale. Statistical analysis performed using Wilcoxon 
signed-rank paired. 
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Figure 4.10: Median fluorescence intensity of BV605 with neutrophils from healthy young 
participants incubated with anti-PD-L1 and anti-CD16  
 
Isolated neutrophils were incubated with BV605-conjugated anti-PD-L1 and either a) 
AF700-conjugated (as shown in Figure 4.8a) or b) FITC-conjugated eBiosciences eBio-CB16 
anti-CD16. Median fluorescence intensity (MFI) of BV605 shown on a log(10) scale. Each 
point represents one independent donor (a: n=6 paired results; b: n=3 paired results). 
Statistical analysis performed using Wilcoxon signed-rank paired test.  
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Figure 4.11: Median fluorescence intensity of BV605 of neutrophils from healthy young 
participants incubated with anti-PD-L1 and either AF700-conjugated anti-IgG1 or anti-
CD16 
 
Isolated neutrophils from healthy young participants (n=4) were incubated with a 
combination of AF700-conjugated IgG1, BV605-conjugated anti-PD-L1 and AF700-
conjugated anti-CD16. The median fluorescence intensity (MFI) of BV605 is shown on a 
log(10) scale. Statistical analysis performed using a Friedman test (shown) with Dunn’s 
multiple comparison. 
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4.2.9 Incubation of neutrophils with different clones of anti-PD-L1 
As the increase in the MFI of PD-L1 occurred with the AF700 fluorophore, an alternative clone 
of anti-PD-L1 was obtained to investigate direct binding of anti-PD-L1 to the AF700 
fluorophore. Neutrophils from a HY participant were incubated with AF700-conjugated anti-
CD16 (clone eBio-CB16) and either clone 29E.2A3 (BioLegend, used in all previous experiments 
conjugated to BV605) or clone 130021 (R&D Systems, conjugated to APC) of anti-PD-L1.  
As previously discussed, incubation of neutrophils with anti-PD-L1 (clone 29E.2A3) and anti-
CD16 resulted in the increase of the MFI of PD-L1 (Figure 4.12a, purple trace). When 
neutrophils were incubated with the alternative anti-PD-L1 antibody (clone 130021) and anti-
CD16, only an increase in the MFI of CD16 was observed (Figure 4.12b, dark red trace). The 
absence of increased PD-L1 signal suggested that anti-CD16 successfully and specifically binds 
CD16 on the neutrophil surface followed by binding of anti-PD-L1 (clone 29E.2A3) to the AF700 
fluorophore – an interaction that was not recapitulated with an alternative anti-PD-L1 clone. 
4.2.10 Direct binding of anti-PD-L1 clone 29E.2A3 to AF700 fluorophore 
To further investigate direct binding of clone 29E.2A3 of anti-PD-L1 to AF700, further analysis 
of previous data was performed. When isolated neutrophils from HY participants were 
incubated with anti-CD16 (BioLegend, clone 3G8) and anti-PD-L1 (BioLegend clone 29E.2A3), 
the MFI of CD16 decreased compared to incubation with anti-CD16 alone (Figure 4.13, median 
MFI [IQR] without anti PD-L1 = 1519 [1199-1713] compared with anti-PD-L1 = 1358 [1031-
1515], p=0.03). These data indicate disruption of the AF700 fluorescence signal. 
Chapter 4  Page | 155  
In order to confirm the requirement of AF700 but negate the requirement of anti-CD16 in the 
binding of anti-PD-L1 (clone 29E.2A3), an AF700-conjugated anti-CD66b antibody was 
obtained. Neutrophils from HY volunteers were incubated with anti-PD-L1 and anti-CD66b 
either separately or together as previously for anti-CD16 antibodies. An increase in the 
detected PD-L1 expression was observed on neutrophils incubated with both antibodies 
(Figure 4.14a). This increase in MFI was less than previously observed with anti-CD16 
incubation (Figure 4.6c), however, expression of CD66b appeared lower than CD16 on 
neutrophils (Figure 4.14b compared with Figure 4.6b). Incubation of neutrophils with this 
clone of anti-PD-L1 also resulted in a reduction in the MFI from CD66b compared with anti-
CD66b alone (Figure 4.14c), supporting disruption of the AF700 signal. Furthermore, 
sequential staining with anti-PD-L1 and then anti-CD16 separated with a wash step failed to 
recapitulate the increase in the expression of PD-L1 (Figure 4.14d). Together, these results 
support the direct binding of anti-PD-L1 (clone 39E.2A3) to the AF700 fluorophore.   
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Figure 4.12: Fluorescence intensity plots of both CD16 and PD-L1 of neutrophils from a 
healthy young participant incubated with anti-CD16 and two clones of anti-PD-L1  
 
Isolated neutrophils from a healthy young participant (n=1) were stained with anti-CD16 
and either anti-PD-L1 a) BioLegend clone 29E.2A3 or b) R&D Systems clone 130021. The 
flow cytometry plots of fluorescent intensity of both AF700 (CD16) and either BV605 (PD-
L1 clone 29E.2A3) or APC (PD-L1 clone 130021) are shown. Each panel shows 5000 
neutrophils from n=1 donor. 
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Figure 4.13: Median fluorescence intensity of CD16 on neutrophils from healthy young 
participants incubated with anti-PD-L1 clone 29E.2A3 and AF700-conjugated anti-CD16 
clone 3G8 antibodies 
 
Isolated neutrophils from healthy young participants (n=6) were incubated with anti-CD16 
in the presence or absence of anti-PD-L1 antibody. The median fluorescence intensity (MFI) 
of AF700 for each sample is shown on a log(10) scale. Statistical analysis performed using 
Wilcoxon signed-rank paired test. 
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Figure 4.14: Median fluorescence intensity of PD-L1 clone 29E.2A3, CD66b and CD16 of 
neutrophils from healthy young participants incubated with anti-PD-L1 and AF700-
conjugated anti-CD66b or anti-CD16 
 
Isolated neutrophils from healthy young participants (n=3) were incubated with 
combinations of anti-PD-L1 (BV605) and anti-CD66 (AF700) and the median fluorescence 
intensity (MFI) of a) BV605 or b) AF700 measured. c) MFI of AF700 in the presence or 
absence of anti-PD-L1 antibody. d) MFI of BV605 on neutrophils incubated with anti-PD-L1 
and washed prior to incubation with anti-CD16 (n=2). The median fluorescence intensity is 
shown on a log(10) scale for all plots. Statistical analysis performed using Wilcoxon signed-
rank paired test. 
Chapter 4  Page | 159  
4.3 Discussion 
PD-L1 expression by circulating immune cells has been implicated in cancer (Bocanegra et al., 
2019), and the potential role of PD-L1 in inflammatory diseases, such as COPD, required 
measurement of PD-L1 surface expression on isolated neutrophils. Flow cytometry is a widely 
used and accepted technology for addressing this question, however, it relies heavily on 
fluorescent target-specific monoclonal antibodies (Maecker and Trotter, 2006). With an array 
of different clones and fluorophores commercially available, it is generally assumed that these 
antibodies are already well-validated and ready to use in complex antibody panels without 
further end-user validation. These series of experiments were carried out to ensure that 
accurate measurement of PD-L1 expression could be determined using flow cytometry in a 
multi-parametric panel.  
As demonstrated, initially it appeared that PD-L1 expression could be induced by the binding 
of CD16 antibodies to neutrophils, raising both an issue for the measurement of baseline 
expression of PD-L1 in different patient groups, but also a potential novel signalling pathway 
in neutrophils. However, careful validation identified that the detected PD-L1 expression was 
due to a previously undescribed interaction between a specific clone of anti-PD-L1 antibody 
and the AF700 fluorophore of the CD16 antibody. These results demonstrate that failure to 
correctly validate this antibody would have led to the incorrect reporting of PD-L1 expression 
by neutrophils, undermining the accuracy of the results. Other such interactions likely exist 
given the number of commercial and specialist antibodies that are produced for flow 
cytometry.  
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4.3.1 Evidence that anti-CD16 may have caused a functional effect 
AF700 was identified as a suitable fluorophore despite having a ‘dim’ relative brightness (BD 
Biosciences, 2014), as CD16 is highly expressed on neutrophils. Introduction of AF700-
conjugated anti-CD16 antibody into the panel appeared to slightly reduce neutrophil viability 
and increase PD-L1 expression. It has previously been shown that cross-linking of the CD16 
molecule on neutrophils can initiate calcium signalling (Kimberly et al., 1990) and, therefore, 
potentially lead to PI3K activation (Chuang et al., 2000). PI3K signalling in neutrophils is linked 
with both activation of neutrophil functions and the inhibition of apoptosis (Klein et al., 2001) 
– in contrast to the slight increase in apoptosis observed in these data. Further repeats 
revealed that viability was not significantly altered, however, apparent robust induction of  
PD-L1 remained. Possible links to the PI3K signalling pathway may explain this effect as PD-L1 
expression in epithelial cells has been linked to PI3K signalling (Ritprajak and Azuma, 2015). 
Therefore, it was feasible that ligation using this anti-CD16 antibody was causing functional 
changes in these isolated neutrophils and raised concerns about the use of this anti-CD16 
antibody for subsequent analysis given the aim of our study was to measure PD-L1 expression 
without manipulation of isolated neutrophils. 
4.3.2 Are changes in PD-L1 due to fluorescence artefacts? 
Due to the chemistry of fluorophore and fluorescent molecules, spectral overlap is an 
important consideration in panel design. Given the separation of AF700 and BV605 in both 
excitation laser and emission wavelength (AF700: excitation laser 640nm, emission peak 
719nm; BV605: excitation laser 405nm, emission peak 605nm) spectral overlap between 
AF700 and BV605 was highly unlikely. Assessing each antibody in turn is the best way to ensure 
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signals are not giving false-positive results and is in line with published guidance (Maecker and 
Trotter, 2006). Following this, no evidence of spectral overlap was detected. Although this 
important step in the validation of multiparametric flow cytometry is highlighted in 
publications and technical bulletins from manufacturers (Roederer, 2001; BD Biosciences, 
2009), it is not usually included within publications or supplemental documents. Given 
spectral overlap did not explain the rise in detected PD-L1 expression and this epitope of anti-
CD16 may be functional, other manufacturers and clones of anti-CD16 were sought.  
4.3.3 Reproducibility of PD-L1 induction with participants and anti-CD16 clones  
It is known that neutrophils change with both age (Whyte et al., 1993; Sapey et al., 2014) and 
the presence of COPD (Yoshikawa et al., 2007; Hughes, Sapey and Stockley, 2019). Therefore, 
it was desirable to understand if the expression of PD-L1 in response to anti-CD16 antibody 
altered in these participant groups as differences may be indicative of alterations in activation 
pathways and protein expression. Presently, no investigations have specifically addressed age-
related changes in PD-L1 expression on any cell type, however, a meta-analysis of the efficacy 
of current PD-1 and PD-L1 inhibitors showed no difference with age (Elias et al., 2018). Based 
on the data presented here, there was a conserved ability of several anti-CD16 antibodies to 
increase the MFI of PD-L1 across these groups that suggested a fundamental response of 
neutrophils that was not altered with age or the presence of COPD.  
Furthermore, several different clones and manufacturers of anti-CD16 antibodies were also 
able to reproduce the increase in PD-L1. Patent law does not require antibody manufacturers 
to disclose or know the binding epitope of the antibody (Domeij, 2000) and, therefore, it was 
not possible to directly implicate the binding location of any anti-CD16 antibody to CD16 with 
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the increase in PD-L1. Functional antibodies do exist and are used in a variety of applications 
including activating T cells through CD3 engagement by anti-CD3 (Lécureuil et al., 2007). 
Functional antibodies are epitope-dependant (Domina et al., 2016), a notion supported by 
affinity-maturation of antibody responses in the adaptive immune system (Mishra and 
Mariuzza, 2018). Together, these provide support that these anti-CD16 antibodies may be 
giving a stimulatory signal to neutrophils. However, as the only antibody tested that did not 
produce this response was conjugated to a different fluorophore (FITC), another avenue arose 
that the effect seen was fluorophore-dependant rather than epitope-dependant.  
Of note, one study found that neutrophils phagocytosed FITC-conjugated bacteria more 
readily than green-fluorescence protein (GFP)-tagged bacteria, suggesting that fluorophores 
could influence neutrophil behaviour. Neutrophils also express an array of surface receptors 
(Futosi, Fodor and Mócsai, 2013) and it was, therefore, poignant to investigate any impact of 
the AF700 fluorophore. Mouse IgG and IgM antibodies are commonly used as isotype controls 
to measure non-specific binding (Hulspas, O’Gorman, et al., 2009) and here could be used to 
identify any functional changes due neutrophils binding the AF700 fluorophore rather than 
the antibody binding the neutrophil. However, this resulted in no detected changes due to 
AF700, prompting an investigation of alternative explanations to the increase in detected PD-
L1 expression.  
4.3.4 A novel and specific antibody binding of a fluorophore 
Previous work has identified that the conjugation of monoclonal antibodies to fluorophores 
can change their binding affinity (Szabó et al., 2018), but there does not appear to be any 
evidence suggesting monoclonal antibodies bind to both a specific antigen and a fluorophore. 
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As demonstrated, a direct head-to-head comparison of anti-CD16 fluorophore revealed 
fluorophore-dependence and that the binding of CD16 was not eliciting a change in PD-L1 
expression. Attention then turned to the anti-PD-L1 antibody and, surprisingly, revealed that 
a different clone of anti-PD-L1 did not recapitulate the increase in detected PD-L1 expression. 
Use of another AF700-conjugated antibody, CD66b, and separating anti-PD-L1 incubation with 
wash steps before AF700-conjugated anti-CD16 staining further supported the interaction 
between the 29E.2A3 clone of anti-PD-L1 and AF700. The reduction in AF700 fluorescence 
when combined with anti-PD-L1 further suggested obstruction of the AF700 fluorophore, 
however, no mention of this effect exists in the literature. Together, these data support a 
novel and unreported interaction between a target-specific monoclonal antibody, clone 
29E.2A3 anti-PD-L1 and a fluorophore, AF700.   
4.3.5 Greater validation and transparency are required in all flow cytometry experiments 
Flow cytometry is a fundamental tool to investigate the surface expression of receptors and 
ligands in immunobiology. The reliability of these data relies on antibodies that bind their 
target with specificity; that do not influence the binding of other antibodies; and are used in 
conjunction with fluorophores that can be detected separately. Despite the wide array of 
guidelines from manufacturers that highlight the importance of panel design (Edinger, no 
date; Thermo Fisher Scientific, 2017), there is no published standard for designing and testing 
custom panels. There have been improvements in tools available to researchers to improve 
the theoretical aspect of panel design (Bashratyan et al., 2017), but each individual panel 
requires real-world validation, especially as antibodies can have functional effects on the cell 
of interest, modifying signalling pathways and altering cellular phenotype (Melidoni, Dyson 
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and McCafferty, 2015). In addition, failure to account for non-specific binding, such as through 
surface Fc receptors on the cells of interest, can lead to false-positive results (Andersen et al., 
2016). The data presented in this chapter highlight this, as the use of AF700-conjugated 
antibodies in combination with anti-PD-L1 (clone 29E.2A3) without validation would lead to 
the incorrect reporting of PD-L1 expression. Importantly, this type of interaction between a 
commercial monoclonal antibody and a commonly available fluorophore has not been 
reported in the literature previously. 
Several papers and articles do describe the need for careful validation and how to use 
appropriate controls to assist in data interpretation (Maecker and Trotter, 2006; Bordeaux et 
al., 2010). Using data presented in this chapter and building upon these publications, there 
should, however, be two distinct validation steps. Firstly, each antibody should be titrated to 
determine the optimum concentration using a known positive, such as a cell known to express 
the marker of interest. Secondly, the baseline expression and fluorescence intensity for each 
marker should be established on the cell of interest in isolation. These data can then be used 
to compare any potential changes when the antibodies are combined. The benefits are 
threefold: identification of spectral overlap, antibody-antibody interactions and functional 
antibodies.  
Given the challenges of good panel design and knowledge of the consequences, clear 
strategies need to be employed to ensure accurate and reliable data are produced. There is a 
serious gap in this information provided by publications of flow cytometry data, with many 
only providing the target and fluorophore conjugate of the antibodies used, neglecting to 
identify the clone used and how it was validated. 
Chapter 4  Page | 165  
4.3.6 Summary and study limitations 
As highlighted, validation of antibodies in multi-parametric flow cytometry is required for 
reliable expression data to be obtained. Here it has been shown that incubation of isolated 
human neutrophils with both AF700-conjugated anti-CD16 and anti-PD-L1 resulted in an 
observed increase in PD-L1 expression. Through careful validation, the increase in MFI of PD-
L1 was not due to increased expression but caused by an artefact of a specific clone of anti-
PD-L1 that was capable of specifically binding the AF700 fluorophore, resulting in false-
positive detection of PD-L1 expression. However, this study does not provide direct evidence 
of this binding interaction. This could be achieved through a technique such as surface 
plasmon resonance. (Hearty, Leonard and O’Kennedy, 2012). These data presented in this 
chapter describe a novel antibody-fluorophore cross-reactivity and further highlight the 
importance of rigorous validation of antibodies used in flow cytometry to prevent false-
positive results. 
The phenotyping of neutrophils performed in this thesis needed to commence prior to the 
completion of this entire validation and, therefore, anti-CD16 was not used in conjunction 
with anti-PD-L1 in subsequent experiments. 
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5 CHAPTER 5: 
PHENOTYPING OF PERIPHERAL 
BLOOD NEUTROPHILS IN HEALTH 
AND STABLE COPD 
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5.1 Brief introduction 
There has been much debate regarding neutrophil phenotypes and subtypes, and if different 
expression of surface receptors and ligands corresponds to different functional states or 
indeed separate and unique cell subtypes, similar to those observed in other immune cells 
such as T cells (Sagiv et al., 2015; Brandau and Hartl, 2017; Christoffersson and Phillipson, 
2018; Hellebrekers, Vrisekoop and Koenderman, 2018; Rosales, 2018; Silvestre-Roig et al., 
2019). The debate is not simply about how we define neutrophils, but has wider implications 
in a disease setting to guide therapies: is a ‘subtype’ of neutrophils detrimental and can it be 
modified, or does the environment the neutrophils encounter require alteration? 
There is also a growing appreciation of the heterogeneity, both biological and clinical, of COPD, 
resulting in patients with varying degrees of lung function decline and responsiveness to 
treatment (Roy et al., 2009; Miravitlles et al., 2013). However, many studies (including clinical 
trials) do not separate patients into different subgroups based on biological differences 
(Calverley and Rennard, 2007): this may be, in part, due to the lack of understanding and 
ineffective tools to easily identify these differences. Stratification tends to be limited to clinical 
parameters, such as lung function or exacerbation frequency, that may poorly reflect the 
underlying molecular and cellular pathogenesis (Calverley and Rennard, 2007). The lack of 
stratification poses limitations when addressing the effectiveness of therapy, as patients may 
not respond to the same degree to a given drug or treatment regime due to differences in the 
underlying biology of COPD.  
Many patients with COPD commonly have other chronic inflammatory conditions, such as CVD 
and T2D, that increase the inflammatory burden in these patients (Grosdidier et al., 2014). 
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The neutrophil is one of the immune cells implicated in COPD, CVD and T2D, and alterations 
in neutrophil function within these diseases is a potential source of heterogeneity in patients 
with COPD (Hughes, McGettrick and Sapey, 2020b). Understanding the difference these co-
morbidities have on neutrophil function and phenotype could determine the potential benefit 
different therapeutic interventions have on different patient populations. 
To explore differences in neutrophil function, neutrophil phenotypes can be investigated by 
measuring the surface expression of receptors and ligands by neutrophils isolated from whole 
blood – a relatively well-established technique in both mice (Takashima and Yao, 2015) and 
humans (Millrud et al., 2017). In many cases, a specific attribute (such as activation) is 
investigated in isolation (Noguera et al., 2001). However, multiple phenotypes have been 
previously described such as immature, senescent and pro-inflammatory and can be 
investigated simultaneously using multi-parametric flow cytometry.  
This study aimed to assess multiple neutrophil phenotypes using a combination of markers 
linked to neutrophil function that may be altered in healthy ageing and COPD. This was 
achieved using two well-validated flow cytometry panels. Neutrophils were obtained from a 
cohort of well-characterised patients with stable COPD, age-matched volunteers without 
COPD (healthy age-matched controls) and HY volunteers. Patients with COPD also had the 
presence of CVD or T2D  recorded to allow stratification based on these co-morbidities. It was 
hypothesised that fundamental differences in neutrophil phenotypes exist between healthy 
people and those with COPD, especially regarding activation status and senescence. These 
differences would be exaggerated if multiple chronic inflammatory conditions were present 
in a given individual. 
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5.2 Results 
5.2.1 Sample quality control  
To ensure robust data collection, various quality control (QC) steps were performed for each 
experiment. These criteria were used to exclude any sample that did not meet these standards 
from further data analysis. 
5.2.1.1 Controlling expression measurement with SpheroBeads 
Consistent fluorescence detection from the flow cytometer was vital to record comparable 
surface expression levels across every patient sample using fluorescence intensity. To achieve 
this, SpheroBeads were used in each experiment to calibrate the laser power as established 
in Section 3.2.8, with target values for each detector determined with a tolerance of ±10% in 
line with EuroFlow guidelines (Kalina et al., 2012). Every SpheroBead preparation collected 
prior to the neutrophil sample was within the 10% tolerance for channels AF700, BV421, 
BV510, BV605, FITC and 7AAD (Figure 5.1a). In the APC channel, run NP030 exceeded the 
upper 10% limit, as did NP042 in BV605 and BV786; NP047 in BV786 and NP004 in PE (Figure 
5.1a). Samples that exceeded the tolerance in any channel were excluded from further 
analysis as the fluorescence intensity recorded was not comparable to other samples. 
5.2.1.2 Exclusion of apoptotic samples 
All samples were measured for viability and phenotype analysis was performed only on live 
cells. However, samples that contained below 25% viable neutrophils in either panel were 
excluded completely from analysis due to both low cell numbers for analysis and variations in 
the fluorescence intensity readings. Using this criterion, a total of 6 samples (7%) were 
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excluded (grey bars) from further analysis (Figure 5.1b). Remaining samples were deemed to 
have accurate fluorescence readings from a large enough sample of live neutrophils for 
phenotyping. 
5.2.2 Gating strategy 
Flow cytometry gating enabled the identification of specific neutrophil populations (Figure 
5.2a). Doublets were excluded by selecting singlets using forward-scatter (FSC) height (-H) vs 
width (-W) and then selecting the granulocyte population by FSC area (FSC-A) vs. side-scatter 
area (SSC-A). Neutrophils were identified as positive for either CD16 (panel 1, see Figure 2.3) 
or CD66b (panel 2, see Figure 2.3). Neutrophil viability was assessed using annexin V and 7-
aminoactinomycin (7AAD), where live cells were negative for both markers, apoptotic cells 
were identified as annexin V positive, necrotic (or alternative cell death) were identified as 
7AAD positive and dead cells defined as positive for both markers. This strategy was followed 
for all neutrophil flow cytometry experiments unless otherwise stated. Additional neutrophil 
phenotypes were identified by gating live neutrophil events from Figure 5.2a as shown (Figure 
5.2b-e). For individual markers, expression is shown with median fluorescence intensity as 
either nearly 100% of neutrophils were positive for a given marker (e.g. CD16) or showed the 
same outcome between the percentage positive events and MFI. 
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Figure 5.1: Sample quality control using SpheroBeads and cell viability  
 
a) Median Fluorescent Intensity (MFI) was recorded for 4000 events in each fluorescent 
channel. Each point represents a separate run (n=100). A range of ±10% from the target 
value (shown in Table 3.7) is shown by the red (+10%) and blue (-10%) dotted lines, where 
any run outside this range was labelled with the run number (NP). b) Neutrophils from 
study participants were isolated and viability measured using annexin V and 7ADD staining. 
Cells negative for both markers were considered live. Bars show mean percentage of live 
cells for n=1 participant, averaged from samples in panel 1 and panel 2, with standard 
deviation. Horizontal line indicates the 25% cut-off value for exclusion, where if either 
value was <25%, the whole sample was excluded (grey bars).  
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Figure 5.2: Gating strategy for neutrophil phenotyping 
 
Neutrophils from whole blood were isolated, stained with antibodies and a) gated for 
single cells (based on forward scatter [FSC] area [A] and height [H]), neutrophils were 
further gated based on FSC-A and side scatter (SSC) and then either CD16+ (for panel 1) or 
CD66b+ (for panel 2) events to specifically identify neutrophils. Viability was assessed using 
annexin V and 7AAD and live cells identified as double negative events. Live events were 
then gated for b) CXCR4 and CD62L, c) CD16 and CD62L, d) CXCR2 and CXCR4, and e) CD66b 
and CD11b expression. Thresholds for gates were determined as detailed in section 3.2.7. 
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5.2.3 Changes in neutrophil phenotype with ageing and COPD 
The expression of 11 surface markers on human neutrophils were measured across two flow 
cytometry panels (P1 and P2, as shown in Table 2.1). These markers were split into groups for 
analysis to assess particular neutrophil functions: activation status (CD11b, CD66b and CD62L); 
senescence (CXCR2 and CXCR4); inflammatory status (HLA-DR, PD-L1 and CD11c); reverse 
transmigration (CD54) and neutrophil maturity (CD10 and CD16). 
5.2.3.1 Patient demographics 
A total of 30 healthy volunteers and 41 patients with COPD were recruited in order to measure 
the peripheral blood neutrophil phenotype. The demographics of these participants can be 
seen in Table 5.1.  There was no significant difference in age or sex between the healthy age-
matched (HE) participants and patients with COPD (Table 5.1). Lung function was not carried 
out on healthy participants, but all had a complete absence of respiratory symptoms. A 
significant difference in smoking status was identified between HY and HE participants, with 
all HY participants being never-smokers (Table 5.1). A significant difference was also observed 
in smoking status and smoking history (measured as pack-years) between HE participants and 
patients with COPD. There was also a significant difference between the number of years HE 
participants had been ex-smokers compared to patients with COPD, with ex-smokers in the 
HE group quitting over twice as long ago. Notably, there were no current smokers in either 
healthy groups compared to 11 current smokers in the COPD group, measured from self-
reported smoking status. 
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Table 5.1: Basic demographics for healthy and unstratified stable COPD study participants 
 HY HE Stable COPD p-value 
(HY vs HE) 
p-value 
(HE vs COPD) 
Number 15 15 41   
Age, median (IQR) 27 (23.5-31) 72 (70.75-74.25) 72 (68-73) <0.01k 0.65k 
Sex, M:F 8:7 10:5 25:16 0.71f 0.76f 
Lung function 
FEV1 % predicted, median (IQR) N/A* N/A* 57 (45-67)1 - - 
FVC % predicted, median (IQR) N/A* N/A* 79 (66-98.5)1 - - 
GOLD Grade (1:2:3:4) N/A* N/A* 5:22:9:41 - - 
Smoking  
Smoking status (NS:Ex:C) 15:0:0 7:7:02 0:30:11 <0.01f <0.01f 
Pack year history, median (IQR) 0 (0-0) 0.35 (0-9.0)2 49 (34.4-77.6) - <0.01k 
Years ex-smoker, median (IQR) N/A 31.5 (14.0-48.0)2 15 (6.5-17.5) - 0.03k 
Legend: Study participants split into healthy young controls without COPD (HY), healthy age-matched controls without COPD (HE) and patients 
with stable COPD (COPD). Median with interquartile range (IQR) to one decimal place are shown where appropriate. Sex shown as a ratio of 
male (M) to female (F). GOLD Grade displayed as a ratio of stage 1:2:3:4. Smoking status shown as ratio of never(NS):ex(Ex):current(C). 
Statistical analysis carried out using Kruskal-Wallis test (k) for continuous data and Fishers Exact test (f) for categorical data. FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity. *Spirometry not performed; 1 One patient was unable to perform spirometry. 
2Data unavailable for one participant. 
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5.2.3.2 Neutrophil activation 
Contrary to the hypothesis, there was no difference in the expression of CD11b, CD66b or 
CD62L by neutrophils isolated from HY or HE participants, or from HE and those with COPD 
(Figure 5.3). However, a proportion of patients with COPD did demonstrate higher levels of 
CD11b and CD66b, indicated by a greater spread in the data (Figure 5.3a and b). 
Measuring the proportion of CD11bbrightCD66bbright neutrophils, using the gating strategy 
shown in Figure 5.2, a similar pattern was observed to the expression of each individual 
marker (Figure 5.3a and b), with no difference between neutrophils isolated from HY or HE 
participants or from HE and those with COPD (Figure 5.4). Again, a small proportion of patients 
with COPD show a higher percentage of CD11bbrightCD66bbright neutrophils compared to both 
healthy groups (Figure 5.4). These data do not support the hypothesis that peripheral 
neutrophils from patients with COPD have an activated phenotype. 
To assess the relationship between these activation markers, linear regression analysis was 
performed between CD11b and CD66b (Figure 5.5a). A significant positive correlation 
between CD11b and CD66b was observed (Figure 5.5a), supporting the use of CD11b and 
CD66b double-positive events to identify neutrophil activation.  














































Figure 5.3: Median fluorescence intensity of activation markers of isolated neutrophils 
from healthy young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) CD11b, b) CD66b or c) CD62L for each 
participant group (HY n=15; HE n=15, COPD n=41). In each case, the horizontal line 
indicates the median value. Statistical analysis performed using Kruskal-Wallis (KW) with 
Dunn’s multiple comparison (indicated between groups).  

























Figure 5.4: Percentage of CD11bbrightCD66bbright live neutrophils isolated from healthy 
young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the percentage 
of CD11bbrightCD66bbright live neutrophils (see Figure 5.2) recorded for each participant 
group (HY n=15; HE n=15, COPD n=41). In each case, the horizontal line indicates the 
median value. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s 
multiple comparison (indicated between groups). 
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Figure 5.5: Correlation of activation markers on neutrophils from healthy young (HY), 
elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) of CD11b and CD66b recorded for each participant group (HY 
n=15; HE n=15, COPD n=41). The correlation between CD11b expression and CD66b is 
shown. Linear regression (solid line) is shown with 95% confidence intervals (dotted line). 
The goodness of fit (r2) and p-values are indicated for the linear regression. 
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5.2.3.3 Neutrophil senescence 
Other studies indicate neutrophil senescence can be identified by a loss of CXCR2 and rise in 
CXCR4 levels. No difference in CXCR2 expression was observed between neutrophils isolated 
from HY or HE (Figure 5.6a). In contrast, neutrophils from patients with COPD showed, on 
average, a 12% reduction in CXCR2 expression (Figure 5.6b) compared with neutrophils from 
HE participants that negatively correlated with CD11b expression (Figure 5.6c). This change 
was not accompanied by an increase in CXCR4 expression, as comparable expression of CXCR4 
was observed on neutrophils from all groups. These data indicate an altered neutrophil 
phenotype in patients with COPD, due to altered CXCR2 expression that correlated with 
activation, but not one consistent with senescence. 
5.2.3.4 Neutrophil overactive senescence 
A study of patients with ischemic stroke identified an increase in a population of neutrophils 
with CXCR4 expression and low CD62L expression, termed overactive senescent neutrophils 
(Weisenburger-Lile et al., 2019). Neutrophils that expressed CXCR4 combined with low levels 
of CD62L were gated (CXCR4+CD62Ldim, Figure 5.2b) and the percentage of CXCR4+CD62Ldim 
events measured (Figure 5.7). No significant differences were identified between neutrophils 
isolated from HY and HE participants, or between HE and patients with COPD. However, there 
was a significant change across the groups as a whole, suggesting overactive senescent 
neutrophils may play a role in ageing and COPD, but further work is needed.  
  




















































Figure 5.6: Median Fluorescence Intensity of senescence markers of isolated neutrophils 
from healthy young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) CXCR2 or b) CXCR4 for each participant group 
(HY n=15; HE n=15, COPD n=41). In each case, the horizontal line indicates the median 
value. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s multiple 
comparison (indicated between groups). c) The correlation between CD11b and CXCR2 
expression. Linear regression (solid line) is shown with 95% confidence intervals (dotted 
line). The goodness of fit (r2) and p-values are indicated for the linear regression. 
 
 
























Figure 5.7: Percentage of CXCR4+CD62Ldim live neutrophils isolated from healthy young 
(HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the percentage 
of CD16+CD62Ldim live neutrophils (see Figure 5.2) recorded for each participant group (HY 
n=15; HE n=15, COPD n=41). The horizontal line indicates the median value. Statistical 
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5.2.3.5 Neutrophil inflammatory status 
In order to assess neutrophil inflammatory status, the expression of HLA-DR, PD-L1 and CD11c 
were measured. In all three markers, no difference in expression was observed between 
neutrophils isolated from HY, HE or patients with COPD (Figure 5.8), with a comparable spread 
in all groups and markers. These data suggest that neutrophils do not change their anti-
inflammatory or pro-inflammatory status in either healthy ageing or COPD. 
5.2.3.6 Neutrophil reverse transmigration 
In order to assess neutrophil reverse transmigration, the expression of CD54 was measured. 
Again, no difference in expression was observed between neutrophils isolated from HY, HE or 
patients with COPD (Figure 5.9), with a comparable spread in all groups. The absence of a 
change in CD54 expression suggests there is not an increase in reverse transmigrated 
neutrophils in healthy ageing or patients with COPD.  
5.2.3.7 Neutrophil maturity 
In order to assess neutrophil maturity, the expression of CD10 and CD16 was measured. No 
difference in CD10 expression was observed between neutrophils isolated from HY, HE or 
patients with COPD (Figure 5.10a). A small proportion of neutrophils from patients with COPD 
showed around an 80% increase in CD10 expression compared to the median expression of 
other patients (Figure 5.10a). A small, but statistically insignificant, increase in CD16 
expression was observed between HY and HE participants (Figure 5.10b). However, a 
significant decrease in CD16 expression, on average by 16%, in neutrophils from patients with 
COPD compared to HE participants (Figure 5.10b). Together, these data suggest there is no 
difference in neutrophil maturity between HY and HE participants, but there may be a small 
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increase in circulating immature neutrophils in patients with COPD compared to HE 
volunteers, but there is large heterogeneity in this patient population. The change in CD16 in 
patients with COPD does not follow the same trend as between HY and HE participants, 
suggesting the difference may not reflect a pathogenic or accelerated ageing change.  
 













































Figure 5.8: Median Fluorescence Intensity of inflammatory markers of isolated 
neutrophils from healthy young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) HLA-DR, b) PD-L1 or c) CD11c for each 
participant group (HY n=15; HE n=15, COPD n=41). In each case, the horizontal line 
indicates the median value. Statistical analysis performed using Kruskal-Wallis (KW) with 





















Figure 5.9: Median Fluorescence Intensity of CD54 of isolated neutrophils from healthy 
young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity measured for CD54 for each participant group (HY n=15; HE n=15, 
COPD n=41). The horizontal line indicates the median value. Statistical analysis performed 
using Kruskal-Wallis (KW) with Dunn’s multiple comparison (indicated between groups). 































Figure 5.10: Median Fluorescence Intensity of CD10 and CD16 of isolated neutrophils 
from healthy young (HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) CD10 or b) CD16 for each participant group 
(HY n=15; HE n=15, COPD n=41). In each case, the horizontal line indicates the median 
value. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s multiple 
comparison (indicated between groups). 
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5.2.3.8 Hypersegmentation 
Previous studies have identified hypersegmented neutrophils by CD16+CD62Ldim expression, 
with potential functional defects in this population (Pillay et al., 2012). Neutrophils that 
expressed CD16 and low levels of CD62L were gated (Figure 5.2c) and the percentage of 
CD16+CD62Ldim events measured (Figure 5.11). A trend of increasing hypersegmented 
neutrophils was observed, with lowest levels in HY participants, increasing with age (HE) and 
further with the presence of COPD (Figure 5.11), however, this was not statistically significant. 
Sample heterogeneity may mask this change, but suggests that neutrophil hypersegmentation 
may be increased with age, and further in COPD, linking with the overall hypothesis of 
accelerated ageing. 
5.2.3.9 Key correlations with clinical parameters 
Clinically relevant parameters are important in guiding patient care and help identify the 
severity of COPD. Using CD11b to investigate correlations with activation status, there was no 
correlation between smoking history and neutrophil CD11b expression or CXCR2 expression 
(Figure 5.12a and c). However, there was a weak significant correlation between FEV1 and 
CD11b expression, suggesting that lower lung function was associated with lower levels of 
peripheral neutrophil activation – although further investigation would be necessary to 
confirm and understand this finding. No correlation was seen with lung function and CXCR2 
expression (Figure 5.12d). There was no difference in CD11b expression on neutrophils from 
patients who were current or ex-smokers (Figure 5.13a), or between GOLD Grades (Figure 
5.13b). 
























Figure 5.11: Percentage of CD16+CD62Ldim live neutrophils isolated from healthy young 
(HY), elderly (HE) and patients with COPD 
 
Neutrophils from whole blood were isolated, stained with antibodies and the percentage 
of CD16+CD62Ldim live neutrophils (see Figure 5.2) recorded for each participant group (HY 
n=15; HE n=15, COPD n=41). The horizontal line indicates the median value. Statistical 
analysis performed using Kruskal-Wallis (KW) with Dunn’s multiple comparison (indicated 
between groups). 
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Figure 5.12: Correlation of CD11b and CXCR2 expression with lung function and smoking 
history 
 
Neutrophils from HE (n=15) and COPD (n=41) whole blood were isolated, stained with 
antibodies and the fluorescence intensity of CD11b and CXCR2 measured. The correlation 
between CD11b median fluorescence intensity (MFI) and a) pack years and b) forced 
expiratory volume in one second (FEV1) in litres (L) or CXCR2 MFI with c) pack years and d) 
smoking history are shown. In each case, linear regression (solid line) is shown with 95% 
confidence intervals (dotted line). The goodness of fit (r2) and p-values are indicated for 
each linear regression. 









































Figure 5.13: Comparisons of CD11b expression with smoking status and GOLD Grade 
 
Neutrophils from patients with COPD (n=41) whole blood were isolated, stained with 
antibodies and the median fluorescence intensity (MFI) of CD11b measured. The 
expression of CD11b was grouped by a) smoking status and b) GOLD Grade. In each case, 
the horizontal line indicates the median value with interquartile range. Statistical analysis 
performed using a) unpaired t-test or b) Kruskal-Wallis test. 
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5.2.4 Changes in neutrophil phenotype in multimorbidity 
As highlighted in the introduction, heterogeneity exists between patients with COPD. A 
potential source of this heterogeneity is the presence of multiple chronic inflammatory 
diseases in a single patient – often referred to as multimorbidity. To investigate how 
neutrophil phenotypes may be altered in multimorbid patients, the cohort of patients with 
COPD was sub-divided into patients with known and clinically diagnosed T2D and CVD. 
Stratification of patients with COPD in this way may identify potential reasons for the 
heterogeneity seen in COPD. As before, neutrophil phenotypes were identified by surface 
expression: activation status (CD11b, CD66b and CD62L); senescence (CXCR2 and CXCR4); 
inflammatory status (HLA-DR, PD-L1 and CD11c); reverse transmigration (CD54) and 
neutrophil maturity (CD10 and CD16).  
5.2.4.1 Participant demographics 
The demographics for healthy age-matched participants and patients with COPD are shown in 
Table 5.2 – note that these patients with COPD are the same patients presented as a group in 
Section 5.2.3. There was no significant difference in age, or sex between any participant group 
(Table 5.2). There was a significant change in both FVC % predicted and GOLD Grade in 
patients with COPD, with those patients with all conditions (COPD, CVD and T2D) having a 
reduced FVC and more patients in GOLD Grade 3 (Table 5.2). Patients with all conditions also 
had a greater smoking history. There was no difference in the ex-smoker years (Table 5.2). 
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Table 5.2: Basic demographics for study participants, divided by co-morbidity for patients with stable COPD 
 HE Stable COPD  Stable COPD  
+CVD 





Number 15 15 12 8 6 - 
Age, median (IQR) 72 (70.75-74.25) 69 (66.0-72.0) 72 (70.3-74.3) 73.5 (67.5-76.0) 72 (67.3-79.5) 0.42k 
Sex, M:F 10:5 9:6 7:5 4:4 5:1 0.79f 
Lung function 
FEV1 % predicted, median (IQR) N/A 59.5 (48.8-65.5)1 66.5 (47.8-93.3) 56.0 (43.5-71.5) 39.5 (31.8-53.8) 0.15k 
FVC % predicted, median (IQR) N/A 94.0 (71.0-107)1 93.5 (74.0-109) 82.5 (76.5-94.3) 60.5 (39.0-67.5) 0.01k 
GOLD Grade N/A 0:11:2:11 4:5:2:1 1:5:1:1 0:1:4:1 0.04f 
Smoking  
Smoking status  7:7:02 0:10:5 0:11:1 0:5:3 0:5:1 <0.01f 
Pack year history, median (IQR) 0 (0-6.75)2 48.9 (22.8-89.0) 40 (22.0-65.0) 47 (35.0-55.0) 80 (47.8-116) <0.01k 
Years ex-smoker, median (IQR) 31.5 (14.0-48.0)2 17.0 (8.0-30.5) 15.5 (8.5-21.0) 7.0 (6.0-9.0) 15.0 (8.5-18.5) 0.13k 
Legend: Study participants split into healthy age-matched controls without COPD (HE), patients with only stable COPD (COPD) and those also with a 
cardiovascular disease (+CVD), type-2 diabetes (+T2D) or both (+CVD+T2D). Median with interquartile range (IQR) to one decimal place are shown where 
appropriate. Sex shown as a ratio of male (M) to female (F). GOLD Grade displayed as a ratio of stage 1:2:3:4. Smoking status shown as ratio of 
never(NS):ex(Ex):current(C).  Statistical analysis carried out using Kruskal-Wallis test (k) for continuous data and Fishers Exact test (f) for categorical data. 
FEV1, forced expiratory volume in one second; FVC, forced vital capacity. 11 patient was not able to perform spirometry. 2Data unavailable for one 
participant. 
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5.2.4.2 Neutrophil activation in multimorbidity 
In order to assess activation status, the expression of CD11b, CD66b and CD62L were 
measured. There was no difference in the expression of CD11b, CD66b or CD62L by 
neutrophils between HE participants or COPD patients with any co-morbidity (Figure 5.14). A 
few patients in each of the COPD groups showed higher CD11b expression compared to the 
HE group (Figure 5.14a), however, this trend was not reproduced for CD66b or CD62L (Figure 
5.14b and c). Investigating the proportion of cells displaying a CD11bbrightCD66bbright 
phenotype, no significant difference was observed between HE participants and any of the 
COPD groups (Figure 5.15). All groups tested showed a low percentage of 
CD11bbrightCD66bbright neutrophils (Figure 5.15), suggesting that systemic activation is 
comparable across all groups tested, but this observation may be hindered by the low sample 
number within the most multimorbid group (COPD with CVD and T2D).  
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Figure 5.14: Median fluorescence intensity of activation markers on isolated neutrophils 
from healthy elderly (HE) and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the median fluorescence intensity (MFI) 
measured for a) CD11b, b) CD66b or c) CD62L. In each case, the horizontal line indicates 
the median value with interquartile range. Statistical analysis performed using Kruskal-
Wallis (KW) with Dunn’s multiple comparison, all compared to HE. 
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Figure 5.15: Percentage of CD11bbrightCD66bbright live neutrophils isolated from healthy 
elderly (HE) and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Live neutrophils were gated based on CD11b and CD66b expression to determine the 
percentage of high-expressing neutrophils (see Figure 5.2). In each case, the horizontal line 
indicates the median value with interquartile range. Statistical analysis performed using 
Kruskal-Wallis (KW) with Dunn’s multiple comparison, all compared to HE. 
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5.2.4.3 Neutrophil senescence 
Patients with COPD were stratified based on their co-morbidities to identify if the reduction 
in CXCR2 expression was altered by multimorbidity. No significant decrease in CXCR2 
expression was observed between HE participants and patients with COPD and no known co-
morbidities, or with those with COPD and T2D (Figure 5.16a). However, a decrease in CXCR2 
expression was observed between HE participants and patients with COPD and CVD, and 
patients with COPD, CVD and T2D (Figure 5.16a). This change was not accompanied by an 
increase in CXCR4 expression, as comparable expression of CXCR4 was observed on 
neutrophils from all groups (Figure 5.16b). Of note, a statistically significant decrease in CXCR2 
was still observed when analysing all the COPD groups collectively (Figure 5.16a). These data 
highlight that not all patients with COPD show an equal reduction in CXCR2 expression, 
indicating potential biological differences between these patient groups.  
5.2.4.4 Overactive senescent neutrophils 
In order to assess neutrophils that may display an overactive senescent phenotype, the 
expression of CXCR4 and CD62L was measured. Neutrophils that expressed CXCR4 combined 
with low levels of CD62L were gated (Figure 5.2b) and the percentage of CXCR4+CD62Ldim 
events measured (Figure 5.17). No significant differences were identified between HE 
participants and any of the patient populations with COPD. However, two patients with both 
COPD and T2D had more than 10% of neutrophils identified with this phenotype. Overall, 
these data support that the proportion of overactive senescent neutrophils is not altered by 
multimorbidity, but a small subset of patients may display this phenotype and could warrant 
further investigation. 
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Figure 5.16: Median fluorescence intensity of senescence markers on isolated 
neutrophils from healthy elderly (HE) participants and patients with COPD alone or with 
co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the median fluorescence intensity measured 
for a) CXCR2 or b) CXCR4. In each case, the horizontal line indicates the median value with 
interquartile range. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s 
multiple comparison, all compared to HE. 
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Figure 5.17: Percentage of CXCR4+CD62Ldim live neutrophils isolated from healthy elderly 
(HE) participants and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the percentage of CD16+CD62Ldim live 
neutrophils recorded (see Figure 5.2). In each case, the horizontal line indicates the median 
value with interquartile range. Statistical analysis performed using Kruskal-Wallis (KW) 
with Dunn’s multiple comparison, all compared to HE. 
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5.2.4.5 Neutrophil inflammatory status 
In order to assess neutrophil inflammatory status, the expression of HLA-DR, PD-L1 and CD11c 
were measured. In all three markers, no difference in expression was observed between 
neutrophils isolated from HE participants and any of the COPD groups (Figure 5.18). 
5.2.4.6 Neutrophil reverse transmigration 
In order to assess neutrophil reverse transmigration, the expression of CD54 was measured. 
Again, similar levels of CD54 expression was observed between neutrophils isolated from HE 
participants or patients with COPD irrespective of other diseases (Figure 5.19). 
5.2.4.7 Neutrophil maturity 
Neutrophil maturity was investigated by measuring the expression of CD10 and CD16. No 
difference in CD10 expression was observed between neutrophils isolated from HE 
participants or patients with COPD alone or with co-morbidities (Figure 5.20a). As seen in 
Figure 5.10, a proportion of neutrophils from patients with COPD showed lower CD10 
expression, and whilst statistically insignificant here, patients with COPD and T2D (with or 
without CVD) showed relatively lower levels of CD10 (Figure 5.20a). The lack of statistical 
significance may be due to number of patients recruited but suggests there may be increased 
numbers of circulating immature neutrophils in these patient groups. 
A small and statistically significant decrease was observed in CD16 expression between HE 
participants and patients with COPD alone (p=0.03) and patients with COPD and T2D (<0.01, 
Figure 5.20b). CD16 expression was reduced, on average, by 18% in neutrophils from patients 
with COPD and 31% in patients with COPD and T2D compared to HE participants (Figure 
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5.20b). In contrast, patients with COPD and CVD or both CVD and T2D did not show the same 
decrease, highlighting differences in CD16 expression for particular multimorbid groups. 
5.2.4.8 Hypersegmentation 
In order to assess neutrophil hypersegmentation, the expression of CD16 and CD62L was 
measured. Neutrophils that expressed CD16 and low levels of CD62L were gated (Figure 5.2c) 
and the percentage of CD16+CD62Ldim events measured (Figure 5.21). Whilst no significant 
differences were identified, the percentage of CD16+CD62Ldim neutrophils varied between the 
different populations tested, with the lowest levels observed in patients with COPD and CVD 
and the highest in patients with COPD and T2D. These data suggest hypersegmented 
neutrophils may be absent in patients with COPD and CVD, but variation makes this 
observation unclear. 
5.2.4.9 Key correlations with clinical parameters 
Neutrophil phenotypes that correlate with clinical parameters could indicate a functional link 
for further investigation, as the study carried out here is underpowered to draw strong 
conclusions. Lung function is one such important clinical parameter and may link with 
neutrophil functions leading to lung damage. Using CD11b as a marker of activation, there was 
no statistically significant correlation between neutrophil CD11b expression and smoking 
history (Figure 5.22a) or FEV1 (Figure 5.22b) in any patient population. However, there was a 
weak negative correlation between smoking history and CD11b expression for patients with 
COPD, CVD and T2D, suggesting a higher pack year history may be related to lower neutrophil 
activation, albeit with very low numbers in this group, yet highlighting differences between 
patients with COPD based on multimorbidity.  
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Again, there were no significant correlations with FEV1 and CXCR2 (Figure 5.23a) or CD16 
(Figure 5.23b) expression. Of note, the most multimorbid group (COPD with CVD and T2D) 
seemed to show the opposite correlation to the group with only COPD. In addition, both 
patients with COPD alone and COPD with T2D showed lower CD16 expression compared to 
HE participants (Figure 5.20b) and patients with both COPD and T2D showed a weak negative 
correlation between CD16 expression and FEV1 (Figure 5.23b). These data suggest that higher 
CD16 expression is associated with reduced lung function in patients without CVD, although 
further investigation is necessary.  
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Figure 5.18: Median fluorescence intensity of inflammatory markers on isolated 
neutrophils from healthy elderly (HE) and patients with COPD alone or with co-
morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the median fluorescence intensity (MFI) 
measured for a) HLA-DR, b) PD-L1 or c) CD11c. In each case, the horizontal line indicates 
the median value with interquartile range. Statistical analysis performed using Kruskal-
Wallis (KW) with Dunn’s multiple comparison, all compared to HE. 
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Figure 5.19: Median fluorescence intensity of CD54 on isolated neutrophils from healthy 
elderly (HE) and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the median fluorescence intensity (MFI) 
measured for CD54. In each case, the horizontal line indicates the median value with 
interquartile range. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s 
multiple comparison, all compared to HE. 
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Figure 5.20: Median fluorescence intensity of maturity markers on isolated neutrophils 
from healthy elderly (HE) and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12)), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the median fluorescence intensity (MFI) 
measured for a) CD10 or b) CD16. In each case, the horizontal line indicates the median 
value with interquartile range. Statistical analysis performed using Kruskal-Wallis (KW) 
with Dunn’s multiple comparison, all compared to HE. 
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Figure 5.21: Percentage of CD16+CD62Ldim live neutrophils isolated from healthy elderly 
(HE) participants and patients with COPD alone or with co-morbidities 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
Neutrophils were stained with antibodies and the percentage of CD16+CD62Ldim live 
neutrophils measured. In each case, the horizontal line indicates the median value with 
interquartile range. Statistical analysis performed using Kruskal-Wallis (KW) with Dunn’s 
multiple comparison, all compared to HE. 
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Figure 5.22: Preliminary assessment of CD11b expression on neutrophils from patients 
with COPD, stratified by co-morbidities, with lung function and smoking history 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
The correlation between CD11b expression and a) pack years and b) forced expiratory 
volume in one second (FEV1) in litres (L) are shown. In each case, linear regression (solid 
line) is shown with 95% confidence intervals (dotted line). The goodness of fit (r2) and p-
values are indicated for each linear regression. 





























































































































































Figure 5.23: Preliminary assessment of CXCR2 and CD16 expression on neutrophils from 
patients with COPD, stratified by co-morbidities, with lung function 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) participants 
or patients with COPD (split into those with COPD alone (n=15), COPD with cardiovascular 
disease (+CVD; n=12), type-2 diabetes (+T2D; n=8), or both conditions (+CVD +T2D; n=6). 
The correlation between forced expiratory volume in one second (FEV1) and a) CXCR2 or 
b) CD16 expression. In each case, linear regression (solid line) is shown with 95% 
confidence intervals (dotted line). The goodness of fit (r2) and p-values are indicated for 
each linear regression. 
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5.2.5 Unassisted analysis using t-Distributed Stochastic Neighbor Embedding (t-SNE) and 
Rphenograph clustering 
Investigating surface expression using MFI and manual gating strategies provide useful 
knowledge-driven analyses, however, there are pitfalls to these approaches with complex 
data sets. Primarily, it is not possible to investigate every possible expression profile, nor 
would this be a robust analysis approach. Dimension-reduction algorithms have been 
developed that enable multi-parameter datasets, such as those where there is expression of 
multiple markers on an induvial cell, to be clustered incorporating all these dimensions and 
visualised in a 2D plot.  
Here, t-SNE visualisation with a clustering algorithm called Rphenograph was utilised to 
perform multi-dimension analysis of gated live neutrophils (Section 2.6.3) in the same 
combinations as presented in this chapter: HY, HE and COPD participants; HE and COPD 
participants stratified based on co-morbidities. These analyses provided a t-SNE plot, showing 
the distribution cells based on the similarities of the clusters (the closer together, the more 
similar the clusters), and quantification of the percentage of cells from each sample within 
each cluster. The expression of each marker for each cluster can also be quantified. 
Broadly speaking, limited differences were identified using these analyses for any of the 
groups, owing to small absolute differences between the populations studied (HY, HE and 
COPD; HE compared with COPD stratified based on multimorbidity), despite statistical 
significance. However, these data still provide an interesting insight into the heterogeneity of 
neutrophils in these different participant groups and will now be described in turn with the 
aforementioned caveats. 
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5.2.5.1 Rphenograph analysis of healthy participants and all patients with COPD  
Analysis of neutrophils from HY and elderly participants alongside patients with COPD a total 
of 25 clusters for panel 1 (Figure 5.24a). There was no clear separation between any of these 
clusters, with small regions with a higher expression for CXCR2, CD11b, CD62L, CD52 and CD10 
(Figure 5.24b). Of note, regions with higher CD11b expression overlay regions with greater 
CD10 expression and lower CD62L expression (Figure 5.24b). There was a homogenous 
distribution of CXCR2 and CD16 in these plots (Figure 5.24b). These indicate a correlation 
between CD11b expression and CD10 expression, but generally a uniform expression profile 
between all neutrophils. 
For panel 2, a total of 28 clusters were identified (Figure 5.25a), again very closely related with 
only clear regions of very low PD-L1 expression separating from neighbouring clusters (Figure 
5.25b). Similarly to the analysis of panel 1, regions of higher CD11b expression appear to 
overlay with higher CD10 expression, CD11c expression and to a lesser extent CD66b 
expression (Figure 5.25b). These data support a correlation between CD11b and CD66b 
expression, but also that CD11c and CD10 expression may also associate with these changes 
on individual cells. 
Taking these clusters, it is possible to separate out the participant groups to see if neutrophils 
within any given cluster comprise a greater or lesser amount of the total neutrophil 
population. Complete cluster percentages for panel 1 (Figure 5.26a) and panel 2 (Figure 5.26b) 
show very similar proportions, but statistically significant differences are highlighted in Figure 
5.26c and d. As shown, patients with COPD had a higher proportion of neutrophils in cluster 4 
and a lower proportion in cluster 21 compared to HE participants from panel 1 (Figure 5.26c) 
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– but with a median percentage change of <1% and 2% respectively. Within panel 2, 
neutrophils from patients with COPD had a greater proportion of neutrophils in cluster 4 and 
a lower proportion in cluster 9 and 15 (Figure 5.26d), with median percentage changes of 2%, 
<1% and <1% respectively. Overall, whilst statistically significant changes were identified, the 
absolute change between groups was very small and comparisons between these expression 
profiles within these clusters are not shown. 
5.2.5.2 Rphenograph analysis of healthy elderly participants and patients with COPD 
stratified based on co-morbidities 
The same analysis was performed as above (Section 5.2.5.1) for neutrophils from HE 
participants and those with COPD, this time stratified post-analysis based on their 
multimorbidity status. A total of 25 clusters were identified from panel 1 (Figure 5.27a). Again, 
regions with higher CD11b expression overlayed regions with greater CD10 expression (Figure 
5.27b). There was a homogenous distribution of CXCR2 and CD16 in these plots (Figure 5.27b). 
These indicate a correlation between CD11b expression and CD10 expression, with only subtle 
differences between each cluster. 
For panel 2, a total of 24 clusters were identified (Figure 5.28a), again very closely related with 
only clear regions of very low PD-L1 expression clearly separating neighbouring clusters 
(Figure 5.28b). Regions of higher CD11b expression appeared to overlay with higher CD10 
expression, and additionally with CD11c expression and to a lesser extent CD66b expression 
(Figure 5.25b), supporting a correlation between these markers on individual cells. 
Quantification of the percentage of neutrophils within each cluster revealed broadly similar 
numbers between participant groups (Figure 5.29a and b). Three clusters from panel 1 (Figure 
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5.29a) and two from panel 2 (Figure 5.29b) showed statistically significant differences 
between groups and are highlighted in Figure 5.29c and d respectively. These differences, 
however, represent very small changes and are likely due to the lack of spread within the HE 
participant group. Both cluster 12 from panel 1 (Figure 5.29c) and cluster 4 from panel 2 
(Figure 5.29d) show that the most multimorbid patients have higher proportions of 
neutrophils in these clusters. Comparing the expression profiles of these clusters to the other 
clusters within the panel, cluster 12 (panel 1; Figure 5.30a) showed slightly lower expression 
of CD10 and cluster 4 (panel 2; Figure 5.30b) was the higher end for CD11b and CD66b 
expression. Together, these may suggest more immature or activated neutrophils in the 
circulation of patients with COPD, CVD and T2D. 
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Figure 5.24: tSNE analysis of surface expression of markers from antibody panel 1 for 
healthy young, elderly and COPD participants clustered using Rphenograph 
 
Neutrophils from whole blood were isolated from healthy young (HY; n=15), healthy 
elderly (HE; n=15) or patients with stable COPD (sCOPD; n=41), stained with panel 1 
antibodies and gated for live cells. Live neutrophils from each sample were then analysed 
using tSNE and Rphenograph clustering based on surface marker expression. Clusters are 
presented for a) each participant group coloured by cluster number or b) combined 
relative surface expression, where red indicates high expression. 




Figure 5.25: tSNE analysis of surface expression of markers from antibody panel 2 for 
healthy young, elderly and COPD participants clustered using Rphenograph 
 
Neutrophils from whole blood were isolated from healthy young (n=15), healthy elderly 
(n=15) or patients with stable COPD (n=41), stained with panel 2 antibodies and gated for 
live cells. Live neutrophils from each sample were then analysed using tSNE and 
Rphenograph clustering based on surface marker expression. Clusters are presented for a) 
each participant group coloured by cluster number or b) combined relative surface 
expression, where red indicates high expression. 
 



























































































Figure 5.26: Cluster abundance of neutrophils from healthy young, elderly and patients 
with COPD following Rphenograph cluster analysis 
 
Neutrophils from whole blood were isolated from healthy young (HY; n=15), healthy 
elderly (HE; n=15) or patients with stable COPD (n=41), stained with panel 2 antibodies and 
gated for live cells. The percentage of live neutrophils identified within each cluster  (Figure 
5.24 and Figure 5.25) are shown for a) panel 1 and b) panel 2. Statistically significant 
changes in cluster percentages between groups are shown in more details for c) cluster 4 
and 21 from panel 1 and d) cluster 4, 9, and 15 from panel 2. In each case, horizontal lines 
indicate the median with the interquartile range. Statistical analysis on cluster percentages 
were performed using two-way ANOVA with Dunnett’s multiple comparisons compared to 
the HE group.  
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Figure 5.27: tSNE analysis of surface expression of markers from antibody panel 1 for 
healthy elderly and COPD participants, stratified by multimorbidity, clustered using 
Rphenograph 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) or patients 
with COPD and either no co-morbidities (n=15); with CVD (n=12); T2D (n=9) or CVD and 
T2D (n=6). Neutrophils were stained with panel 1 antibodies and gated for live cells. Live 
neutrophils from each sample were then analysed using tSNE and Rphenograph clustering 
based on surface marker expression. Clusters are presented for a) each participant group 
coloured by cluster number or b) combined relative surface expression, where red 
indicates high expression. 
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Figure 5.28: tSNE analysis of surface expression of markers from antibody panel 2 for 
healthy elderly and COPD participants, stratified by multimorbidity, clustered using 
Rphenograph 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) or patients 
with COPD and either no co-morbidities (n=15); with CVD (n=12); T2D (n=9) or CVD and 
T2D (n=6). Neutrophils were stained with panel 2 antibodies and gated for live cells. Live 
neutrophils from each sample were then analysed using tSNE and Rphenograph clustering 
based on surface marker expression. Clusters are presented for a) each participant group 
coloured by cluster number or b) combined relative surface expression, where red 
indicates high expression. 
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Figure 5.29: Cluster abundance of neutrophils from healthy elderly and patients with 
COPD, stratified based on multimorbidity, following Rphenograph cluster analysis 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) or patients 
with COPD with either no co-morbidities (n=15); with CVD (n=12); T2D (n=9) or CVD and 
T2D (n=6). The percentage of live neutrophils identified within each cluster (Figure 5.27 
and Figure 5.28) are shown for a) panel 1 and b) panel 2. Statistically significant changes in 
cluster percentages between groups are shown in more details for c) cluster 6, 12 and 16 
from panel 1 and d) cluster 4, and 18 from panel 2. In each case, horizontal lines indicate 
the median with the interquartile range. Statistical analysis on cluster percentages were 
performed using two-way ANOVA with Dunnett’s multiple comparisons compared to the 
HE group.  
 




Figure 5.30: Surface expression for neutrophils within each cluster identified using 
Rphenograph 
 
Neutrophils from whole blood were isolated from healthy elderly (HE; n=15) or patients 
with COPD with either no co-morbidities (n=15); with CVD (n=12); T2D (n=9) or CVD and 
T2D (n=6), stained with antibodies and the fluorescence intensity (MFI) measured for each 
marker (see Table 1). Key clusters highlighted in Figure 5.29 for a) panel 1 and b) panel 2 
are identified to show the expression for each marker compared to the other clusters (grey 
traces).  
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5.2.6 Differential gene expression in neutrophils in patients with COPD 
As our understanding of neutrophil biology has evolved, it has become clearer that neutrophils 
are capable of changing their gene expression profile, especially in response to pathogens 
(Terkawi, Takano and Kato, 2018). RNA was extracted from neutrophils isolated from each 
participant group, HY, HE, COPD (without stratification for multimorbidity) and prepared for 
RNA sequencing (RNASeq).  
5.2.6.1 Quality control and sample selection 
QC steps were carried out prior to shipping of isolated RNA samples. Immediately after 
extraction, absorbance readings using a nanodrop were performed. Ratios (260nm to 280nm 
and 260nm to 230nm) above 2.0 indicated good sample purity, between 2.0 and 1.8 indicated 
adequate purity and below 1.8 indicated poor purity. Using the 260/280 ratio to distinguish 
RNA from DNA, 23 of 30 samples achieved good purity and 5 adequate purity, with 2 samples 
failing to contain any RNA (Table 5.3). Using the 260/230 ratio to identify potential 
contaminants from the isolation buffers, none of the samples achieved good purity and only 
6 adequate purity (Table 5.3). These data indicate that whilst pure RNA was extracted with 
little DNA contamination, potential contaminants that absorb at 230nm were present. 
Further QC was carried out on all successful RNA: an RNA integrity score (RIN) was measured 
using a Tapestation and accurate RNA quantification performed using a Qubit fluorescence 
reader. For RNA sequencing, a RIN score of 8 or higher is considered good, between 7 and 8 
adequate and below 7 as poor. Using these criteria, 5 samples were of good integrity, 10 of 
adequate integrity and 13 poor integrity (Table 5.3). Across these three quality control 
measures, 5 samples in the HY, HE groups and 10 samples from the COPD group (not stratified 
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based on multimorbidity due to sample number) with an adequate quantity of RNA, with the 
highest purity and integrity scores were chosen for downstream RNASeq. 
5.2.6.1 Differentially expressed genes between participant groups 
Differential gene expression analysis was performed (see Section 2.10.1 for method) and 
revealed that there were no significant differences in gene expression between HY and HE. 
One gene, ARHGAP24, was differentially expressed between HE and stable COPD. Due to only 
one gene being identified, further analysis was not performed.  
5.2.6.2 Does gene expression match surface protein expression? 
The genes corresponding to the surface markers investigated in Sections 5.2.3-5.2.4 were 
identified and plotted on a heatmap for each participant group. Whilst there was sample to 
sample variation and no statistically significant differences (Figure 5.31a), patterns were 
observed at a group level (Figure 5.31b). Notably, gene expression of CEACAM8 (CD66b) and 
ITGAM (CD11b) was relatively higher in stable COPD compared with both healthy groups 
(Figure 5.31b). 
Neutrophils from participants where both surface expression (as shown in Section 5.2.3-5.2.4) 
and gene expression data were available were used to directly compare these data. The small 
sample number with both data sets limits the comparison of surface and gene expression due 
to lack of power, and no statistically significant correlations were observed in all investigated 
parameters (Figure 5.32 and Figure 5.33). These data may however highlight the differences 
between gene expression and protein levels on the surface of neutrophils.  
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1 COPD 2.08 1.94 6.5 53 RNAC01 
2 COPD 2.07 1.98 6.2 66.8 RNAC06 
3 COPD 2.05 1.58 7.9 60.6 RNAC03 
4 COPD 2.05 1.64 8.7 71 RNAC04 
5 COPD 2.06 1.85 8.9 79 RNAC05 
8 COPD 1.93 -0.53 6.5 20.2  
9 HY 2.08 1.19 7.7 33.8 RNAY01 
10 HY 2.08 1.75 6.4 52.6 RNAY04 
11 HE FAIL FAIL N/A N/A  
12 HE FAIL FAIL N/A N/A  
13 HE 1.99 1.53 5.7 63.2  
14 HY 2.03 0.96 7 29.8 RNAY02 
15 COPD 2.1 1.56 6 69.8  
16 COPD 1.86 1.05 4.9 18.5  
17 HY 2.07 0.18 7 23.8 RNAY05 
18 COPD 2.14 0.26 6.6 19.8 RNAC08 
19 HY 2.14 0.27 6.3 21.6 RNAY03 
20 HY 2.08 0.43 6 37.4  
21 COPD 2.08 0.53 7.7 102 RNAC09 
22 COPD 2.08 1.83 7.9 39.6 RNAC07 
23 COPD 2.34 1.64 6.2 17.1  
24 COPD 2.07 1.69 7.4 75 RNAC10 
25 HE 1.95 1.17 5.9 53.6  
26 HE 2.03 1.76 7.3 41.2 RNAE02 
27 HE 2.06 1.82 8 61.8 RNAE03 
28 HE 2.02 1.44 7.1 30.2 RNAE04 
29 COPD 2.09 1.72 8 42 RNAC02 
30 COPD 1.97 1.12 4.3 11.6  
31 HE 2.07 1.99 8.1 126 RNAE05 
32 HE 2.06 1.77 7 65.8 RNAE01 
Legend: Participant group indicates neutrophil donor: healthy young (HY); healthy elderly 
(HE); stable COPD (COPD). Ratios based on absorbance readings at 280nm, 260nm and 
230nm. RNA integrity score (RIN) measured using a Tapestation and RNA concentration 
using fluorescence quantification where N/A indicates sample not assessed.  
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Table 5.4: Corresponding genes for the surface proteins investigated via flow cytometry 













Legend: The associated gene for each surface protein investigated in Section 5.2.3-6.2.2.  
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Figure 5.31: Normalised expression of genes corresponding to selected surface markers 
 
Gene counts for mRNA extracted from neutrophils was normalised for gene length and total read 
number. Gene expression shown for selected markers (Table 5.4) for either a) each individual 
participant or b) mean expression for each participant group. Genes were clustered using Euclidean 
spacing and coloured based on the z-score generated from per-gene normalisation.  
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Figure 5.32: Correlation of neutrophil activation markers from surface protein expression 
and gene expression 
 
Neutrophils from healthy elderly participants (HE, n=3; green circles) and patients with 
stable (COPD, n=8; yellow squares) were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) of measured. RNA was also extracted from these samples, 
processed for RNASeq and gene expression. The correlation between surface and gene 
expression of a) CD11b b) CD66b and c) CD62L are shown. In each case, linear regression 
(solid line) is shown with 95% confidence intervals (dotted line). The goodness of fit (r2) 
and p-values are indicated for each linear regression. 
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Figure 5.33: Correlation of neutrophil CXCR2, CD10 and CD16 from surface protein 
expression and gene expression 
 
Neutrophils from healthy elderly participants (HE, n=3; green circles) and patients with 
stable (COPD, n=8; yellow squares) were isolated, stained with antibodies and the median 
fluorescence intensity (MFI) of measured. RNA was also extracted from these samples, 
processed for RNASeq and gene expression. The correlation between surface and gene 
expression of a) CXCR2 b) CD16 and c) CD10 are shown. In each case, linear regression 
(solid line) is shown with 95% confidence intervals (dotted line). The goodness of fit (r2) 
and p-values are indicated for each linear regression. 
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5.3 Discussion 
Many studies have begun to investigate neutrophil phenotypes and how these may be linked 
to a variety of diseases, however, not much is known about some of these neutrophil 
phenotypes in COPD. Here, a novel integrated panel was used to assess a variety of neutrophil 
phenotypes both in healthy ageing, stable COPD and associated co-morbidities. 
Broadly speaking, neutrophil phenotypes were similar in both healthy donors and patients 
with stable COPD regardless of multimorbidity. Notably, a reduction in CXCR2 expression was 
observed in stable COPD, specifically in patients with COPD and CVD that may suggest a 
reduced ability of neutrophils to migrate accurately and a differential impact of CVD and T2D 
in COPD.  
5.3.1 The activation status of neutrophils 
Neutrophil activation is required for effective neutrophil function, however, chronic activation 
and systemic activation results in excessive damage without the resolution of inflammation. 
Whilst many changes occur with neutrophil activation, the expression of CD11b and CD66b 
have shown to increase and CD62L decrease (Rosales, 2018) when neutrophils are exposed to 
inflammatory stimuli such as surgery (Orr et al., 2007), exposure to inflammatory cytokines or 
other activated immune cells (Costantini et al., 2010), or direct receptor engagement (Skubitz, 
Campbell and Skubitz, 1996). Patients with COPD are also commonly diagnosed with other 
chronic inflammatory conditions, and given the association of CVD and T2D with systemic 
inflammation (Hughes, McGettrick and Sapey, 2020b), stratification of patients may help 
elucidate differences due to multimorbidity. 
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Based on CD11b, CD66b and CD62L expression, there was no change in neutrophil activation 
status between either healthy groups, or between HE and COPD patients – regardless of 
multimorbidity – suggesting there was not systemic activation of neutrophils either with 
increasing age or presence of stable COPD. In addition, none of these proteins were 
significantly altered at the gene expression level on the subset of samples tested. Other 
studies have also suggested that peripheral CD11b expression was not altered in COPD (J. 
Stockley, 2015; Lokwani, Wark, Baines, Fricker, et al., 2019), yet CD62L expression was shown 
to be reduced in one of these studies (Lokwani, Wark, Baines, Fricker, et al., 2019). A potential 
reason for the latter observation was that antibody staining was performed in whole blood in 
the presence of other cell types that may alter priming signals received by these neutrophils. 
In addition, studies in patients with coronary artery disease (Särndahl et al., 2007) and patients 
with T2D (Sampson et al., 2002) detected similar levels of CD11b on neutrophils when 
compared to healthy controls. A couple of studies have suggested increases in CD11b 
expression on circulating neutrophils from patients with COPD (Noguera et al., 1998; 
Yamagata et al., 2007), however, both studies showed large variation between patients, or 
substantially lower lung function (Noguera et al., 1998) than patients included in this thesis. 
Of note, the only statistically significant correlation from the data in this thesis was 
demonstrated with CD11b and pack year history in the most multimorbid patients (COPD with 
CVD and T2D), with a lower smoking history indicative of increased activation – a finding that 
may be due to the low sample number as this was not replicated in any other group. However, 
the data presented in this thesis and by Lokwani et al., used healthy controls that did not have 
a comparable smoking history to patients with COPD, nor were controls with a smoking history 
excluded. This may reduce the ability to detect changes that are caused by smoking, as 
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another small study of 5 patients with COPD and 9 without, both long-term smokers, 
demonstrated that CD11b expression was comparable between these two groups, but higher 
than 8 healthy non-smokers (Stockfelt et al., 2020). One confounder of this study was the 
isolation of white blood cells using Ficoll gradient separation followed by red blood cell lysis 
that differs from the methodology described by Lokwani et al. and in this thesis. Another study 
also suggested small increases in surface CD11b expression were observed between healthy 
non-smokers (n=22) and patients with COPD (n=18) when staining was performed in whole 
blood (Blidberg et al., 2013).  
Differences in the detection of activated neutrophils between studies may, therefore, be 
explained by differences in blood collection, staining, isolation methods and the patient 
cohort used. The use of a dextran sedimentation step, used in this thesis, has been suggested 
to promote neutrophil activation and increase CD11b expression and reduce CD62L 
expression (Quach and Ferrante, 2017) that may impact on the activation phenotype observed 
in this study. However, in vitro stimulation with a physiological stimulant, fMLP (shown in 
Section 3.2.7), resulted in increases in surface activation markers, suggesting a lack of 
activation signal was not due to these cells already being activated. Avoiding cell isolation 
altogether and using whole blood flow cytometry also has pitfalls as the red blood cell lysis 
step can also alter neutrophil behaviour and ability to be activated, or fixes the cells preventing 
any functional analysis (Vuorte, Jansson and Repo, 2001). Given the diversity of neutrophil 
isolation procedures and the impact these can have on cellular activation, this remains a big 
problem in comparing the outcomes of studies. 
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These data suggest peripheral blood neutrophil activation remains unaltered in stable COPD 
with or without co-morbidities. They also highlight, in combination with previous studies, that 
experimental procedures and matching of patients with correct controls are confounders in 
these data and are important considerations when comparing studies. 
5.3.2 Accelerated ageing, senescence and changes in chemokine sensing 
The concept of accelerated ageing in COPD comes from parallels between ‘healthy’ ageing and 
COPD, where processes such as a decline in lung function, cellular senescence and increased 
oxidative stress are all exaggerated in COPD (Mercado, Ito and Barnes, 2015). Little attention, 
however, has been given specifically to the neutrophil and the nuanced senescence that 
neutrophils undergo. As a terminally differentiated cell, neutrophils are already in cell cycle 
arrest - a feature of cellular senescence (van Deursen, 2014). For neutrophils, experiments in 
mice describe the neutrophil senescence phenotype as a rise in CXCR4 expression and a 
decline in CXCR2 expression (Martin et al., 2003).  
The low level of CXCR4 expression detected on neutrophils from all participant groups 
suggested that peripheral neutrophil senescence did not occur with healthy ageing or in COPD. 
These results are supported by previous studies in healthy individuals (Rankin, 2010), but 
investigations in either COPD, CVD and T2D are distinctly lacking. In murine studies, it is 
possible that any CXCR4bright expressing neutrophils are promptly sequestered from the 
circulation in the bone marrow (Martin et al., 2003), potentially suggesting that CXCR4bright 
neutrophils may not be detected in the circulation. Indeed, detection of CXCR4 expressing 
neutrophils has only been robustly detected during in vitro ageing of human neutrophils 
(Yildirim et al., 2005) or at sites of inflammation in humans (Rudd et al., 2019) and zebrafish 
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(Isles et al., 2019). Combined with the lack of circulating CD54 expressing neutrophils, it seems 
unlikely that COPD is linked with an increased burden of circulating senescent cells, including 
the reverse transmigration of any senescent cells from the lungs. 
Linked with neutrophil senescence based on CD62L and CXCR4 expression, a previous study 
described an ‘overactive senescence’ neutrophil phenotype in patients with ischemic stroke 
(Weisenburger-Lile et al., 2019), defined as being CXCR4+CD62Ldim. Indeed, a small trend 
(statistically significant at the group level) of an increasing proportion of these neutrophils was 
seen between HY, HE and patients with COPD - potentially suggesting an age and disease 
associated increase. Of note, patients with COPD and CVD were not significantly different from 
other stable COPD patients.  
Whilst ageing also had no impact on CXCR2 levels, COPD led to a small but significant decline 
in surface CXCR2 expression, most marked in patients with both COPD and either CVD alone 
or with T2D, suggesting chemokine sensing may be altered in these cells. Expression of CXCR2 
also negatively correlated with CD11b expression, suggesting whilst activation was not 
significantly altered between groups, lower CXCR2 levels is associated with activation. These 
data raise two key points: the lack of change between HY and HE suggest these changes in 
CXCR2 expression do not reflect accelerated ageing; and CXCR2 expression is not reduced in 
all patients with COPD, showing heterogeneity in patients with COPD based on the presence 
of CVD. It cannot be overlooked, however, that these changes represent an overall 12% 
reduction in CXCR2 expression that is unlikely to completely alter downstream CXCR2 
signalling. Whilst further investigation would be required to assess the biological impact of 
this reduction, existing data on changes in neutrophil responses to CXCL8 (a major ligand of 
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the CXCR2 receptor) from patients with COPD (Yoshikawa et al., 2007) and blocking of CXCR2 
inhibits chemotaxis to CXCL8 (White et al., 1998) may indicate this reduction is able to 
modulate neutrophil responses. 
Several previous studies have investigated CXCR2 expression on circulating neutrophils. One 
study also showed reduced CXCR2 expression in stable COPD (Pignatti et al., 2005) compared 
to healthy controls. Other studies have reported lower CXCR2 levels (Traves et al., 2004; Sapey 
et al., 2011), but without statistical significance – potentially due to sample number, variation 
within control groups or, as highlighted by this thesis, the heterogeneity in the COPD patient 
population. Interestingly, CXCR2 expression on neutrophils has not been directly investigated 
in CVD, atherosclerosis or T2D, despite clinical trials investigating CXCR2 inhibition in CVD 
(Joseph et al., 2017), linking CXCR2 as an important factor in neutrophil-mediated damage in 
diabetes (Collier et al., 2017) and linking macrophage CXCR2 with atherosclerosis (Boisvert, 
Curtiss and Terkeltaub, 2000). However, the suggestion that CXCL2 is raised in the circulation 
of patients with CVD (Guo et al., 2020) may pose a potential mechanism to reduce neutrophil 
CXCR2 expression due to receptor internalisation and may also link with the activation 
markers on these cells. 
Collectively, alterations in CXCR2 may suggest a potential mechanism for the reduced 
migratory accuracy of neutrophils from patients with COPD – a defect that has been previously 
described (Sapey et al., 2011). Indeed, reduced CXCR2 expression on neutrophils from patients 
with ANCA-associated vasculitides also reported reduced migration of neutrophils through 
endothelium in vitro (Hu et al., 2011). The inability to accurately sense key chemokines such 
as CXCL2 and CXCL8 may increase the collateral damage caused by neutrophils that fail to 
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migrate accurately to inflammatory sites – although the lack of correlation (albeit 
underpowered) between CXCR2 expression and lung function in patients with COPD weakens 
the link between this phenotype and lung damage. Further mechanistic studies would be 
required to determine if this is because of persistent receptor signalling resulting in 
internalisation, or indeed a different phenotype pre-disposing to these diseases and the 
clinical impact this may have.  
5.3.3 Neutrophil maturity 
Immature neutrophils are rarely seen in the circulation of healthy individuals as maturation 
occurs within the bone marrow, only entering the circulation as CD10-expressing mature 
neutrophils (Hughes, Sapey and Stockley, 2019). Previous studies have revealed that 
inflammation, specifically acute inflammation, can lead to premature release of neutrophils 
into the circulation (referred to as emergency granulopoiesis) and has been seen during sepsis 
(Taneja et al., 2008), after invasive cardiac  surgery (Orr et al., 2005) and in severe COVID-19 
(Carissimo et al., 2020). 
The data presented here showed that in healthy ageing and the presence of COPD regardless 
of multimorbidity, there was no change in the maturity of circulating neutrophils, indicating 
correct regulation of neutrophil maturation. However, neutrophils from multimorbid patients 
with COPD, and T2D (with or without CVD) potentially showed lower CD10 expression, 
supported by Rphenograph analysis – but more participants are required to draw this 
conclusion. There currently is a gap in the current research investigating neutrophil maturity 
in stable COPD, CVD and T2D, however, the data presented here suggest it may not play a role 
in these disease areas.  
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Whilst CD16 expression is commonly used as a marker to identify neutrophils, it has also been 
linked with changes in neutrophil function and neutrophil maturity (Elghetany et al., 2004; 
Donnelly and Barnes, 2012). Here, CD16 expression was reduced on neutrophils from patients 
with COPD compared with HE and to a greater extent in patients with COPD alone or with T2D 
– suggesting an influence of both multimorbidity and chronic disease. Combined with CD10 
expression, there may be evidence of neutrophil immaturity in patients with both COPD and 
T2D. Studies specifically looking at CD16 expression in COPD, T2D and CVD are, again, lacking, 
but reduced neutrophil CD16 expression has been reported in several other circumstances: as 
a response to heat-shock prior to apoptosis (Guzik et al., 2011) and in systemic inflammatory 
response syndrome as a marker of immature ‘banded’ neutrophils (Drifte et al., 2013), also 
described as CD16dimCD62Lbright cells (Pillay et al., 2012). Previous studies have offered 
conflicting reports of the role CD16 may play in neutrophil function: enzymatic removal of 
CD16 did not appear to impair neutrophil phagocytosis or bacterial killing (Fossati et al., 
2002b), but CD16 expression on a cohort of HE volunteers negatively correlated with a 
reduced phagocytic index (Butcher et al., 2001) – although these studies used different 
bacteria and opsonisation conditions. Our data may suggest a potential mechanism for 
reduced phagocytosis observed in patients with COPD (Donnelly and Barnes, 2012), although 
neutrophils are not the only phagocytes found in the lung.  
In summary, these data suggest that immature neutrophils may be present in patients with 
both COPD and T2D without CVD based on both CD10 and CD16 expression, but these may 
represent slightly different maturity phenotypes. Reduced CD16 expression might be linked 
with chronic inflammation seen in COPD that may indicate why patients with COPD have a 
reduced ability to clear bacteria. 
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5.3.4 Inflammatory status and reverse transmigration 
Neutrophils have also been reported to display pro-inflammatory or anti-inflammatory 
properties through either the expression of an antigen presentation molecule, HLA-DR (Vono 
et al., 2017) or inhibiting T cell responses via PD-L1 (Keir et al., 2008; Wei et al., 2013). CD11c 
has also been linked with a predictive marker in SIRS (Lewis et al., 2015) and CD54 with 
neutrophil reverse transmigration (Buckley et al., 2006).  
In this study, little or no HLA-DR expression was detected on neutrophils from any participant 
group, with no changes in PD-L1, CD11c expression or CD54 expression in health or stable 
COPD – suggesting neutrophils do not display pro-inflammatory, anti-inflammatory or reverse 
transmigration properties in these patients. However, one study showed an increase in HLA-
DR-expressing neutrophils in current smokers with COPD compared to both former smokers 
with COPD and smokers with normal lung function (Scrimini et al., 2013). Differences in the 
populations used compared to this thesis may, therefore, explain this discrepancy. All these 
phenotypes have not been described yet in any detail in COPD, T2D or CVD, and the data here 
suggest that they do not exist in the circulation of patients with COPD regardless of 
multimorbidity. The lack of CD54 expression also suggests that it is unlikely that pro-
inflammatory conditions in the lung could lead to systemic effects by altering the neutrophil 
phenotype before they return to the circulation – a hypothesis that could link COPD and 
related co-morbidities. 
Another study identified a different potentially immunosuppressive neutrophil phenotype, 
CD16+CD62Ldim, identified to be increased in response to systemic LPS in healthy human 
volunteers (Pillay et al., 2012). Recently, CD16+CD62Ldim neutrophils have also been linked as 
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a prognostic marker for the development of pulmonary embolisms in COVID-19 patients 
(Spijkerman et al., 2021). There was a slight suggestion that the most multimorbid patients 
(COPD and CVD and T2D) may have an increased proportion of these cells, but these findings 
were not statistically significant, potentially suggesting little involvement of this particular 
immunosuppressive phenotype in COPD.  
5.3.5 Neutrophil heterogeneity 
The data discussed so far has focussed on average differences between population groups, 
but does not fully address the heterogeneity of the neutrophil population; a concept that is 
being increasingly appreciated. The role different neutrophil populations play in causing 
disease is largely unknown as it is challenging to determine if changes occur in the neutrophil 
before disease pathogenesis, or as a result of the disease (Rosales, 2018).  
The use of dimension-reduction algorithms, such as t-SNE as utilised in this chapter, aid 
identification of complex surface expression changes, but highlight that neutrophils are 
broadly similar within a given population. Even between healthy individuals and those with 
COPD, broadly similar phenotypes are observed, further illustrating that there is a finer, subtle 
shift in surface expression rather than dramatic distinctions between these populations. The 
ability of these tools to dissect complex and non-discrete datasets has been previously 
investigated, showing that clear separation is not generally seen when PBMCs are investigated 
in healthy individuals (Toghi Eshghi et al., 2019). Indeed, there are very few neutrophil 
proteins that have been shown to have bi-modal distributions. CD177, with as yet 
undetermined functional relevance does show a distinct bi-modal distribution in healthy 
people and appears to co-localise with bi-modal expression of PR3 on the neutrophil cell 
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membrane (Bauer et al., 2007). The lack of distinct bi-modal expression in the markers utilised 
in these panels within this thesis may confound the ability of this technique to identify 
completely separate neutrophil populations. The usefulness in multi-dimension analysis in 
neutrophils, therefore, is not in identifying discrete subsets, but suggesting where differences 
may exist between neutrophil populations in a more subtle manner.  
From these data, overlap of neutrophils expressing higher levels of CD11b, CD66b and CD11c 
builds on the single-marker analysis and suggests a role of CD11c in the activated neutrophil 
phenotype, despite none of the markers being significantly different when investigated alone. 
These analyses highlight that neutrophil phenotypes may be more complex than binary 
positive/negative populations or those identified by expression of a single marker. These data 
also support that expression of surface molecules, in general, are a gradient with no clear 
‘subsets’ emerging, indicating that therapeutics will need to shift, rather than eliminate, 
certain neutrophil phenotypes.  
5.3.6 The impact of gene expression on neutrophil phenotype 
RNASeq analysis of mRNA isolated from neutrophils provides data on the gene expression 
profile of these cells. Previous work has identified multiple different areas where neutrophil 
gene expression was altered, including after in vitro stimulation of healthy neutrophils with 
TNF-α leading to increased expression of IL-1β, CXCL8 and CD54, where increased IL-1β 
expression was also identified in patients with COPD (Oudijk et al., 2005). In the present study, 
no ex vivo stimulation was performed and, therefore, all changes identified were altered by in 
vivo processes. No genes were identified as differentially expressed between HY or HE 
participant groups, indicating that the gene expression profile of neutrophils does not 
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significantly change with age. Several other studies have found variable numbers of 
differentially expressed genes in peripheral blood with age, but none specifically investigate 
neutrophils in isolation and focused either on whole blood (Nakamura et al., 2012) or PBMCs 
(Joehanes et al., 2012). It is possible, with the caveat of only 5 samples in each group, that 
neutrophils in the circulation do not show age-related changes in either gene expression or 
surface expression at baseline. These analyses were performed using stringent cut-off criteria 
for p-value adjustment and this may be another possible reason for the failure to detect 
differentially expressed genes. 
Only one gene showed significantly higher expression in neutrophils from patients with COPD 
compared with HE: ARHGAP24; encoding for filamin A-binding RhoGTPase-activating protein 
(FilGAP) (Ohta, Hartwig and Stossel, 2006). FilGAP has been shown to control actin 
remodelling processes (Ohta, Hartwig and Stossel, 2006) vital for cell polarisation and was 
shown to negatively regulate chemotaxis in lymphocytes by inhibiting lamellae extension (Iida 
et al., 2016). Therefore, constitutively higher expression of ARHGAP24 may prevent efficient 
chemotaxis of neutrophils, a feature that has previously been shown in patients with COPD 
(Sapey et al., 2011), demonstrating a potential mechanism. However, it cannot be overlooked 
that a complex process such as chemotaxis is not controlled by a single gene and, therefore, 
further investigation would be necessary to confirm the role of ARHGAP24 in COPD.  
The expression of genes linked with anti-ageing processes such as sirtuins - protein 
deacetylases that are linked with maintaining genomic stability (Bosch-Presegué and Vaquero, 
2014) - was also of interest. SIRT1 has previously been shown to be reduced in PBMCs 
(Nakamaru et al., 2009) and lung tissue (Rajendrasozhan et al., 2008) from patients with COPD. 
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The data in the present study suggest that sirtuin expression was not altered in peripheral 
neutrophils in patients with stable COPD, suggesting a similar mechanism of accelerated 
ageing was not found in neutrophils and may instead be limited to regulation of maturation 
(X. Chen et al., 2015). 
5.3.7 Summary 
Previous work has implicated multiple neutrophil phenotypes with COPD. Here, evidence from 
a novel antibody panel suggests that neutrophils from patients with COPD, on average, do not 
have higher surface expression of activation markers regardless of multimorbidity, suggesting 
that neutrophils are not systemically activated, and increased activation does not link the 
pathologies of COPD, CVD and T2D.  
Circulating neutrophils do, however, show lower CXCR2 expression that is enhanced in 
patients with CVD (compared to healthy controls), suggesting an inflammatory-mediated 
regulation of CXCR2 expression. In addition, lower CD16 expression was detected on 
neutrophils from patients with COPD, specifically in patients with COPD alone or with T2D, 
potentially suggesting a mechanism of reduced bacterial clearance. The number of patients 
included in these studies means it was underpowered to draw sound comparisons between 
the differences in neutrophil phenotype and clinical parameters, or between surface and gene 
expression. However, these data reveal differences in patients based on multimorbidity, 
further highlighting how not all patients with COPD are the same and provides a basis for 
consideration in future studies. 
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Here, for the first time, comprehensive neutrophil phenotyping reveals subtle neutrophil 
phenotype differences in patient subsets based on multimorbidity in COPD. These changes 
may provide mechanisms of neutrophil dysfunction and avenues for therapeutics, but further 
study is required to elucidate the functional and clinical impact of these phenotypes. 
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6 CHAPTER 6: 
PHENOTYPING OF PERIPHERAL 
BLOOD NEUTROPHILS IN AECOPD 
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6.1 Brief introduction 
Clinically, an exacerbation of COPD can be defined as “an acute worsening of respiratory 
symptoms that results in additional therapy” (GOLD, 2021) – a general definition that has not 
changed for some time. Exacerbations are associated with long term health impacts (Celli and 
Wedzicha, 2019) and patients who exacerbate frequently are more likely to experience 
adverse cardiovascular events (Donaldson et al., 2010). In addition, exacerbations are linked 
with changes in cellular function, such as impaired alveolar macrophage function (Berenson 
et al., 2014) and reduced phagocytosis by neutrophils (Lavinskiene et al., 2011). Previous data 
from Professor Sapey’s group has also shown that the speed and accuracy of neutrophil 
chemotaxis is also significantly reduced in AECOPD (awaiting publication; Figure 6.1) These 
patients represent a distinct population where acute changes occur in a chronic disease and 
the investigation of neutrophils here allows insight to changes that are because of acute 
inflammation. The change in phenotype in the systemic neutrophil population may provide 
evidence that link changes in respiratory symptoms to altered neutrophils in the circulation 
that could impact on their function at distant sites.  
It is well established that neutrophils play a role in COPD (Stockley, 2002), but less is known 
about neutrophil function during AECOPD. This study aimed to assess multiple neutrophil 
phenotypes using a combination of markers linked to neutrophil function that may be altered 
COPD. This was achieved using two well-validated flow cytometry panels as previously 
described using neutrophils obtained from a cohort of well-characterised patients with either 
stable COPD or patients currently experiencing an acute exacerbation of COPD (recruited <24 
hours after their hospital admission). It was hypothesised that fundamental differences in 
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neutrophil phenotypes exist between the stable and unstable state, especially regarding 
activation status and these neutrophils would show systemic activation in patients with 
AECOPD. 
6.2 Results 
For clarity, the results in this chapter follow the same format as those in Chapter 5: 
investigating neutrophil phenotypes based on surface expression following traditional gating; 
using multi-dimension clustering analysis; and investigation of gene expression. Sample 
quality control and gating strategies are the same as shown in Chapter 5 (Section 5.2.1). 
6.2.1 Sample quality control  
SpheroBeads were used to ensure consistent fluorescence detection from the flow cytometer 
for each sample, based on previously published EuroFlow guidelines (Kalina et al., 2012). Every 
SpheroBead preparation collected prior to the neutrophil sample was within the 10% 
tolerance for all channels (Figure 6.2a).  
Analysis was performed only on live cells and all samples from patients with AECOPD or the 
matched stable COPD were included in phenotype analysis as neutrophil viability was greater 
than 25% in all but 1 sample (3%; Figure 6.2b).  
  





















































































Figure 6.1: The effect of an acute exacerbation of COPD on neutrophil chemotaxis. 
 
Neutrophils from whole blood were isolated, placed in an Insall chamber and chemotaxis 
towards either a,c) CXCL8 or b,d) fMLP recorded using time-lapse imaging for 12 minutes 
(n=33 each). Two parameters are shown: a,b) speed and c,d) velocity. In each case, the 
horizontal line indicates the median value with the interquartile range. Statistical analysis 
performed using a Mann-Whitney test. 
 
These data were collected by other researchers and not the author of this thesis. 
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Figure 6.2: Quality control using SpheroBeads and apoptotic exclusion 
  
a) Median Fluorescent Intensity (MFI) was recorded for 4000 events in each fluorescent 
channel. Each point represents a separate run (n=31). A range of ±10% from the target 
value (shown in Table 3.7) is shown by the red (+10%) and blue (-10%) dotted lines. b) 
Neutrophils from study participants (n=31) were isolated and viability measured using 
annexin V and 7ADD staining. Cells negative for both markers were considered live. Bars 
show mean percentage of live cells for n=1 participant, averaged from samples in panel 1 
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6.2.2 Changes in neutrophil phenotype in patients with an acute exacerbation of COPD 
Acute worsening of symptoms in COPD is known to increase the likelihood of hospitalisation 
and death (Kong and Wilkinson, 2020). Patients that were hospitalised with AECOPD were 
recruited within 24 hours of admission and their neutrophils isolated. These were matched by 
age and FEV1 to 15 patients with stable COPD (from the cohort shown in Section 5.2.3).  
6.2.2.1 Patient demographics 
There were no significant differences between age, sex, lung function or smoking history 
between patients with stable or acute exacerbations of COPD (Table 6.1). A greater proportion 
of patients with an acute exacerbation of COPD were in GOLD Stage 3 than patients with stable 
COPD, but this was not statistically significant (Table 6.1). 
6.2.2.2 Neutrophil activation in AECOPD 
In order to assess activation status, the expression of CD11b, CD66b and CD62L were 
measured. On average, expression of CD11b increased two-fold between patients with 
AECOPD and stable COPD (Figure 6.3a). However, 4 patients with AECOPD had comparable 
levels of CD11b to patients with stable COPD. A similar trend was observed with CD66b, 
however, this increase was not statistically significant (Figure 6.3b). Expression of CD62L was 
comparable between stable and exacerbation groups (Figure 6.3c). Of note, a higher 
proportion of apoptotic neutrophils was identified in samples from patients with AECOPD 
compared with stable COPD. There was also a statistically significant increase in the 
percentage of CD11bbrightCD66bbright neutrophils from patients with AECOPD compared with 
stable COPD (Figure 6.4). Together these data suggest that neutrophils in patients with 
AECOPD are systemically activated and may show enhanced levels of apoptosis. 
Chapter 6  Page | 246  
Table 6.1: Basic demographics for study participants during an acute exacerbation of COPD and respective matched stable COPD patients.  
 Stable COPD Acute exacerbation of COPD (AECOPD) p-value 
Number 15 15  
Age, median (IQR) 72 (71-76) 73 (68-76) 0.86k 
Sex, M:F 10:5 8:7 0.71f 
Lung function 
FEV1 % predicted, median (IQR) 52 (40.0-67.0) 45 (35.8-61.8)1 0.43k 
FVC % predicted, median (IQR) 95.0 (69.0-106) 92 (67.8-100)1 0.51k 
GOLD Stage (1:2:3:4) 2:7:3:3 1:5:7:11 0.40f 
Smoking  
Smoking status (NS:Ex:C) 0:13:2 0:12:21 1.00f 
Pack year history, median (IQR) 48.8 (23.0-70.5) 47.5 (34.3-63.8)1 0.95k 
Years ex-smoker, median (IQR) 8 (5.75-17.3) 10 (4-17)1 0.89k 
Patient demographics.  Study participants split into those with stable COPD (sCOPD) or with an acute exacerbation of COPD (AECOPD). Median with 
interquartile range (IQR) to one decimal place are shown where appropriate. Sex shown as a ratio of male (M) to female (F). GOLD Stage displayed as a 
ratio of stage 1:2:3:4. Smoking status shown as ratio of never(NS):ex(Ex):current(C).   Statistical analysis carried out using Kruskal-Wallis test (k) for 
continuous data and Fishers Exact test (f) for categorical data. FEV1, forced expiratory volume in one second; FVC, forced vital capacity. 1 Information 
from one AECOPD patient was unavailable. 































































Figure 6.3: Median fluorescence intensity of activation markers of isolated neutrophils 
from patients with stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (sCOPD; n=15) 
or exacerbations of COPD (AECOPD, n=15), stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) CD11b, b) CD66b or c) CD62L or d) the 
percentage of apoptotic cells. In each case, the horizontal line indicates the median value. 
Statistical analysis performed using a Mann-Whitney test. 
 
























Figure 6.4: The percentage of CD11bbrightCD66bbright live neutrophils from patients with 
stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (sCOPD; n=15) 
or exacerbations of COPD (AECOPD, n=15), stained with antibodies and the percentage of 
CD11bbrightCD66bbright live neutrophils recorded. In each case, the horizontal line indicates 
the median value. Statistical analysis performed using a Mann-Whitney test. 
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6.2.2.3 Neutrophil senescence in AECOPD 
In order to assess neutrophil senescence, the expression of CXCR2 and CXCR4 were measured. 
There was a significant reduction of CXCR2 expression (on average by 30%) in patients with 
AECOPD when compared to patients with stable COPD (Figure 6.5a). In contrast, CXCR4 
expression was comparable between these two groups (Figure 6.5b). These data suggest an 
altered neutrophil phenotype between AECOPD and stable COPD – but not one consistent 
with previously reported neutrophil senescence. 
An increase in the proportion of CXCR4+CD62Ldim ‘overactive senescent’ neutrophils was 
found in patients with AECOPD compared to COPD (Figure 6.5c), suggesting that whilst 
traditional senescence is not observed in patients with AECOPD, an alternative senescence 
phenotype may be present. 
6.2.2.4 Neutrophil inflammatory status in AECOPD 
In order to assess neutrophil anti-inflammatory status, the expression of PD-L1, HLA-DR and 
CD11c was measured. Whilst CD11c expression was not altered (Figure 6.6c), a significant 
increase, on average of 85%, in PD-L1 expression was observed in neutrophils isolated from 
patients with AECOPD compared to stable COPD (Figure 6.6a). The absolute increase, 
however, was relatively small and may indicate only a small shift towards an anti-
inflammatory phenotype and may not be clinically or biologically relevant. No difference was 
found in the expression of HLA-DR or between AECOPD and stable COPD, suggesting 
neutrophils do not show evidence of a pro-inflammatory phenotype during AECOPD (Figure 
6.6c). 
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6.2.2.5 Neutrophil reverse transmigration and maturity 
Similar levels of CD54 (Figure 6.7), CD10 (Figure 6.8a) and CD16 (Figure 6.8b) expression were 
observed between neutrophils isolated from patients with AECOPD and stable COPD, 
suggesting no alteration in neutrophil reverse transmigration of maturity occurred during 
exacerbation. 
6.2.2.6 Hypersegmentation 
Neutrophil hypersegmentation based on the percentage of CD16+CD62Ldim neutrophils was 
not altered in AECOPD compared with stable COPD (Figure 6.9). However, substantial patient-
to-patient variation was seen in both groups (Figure 6.9). These data suggest the proportion 
of hypersegmented neutrophils shows considerable variation in patients with COPD 
regardless of exacerbation status. 
 
 















































Figure 6.5: Median fluorescence intensity of senescence markers on isolated neutrophils 
from patients with stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (sCOPD; n=15) 
or exacerbations of COPD (AECOPD, n=15), stained with antibodies and the median 
fluorescence intensity measured for a) CXCR2, b) CXCR4 or c) the percentage of 
CXCR4+CD62Ldim neutrophils. In each case, the horizontal line indicates the median value. 
Statistical analysis performed using an unpaired t-test. 











































Figure 6.6: Median fluorescence intensity of PD-L1, HLA-DR and CD11c on isolated 
neutrophils from patients with stable COPD or AECOPD 
 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
exacerbations of COPD (AECOPD, n=15), stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) PD-L1 b) HLA-DR or c) CD11c. In each case, 
the horizontal line indicates the median value. Statistical analysis performed using a Mann-
Whitney test. 
 














Figure 6.7: Median fluorescence intensity of CD54 on isolated neutrophils from patients 
with stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
exacerbations of COPD (AECOPD, n=15), stained with antibodies and the median 
fluorescence intensity (MFI) measured for CD54. The horizontal line indicates the median 



























Figure 6.8: Median fluorescence intensity of CD10 and CD16 on isolated neutrophils from 
patients with stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
exacerbations of COPD (AECOPD, n=15), stained with antibodies and the median 
fluorescence intensity (MFI) measured for a) CD10 or b) CD16. In each case, the horizontal 
line indicates the median value with interquartile range. Statistical analysis performed 
using a Mann-Whitney test. 
 























Figure 6.9: Percentage of live CD16+CD62Ldim neutrophils isolated from patients with 
stable COPD or AECOPD 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
exacerbations of COPD (AECOPD, n=15), stained with antibodies and the percentage of 
CD16+CD62Ldim live neutrophils measured. In each case, the horizontal line indicates the 
median value with interquartile range. Statistical analysis performed using a Mann-
Whitney test. 
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6.2.3 Unassisted analysis using t-Distributed Stochastic Neighbor Embedding (t-SNE) and 
Rphenograph clustering 
As shown in Chapter 5, some of the limitations of conventional gating strategies can be 
overcome by the use of multi-dimensional clustering and dimension-reduction algorithms – 
allowing the analysis of all parameters simultaneously. Here, t-SNE visualisation with a 
clustering algorithm called Rphenograph was utilised to separate live neutrophils (gating 
strategy shown in Figure 2.3) based on surface expression, where the closer together each 
cluster, the more similar they are. The percentage of neutrophils in each cluster can then be 
quantified and the expression of each marker for each cluster can be compared. 
6.2.3.1 Rphenograph analysis of patients with stable COPD or AECOPD 
Rphenograph analysis identified a total of 22 clusters for panel 1 with no clear separation 
between clusters (Figure 6.10a). Regions of higher CD11b expression overlayed with higher 
CD10 expression (Figure 6.10b), with some regions showing greater CXCR2, CD62L and CD54 
expression, with homogenous CXCR4 and CD16 expression. Of the 20 clusters identified for 
panel 2 (Figure 6.11a), there appeared to be some separation in the clusters with one region 
of lower PD-L1 expression (Figure 6.11b). Regions of higher CD11b, CD66b, CD11c and CD10 
appeared to overlay. These data suggest similar CXCR4 and CD16 expression across all the 
samples, with a link between CD11b, CD66b, CD11c and CD10 expression. 
Overall, there were no statistically significant differences between the percentage of 
neutrophils within each cluster between patients with AECOPD and stable COPD (Figure 6.12a 
and b). However, there were changes in the median values between groups that, whilst not 
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statistically significant, approached significance and may still provide biological insight and 
warrant further investigation.  
Neutrophils in cluster 10 and 18 from panel 1 were less abundant in patients with AECOPD 
compared to stable COPD, contrasting with cluster 21 and 22 that were more abundant in 
patients with AECOPD compared to stable COPD (Figure 6.12c). From panel 2, the percentage 
of neutrophils in cluster 11 and 16 was reduced and cluster 4 and 20 increased in patients with 
AECOPD compared to stable COPD (Figure 6.12d). These changes suggest subtle differences 
in the neutrophil phenotype between AECOPD and stable COPD.  
The expression levels within these clusters were then identified to link them to potential 
biological differences. For panel 1, the highlighted clusters (10,18,21 and 22) show broadly 
similar expression profiles for CXCR4, CD16, CD54 (Figure 6.13a), supporting the individual 
marker analysis that senescence, maturity and reverse transmigration are not altered. Cluster 
10 and 18, both reduced in AECOPD, showed lower CD11b and CD10 expression, but similar 
CD62L expression to the other highlighted clusters (Figure 6.13a). In contrast, cluster 21, 
increased in patients with AECOPD, had higher CD11b and lower CD62L expression than the 
other peaks (Figure 6.13a). Cluster 22, again increased in AECOPD, showed lower CXCR2 
expression than all other clusters (Figure 6.13a). Together, these support an increase in 
activated neutrophils in AECOPD, but also highlight how CD10 expression may also play a role 
in this phenotype. They also suggest that neutrophils with lower CXCR2 may be exaggerated 
in a subset of activated cells, as cluster 22 showed the lowest CXCR2 expression with 
intermediate CD11b expression (Figure 6.13a). 
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Within panel 2, all clusters had similar expression of PD-L1 and HLA-DR (Figure 6.13b). Cluster 
11 and 16, reduced in patients with AECOPD compared to stable COPD, showed very similar 
expression profiles with lower CD11b, CD66b, CD11c and CD10 expression whilst the opposite 
was true for cluster 4 and 20 (increased in patients with AECOPD) with higher expression of 
these markers (Figure 6.13b). These data further support that neutrophils with an activated 
phenotype are present in the circulation of patients with AECOPD in greater frequency than 
in stable COPD. They also highlight that these cells may also express higher levels of CD11c 
and CD10 and, therefore, do not represent an immature neutrophil population. 
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Figure 6.10: tSNE plots of surface expression of markers from antibody panel 1 for 
patients with stable COPD or AECOPD clustered using Rphenograph 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
acute exacerbation of COPD (AECOPD; n=15). Neutrophils were stained with panel 2 
antibodies and gated for live cells. Live neutrophils from each sample were then analysed 
using tSNE and Rphenograph clustering based on surface marker expression. Clusters are 
presented for a) each participant group coloured by cluster number or b) combined 
relative surface expression, where red indicates high expression. 
 
Chapter 6  Page | 259  
  
 
Figure 6.11: tSNE plots of surface expression of markers from antibody panel 2 for 
patients with stable COPD or AECOPD clustered using Rphenograph 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) or 
acute exacerbation of COPD (AECOPD; n=15). Neutrophils were stained with panel 2 
antibodies and gated for live cells. Live neutrophils from each sample were then analysed 
using tSNE and Rphenograph clustering based on surface marker expression. Clusters are 
presented for a) each participant group coloured by cluster number or b) combined 
relative surface expression, where red indicates high expression. 
 
Chapter 6  Page | 260  
  
























































































Figure 6.12: Percentage of neutrophils within each cluster following Rphenograph cluster 
analysis for each antibody panel 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) and 
AECOPD (n=15), stained with antibodies and the median fluorescence intensity (MFI) 
measured for each marker. The percentage of live neutrophils identified within each 
cluster (Figure 6.10 and Figure 6.11) are shown for a) panel 1 and b) panel 2. c) Cluster 10, 
18, 21 and 22 from panel 1 and d) cluster 4, 11, 16 and 20 from panel 2 are shown in further 
detail (highlighted in grey squares and circles respectively). In each case, horizontal lines 
indicate the median with the interquartile range. Statistical analysis on cluster percentages 
were performed using multiple t-tests using the Holm-Sidak method for multiple analysis.  
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Figure 6.13: Surface expression for neutrophils within each cluster identified using 
Rphenograph 
 
Neutrophils from whole blood were isolated from patients with stable COPD (n=15) and 
AECOPD (n=15), stained with antibodies and the fluorescence intensity measured for each 
marker (see Table 1). Key clusters highlighted in Figure 6.12 for a) panel 1 and b) panel 2 
are identified to show the expression for each marker compared to the other clusters (grey 
traces).  
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6.2.4 Differential gene expression in neutrophils in patients with COPD 
As our understanding of neutrophil biology has evolved, it has become clearer that neutrophils 
are capable of changing their gene expression profile, especially in response to pathogens 
(Terkawi, Takano and Kato, 2018). RNA was extracted from neutrophils isolated from patients 
with both stable COPD and AECOPD and prepared for RNA sequencing (RNASeq).  
6.2.4.1 Quality control and sample selection 
QC steps were carried out ensure RNA purity, based on a ratio of absorbance at 260nm and 
280nm to determine DNA contamination and 260nm to 230nm to determine salt or organic 
compound contamination. Ratios above 2.0 indicated good sample purity, between 2.0 and 
1.8 indicated adequate purity and below 1.8 indicated poor purity. For 260/280 ratios, all 
samples achieved good or adequate purity (Table 6.2). For 260/230 ratios, none of the samples 
achieved good purity and 4 with adequate purity (Table 6.2). These data indicate that whilst 
pure RNA was extracted with little DNA contamination, potential contaminants that absorb at 
230nm were present – but these should not impact on sequencing. 
RNA integrity and quantity were assessed using an RNA integrity score (RIN), measured using 
a Tapestation, and accurate RNA quantification performed using a Qubit fluorescence reader. 
For RNA sequencing, a RIN score of 8 or higher is considered good, between 7 and 8 adequate 
and below 7 as poor. Using these criteria, 5 samples were of good integrity, 8 of adequate 
integrity and 8 poor (Table 6.2). Across these three quality control measures, 5 samples from 
patients with AECOPD and 10 samples from the COPD group (not stratified based on 
multimorbidity due to sample number) with an adequate quantity of RNA, with the highest 
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purity and integrity scores were chosen for downstream RNASeq (shown by the assignment 
of an RNASeq ID). 
6.2.4.2 Differentially expressed genes between participant groups 
Differential gene expression analysis was performed (see Section 2.10.1 for method) and 
revealed 102 genes were differentially expressed between neutrophils from patients with 
stable COPD and AECOPD (Table 6.3).  
Pathway analysis of all 102 differentially expressed genes between neutrophils from patients 
with stable or acute exacerbations of COPD revealed 7 main processes that were altered:  
neuroinflammatory response; platelet function; heterotypic cell-cell adhesion; homotypic 
cell-cell adhesion; regulation of bone development; carbohydrate transmembrane 
transporter activity and cell-cell adhesion mediator activity (Figure 6.14). The reactome and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) were also used to incorporate potential 
disease pathways and molecular interactions (Kanehisa et al., 2017; Jassal et al., 2020).  
Platelet function, heterotypic and homotypic cell-cell adhesion grouped together and 
encompassed the greatest number of processes. Integrin genes (ITG) ITGA7, ITGB3 and 
ITGA2B featured many links within this group (Figure 6.14). These analyses also identified 
three cardiac conditions (hypertrophic, dilated and arrhythmogenic right ventricular 
cardiomyopathy) due to their association with integrins ITGA7, ITGB3, ITGA2B and the gene 
for Calcium Voltage-Gated Channel Auxiliary Subunit Gamma 6 (CACNG6). These genes were 
all upregulated in AECOPD (Table 6.3), suggesting a link between neutrophils and the 
increased risk of these diseases in this patient group. In addition to integrins, CACNG6, SPARC 
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and SYTL4 were involved in platelet function (Figure 6.14), all of which had higher expression 
in neutrophils from patients with AECOPD compared with stable COPD (Table 6.3).  
Closely linked to cell adhesion was cell-cell adhesion mediator activity. Both PDLIM1 and ESAM 
were increased in neutrophils from patients with AECOPD compared with stable COPD, but 
JUP expression (coding for the cell junction protein plakoglobin) was reduced (Table 6.3 and 
Figure 6.14).  
Several genes were also identified that linked to neuroinflammation (Figure 6.14): however, 
BACE2 expression was lower and three other genes higher in AECOPD compared with stable 
COPD (Table 6.3 and Figure 6.14), suggesting some evidence of the role of neutrophils in 
neuroinflammation, but one that requires further investigation. 
There were also two other processes identified: regulation of bone development and 
carbohydrate transmembrane transporter activity (Figure 6.14). Two of the three genes 
associated with bone development had reduced expression in neutrophils from AECOPD 
compared with stable COPD (FBN1 and RFLNB, Table 6.3), whereas all genes associated with 
transporter activity were increased (Table 6.3 and Figure 6.14). Together, these may indicate 
neutrophils in AECOPD have altered involvement in bone development regulation and 
changes in carbohydrate transport. 
More detailed analysis was performed on the top 50 differentially expressed genes, clustering 
based on normalised gene expression (Figure 6.15). Four main clusters were identified: two 
where genes were upregulated (cluster 1 and 3) and two where genes were downregulated 
(cluster 2 and 4) in neutrophils from patients with AECOPD compared with stable COPD (Figure 
6.15).  
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Gene ontology (GO) analysis of both clusters of genes upregulated in neutrophils from 
AECOPD patients revealed links with 41 GO biological processes (Table 6.4), including “platelet 
activation”, “coagulation”, “cell-cell adhesion” and “positive regulation of cell motility”. These 
genes were also associated with two GO molecular functions (Table 6.4): “fibrinogen binding” 
and “extracellular matrix binding”, suggesting activation and adhesion processes are 
increased during an acute exacerbation.  Those genes downregulated in neutrophils from 
patients with AECOPD were associated with the GO biological process “cellular responses to 
drugs” and GO molecular functions including transmembrane signalling activity and lipase 
activity (Table 6.4), suggesting neutrophils from patients with AECOPD may have a reduced 
ability to sense their external environment compared with stable COPD. 
The Kyoto Encyclopedia of Genes and Genomes (KEGG) resource can also be used to identify 
high-level functions of cells related to gene expression. Genes upregulated in patients with 
AECOPD were associated with several pathways, including PI3K-signalling due to the increased 
expression of integrin molecules that signal via PI3K (Table 6.4). There were no statistically 
significant related KEGG-identified functions in genes downregulated in neutrophils from 
patients with AECOPD.  
Together, these data point to several hypotheses: that neutrophils from patients with AECOPD 
are pro-inflammatory with higher expression of adhesion molecules; they have reduced 
expression of extracellular sensing receptors; and have increased activity of pathways 
controlling cell migration.  
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1 COPD 2.08 1.94 6.5 53 RNAC01 
2 COPD 2.07 1.98 6.2 66.8 RNAC06 
3 COPD 2.05 1.58 7.9 60.6 RNAC03 
4 COPD 2.05 1.64 8.7 71 RNAC04 
5 COPD 2.06 1.85 8.9 79 RNAC05 
6 AECOPD 2.05 1.77 8.4 42.6 RNAA01 
7 AECOPD 2.05 0.71 7.8 50 RNAA02 
8 COPD 1.93 -0.53 6.5 20.2  
15 COPD 2.1 1.56 6 69.8  
16 COPD 1.86 1.05 4.9 18.5  
18 COPD 2.14 0.26 6.6 19.8 RNAC08 
21 COPD 2.08 0.53 7.7 102 RNAC09 
22 COPD 2.08 1.83 7.9 39.6 RNAC07 
23 COPD 2.34 1.64 6.2 17.1  
24 COPD 2.07 1.69 7.4 75 RNAC10 
29 COPD 2.09 1.72 8 42 RNAC02 
30 COPD 1.97 1.12 4.3 11.6  
33 AECOPD 1.87 0.99 8 60  
34 AECOPD 2 1.75 7.3 45.2 RNAA03 
35 AECOPD 1.96 1.39 7.5 35.2 RNAA04 
36 AECOPD 1.89 0.98 7.5 20 RNAA05 
Legend: Participant group indicates neutrophil donor: healthy young (HY); healthy elderly 
(HE); stable COPD (COPD) and acute exacerbation of COPD (AECOPD). Ratios based on 
absorbance readings at 280nm, 260nm and 230nm. RNA integrity score (RIN) measured 
using a Tapestation and RNA concentration using fluorescence quantification where N/A 
indicates sample not assessed. Patients with COPD included in this table are the same as 
shown in Chapter 5 Table 5.3. 
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 Table 6.3: Differentially expressed genes between neutrophils from patients with stable 













NAIPP1 <0.001 BACE2 0.006 PTGS1 0.021 GALNT14 0.036 
SH3BGRL2 <0.001 OLAH 0.008 LINC01271 0.021 LINC02751 0.036 
SPNS3 <0.001 JUP 0.009 LGALS2 0.021 LINC01232 0.037 
CYSLTR2 <0.001 CLVS1 0.011 NME8 0.023 PCSK6 0.037 
SIGLEC8 <0.001 IL5RA 0.012 PINX1 0.023 LRRC6 0.038 
ASPH <0.001 H2BC11 0.012 CCDC86 0.023 TMEM119 0.038 
SYTL4 <0.001 ITPKC 0.012 ADM2 0.023 ZDHHC19 0.040 
AC007877.
1 <0.001 MYL9 0.013 AP3B2 0.025 SYN2 0.044 
ITGB3 <0.001 MIR5690 0.014 PEAR1 0.026 BCAT1 0.044 
GUCY1B1 0.001 CLC 0.014 ESAM 0.026 
AL049836.
1 0.044 
TMEM40 0.001 TUBB1 0.015 C2orf88 0.027 RFLNB 0.044 
SLC29A1 0.001 CCR3 0.015 FBN1 0.029 CST7 0.046 
AL157823.
2 0.001 CALHM6 0.016 RPL22P2 0.030 ABLIM3 0.047 
LINC01270 0.001 SMPD3 0.018 ZDHHC1 0.030 CROCCP2 0.047 
TREML1 0.001 NUDT17 0.018 COX6B2 0.030 MYO10 0.047 
TPPP3 0.002 
AC020636.





2 0.030 FLNB 0.047 
ADGRE4P 0.002 DTX4 0.018 
AL021978.
1 0.032 GNG11 0.047 










CACNG6 0.003 PLD4 0.019 AQP10 0.034 ABCC11 0.047 
LYSMD4 0.003 BTBD11 0.020 CAPN13 0.034 SAMSN1 0.047 
ITGA7 0.003 PDLIM1 0.021 C5orf67 0.034 TEF 0.047 
P2RY2 0.004 SRPX2 0.021 LINC02193 0.034 PLAAT5 0.049 
Z85996.2 0.006 PPBP 0.021 EFNA1 0.035   
HRH4 0.006 PRL 0.021 CLU 0.036   
Legend: Normalised gene counts from neutrophils with patients with stable or acute 
exacerbations of COPD were compared. Each gene with a p-value <0.05 is shown. Genes are 
highlighted based on upregulation (orange) or downregulation (blue) in neutrophils from 
patients with AECOPD compared with stable COPD. 
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Figure 6.14: ClueGO visualization including gene labels and links of differentially 
expressed genes between stable COPD and those with an acute exacerbation of COPD 
 
All differentially expressed genes identified between patients with stable and an acute 
exacerbation of COPD were selected as the input to ClueGO. Gene ontology (GO, circle), 
Reactome (octagon) and Kyoto Encyclopedia of Genes and Genomes (KEGG, diamond) 
databases were selected to match genes to biological processes. Shape size corresponds 
to the significance of association between the gene list and the process. Links between 
processes are indicated by the grey lines and links between each gene and process are 
indicated by coloured lines.  
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Figure 6.15: Differential gene expression between neutrophils from patients with stable 
and exacerbations of COPD 
 
Gene counts for mRNA extracted from neutrophils was normalized for gene length and 
total read number. Differential gene expression analysis performed using DESeq2. The top 
50 differentially expressed genes are shown, scaled by gene counts per gene and coloured 
according to the resulting z-score; clustered using Euclidean spacing. Differentially 
expressed genes were annotated using ShinyGo to identify potentially altered biological 
processes. Gene ontology biological processes; molecular functions and Kyoto 
Encyclopedia of Genes and Genomes databases were selected to match genes to biological 
processes, where genes significantly associated with these categories are shown by a dot 
in the corresponding column.  
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Table 6.4: Gene ontology analysis of differentially expressed genes between neutrophils from patients with stable and AECOPD  
Outcome GO 
analysis 
















Related to chemotaxis 
0.005 
Positive regulation of endothelial cell 
migration  SPARC SRPX2 ITGB3    3 
0.010 
Positive regulation of epithelial cell 
migration  SPARC SRPX2 ITGB3    3 
0.011 Regulation of endothelial cell migration  SPARC SRPX2 ITGB3    3 
0.012 Extracellular matrix organization  ITGA2B SPARC ITGA7 ITGB3   4 
0.019 Endothelial cell migration  SPARC SRPX2 ITGB3    3 
0.019 Extracellular structure organization  ITGA2B SPARC ITGA7 ITGB3   4 
0.022 Regulation of epithelial cell migration  SPARC SRPX2 ITGB3    3 
0.025 Cell-matrix adhesion  ITGB3 ITGA2B ITGA7    3 
0.026 Positive regulation of cell migration  SPARC ITGA2B SRPX2 ITGB3   4 
0.027 Positive regulation of cell motility  SPARC ITGA2B SRPX2 ITGB3   4 
0.028 Epithelium migration  SPARC SRPX2 ITGB3    3 
0.028 Epithelial cell migration  SPARC SRPX2 ITGB3    3 
0.028 Positive regulation of locomotion  SPARC ITGA2B SRPX2 ITGB3   4 
0.029 Tissue migration  SPARC SRPX2 ITGB3    3 
Related to maturity 
0.028 Regulation of megakaryocyte differentiation  ITGA2B MYL9     2 
Related to activation 
0.003 Platelet activation  MYL9 ITGA2B TREML1 ITGB3   4 
0.003 Platelet aggregation  MYL9 ITGA2B ITGB3    3 
0.004 Homotypic cell-cell adhesion  MYL9 ITGA2B ITGB3    3 
0.007 Integrin-mediated signalling pathway  ITGA2B ITGB3 ITGA7    3 
0.010 Cell-cell adhesion  MYL9 SRPX2 ITGA2B PDLIM1 ITGB3 ITGA7 6 
0.011 Blood coagulation  MYL9 ITGA2B TREML1 ITGB3   4 
0.028 Heterotypic cell-cell adhesion  ITGA7 ITGB3     2 
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Table 6.4: Gene ontology analysis of differentially expressed genes between neutrophils from patients with stable and AECOPD  
Outcome GO 
analysis 
p-value GO term Associated genes # of associated 
genes 
Other 
0.003 Wound healing  MYL9 ITGB3 SYTL4 ITGA2B SPARC TREML1 6 
0.003 Platelet degranulation  ITGA2B SYTL4 SPARC ITGB3   4 
0.004 Response to wounding  MYL9 ITGB3 SYTL4 ITGA2B SPARC TREML1 6 
0.011 Haemostasis  MYL9 ITGA2B TREML1 ITGB3   4 
0.011 Coagulation  MYL9 ITGA2B TREML1 ITGB3   4 
0.027 Regulation of body fluid levels  MYL9 ITGA2B TREML1 ITGB3   4 
0.028 
Positive regulation of cellular component 
movement  SPARC ITGA2B SRPX2 ITGB3   4 







0.001 Fibrinogen binding  ITGB3 ITGA2B 2 





Related to chemotaxis 
<0.001 Focal adhesion MYL9 ITGA2B ITGA7 ITGB3 4 
<0.001 ECM-receptor interaction ITGA2B ITGA7 ITGB3  3 
<0.001 Regulation of actin cytoskeleton MYL9 ITGA2B ITGA7 ITGB3 4 
0.012 PI3K-Akt signalling pathway ITGA2B ITGA7 ITGB3  3 
Related to phagocytosis 
0.016 Phagosome ITGB3 TUBB1   2 
Related to activation 
0.001 Platelet activation GUCY1B1 ITGA2B ITGB3  3 
Other 
<0.001 Hypertrophic cardiomyopathy (HCM) ITGA2B ITGA7 ITGB3  3 
<0.001 Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) ITGA2B ITGA7 ITGB3  3 
<0.001 Dilated cardiomyopathy (DCM) ITGA2B ITGA7 ITGB3  3 
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Table 6.4: Gene ontology analysis of differentially expressed genes between neutrophils from patients with stable and AECOPD  
Outcome GO 
analysis 
p-value GO term Associated genes # of associated 
genes 
0.010 Gap junction GUCY1B1 TUBB1   2 
0.011 Hematopoietic cell lineage ITGA2B ITGB3   2 
0.011 Human papillomavirus infection ITGA2B ITGA7 ITGB3  3 
0.015 Vascular smooth muscle contraction MYL9 GUCY1B1   2 
0.015 Fluid shear stress and atherosclerosis ITGA2B ITGB3   2 
0.016 Oxytocin signalling pathway MYL9 GUCY1B1   2 
0.017 CGMP-PKG signalling pathway MYL9 GUCY1B1   2 
























0.016 Phospholipase activity  SMPD3 PLD4    2 
0.016 Transmembrane signalling receptor activity  IL5RA HRH4 CYSLTR2 P2RY2 SIGLEC8 5 
0.016 Phosphoric diester hydrolase activity  SMPD3 PLD4    2 
0.016 Lipase activity  SMPD3 PLD4    2 
0.023 Signalling receptor activity  IL5RA HRH4 CYSLTR2 P2RY2 SIGLEC8 5 
0.023 Molecular transducer activity  IL5RA HRH4 CYSLTR2 P2RY2 SIGLEC8 5 
Legend: Complete combined list of differentially expressed genes of neutrophils from patients with stable COPD compared with AECOPD associated with 
biological processes, molecular functions or (KEGG) pathways using ShinyGO gene ontology (GO) analysis. Terms are grouped based on upregulated 
(orange) or downregulated (blue) in AECOPD compared to stable COPD and if terms are related to chemotaxis, phagocytosis, maturity or activation.  
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6.2.4.3 Does gene expression match surface protein expression? 
The genes corresponding to the surface markers (shown in Chapter 5 Table 5.4) investigated 
in Section 6.2.2 were identified and plotted on a heatmap for both participant groups (Figure 
6.16). There were no statistically significant changes in expression of these genes, although 
visually it appeared CEACAM8 expression was reduced and CXCR2 expression increased. 
Due to the limited sample number, correlations between surface and gene expression were 
not included. 
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Figure 6.16: Normalised expression of genes corresponding to selected surface markers 
 
Gene counts for mRNA extracted from neutrophils was normalised for gene length and 
total read number. Gene expression shown for selected markers (Table 5.4) for either a) 
each individual participant or b) mean expression for each participant group. Genes were 
clustered using Euclidean spacing and coloured based on the z-score generated from gene 
normalisation.  
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6.3 Discussion 
Many studies have begun to investigate neutrophil phenotypes and how these may be linked 
to a variety of diseases, but less is known about these neutrophil phenotypes change in 
AECOPD. Here, a novel integrated panel was used to assess a variety of neutrophil phenotypes 
both in stable COPD and during an exacerbation, based on evidence that neutrophil migration 
was reduced in AECOPD (McIver et al., 2019). 
Neutrophils from patients with AECOPD showed increases in the expression of activation 
markers, increased apoptosis, a reduction in CXCR2 expression, and increased expression of 
genes linked to chemotaxis and activation. 
6.3.1 The activation status of neutrophils 
Based on expression of CD11b, CD66b and CD62L, previously linked with neutrophil activation 
(Rosales, 2018), neutrophils from patients with AECOPD were systemically activated; showing 
higher expression of CD11b and CD66b (although CD66b expression did not quite achieve 
statistical significance). Notably, a reduction in CD62L was not observed. A similar activation 
pattern has been observed in patients with sepsis (Lewis et al., 2015) and following cardiac 
surgery (Orr et al., 2007), where CD62L expression was not lower, potentially suggesting that 
these changes in systemic neutrophil activation are in response to the acute increased 
inflammatory burden in AECOPD rather than chronic disease. A subset of patients also showed 
increased levels of apoptosis that may partly link to increased activation as previously 
observed (Noguera et al., 2004) and could suggest altered mechanisms of neutrophil 
clearance or survival.  
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6.3.2 Senescence and changes in chemokine sensing 
Previous studies have described neutrophil senescence based on the increase of chemokine 
receptor CXCR4 (Martin et al., 2003; Weisel et al., 2009). The low level of CXCR4 expression 
detected on neutrophils patients with COPD and AECOPD in this thesis suggest that increased 
senescence is not observed in the circulating neutrophil population and  These results are 
supported by previous studies in healthy individuals (Rankin, 2010), but has not previously 
been reported in AECOPD.  
Linked with neutrophil senescence, a previous study described an ‘overactive senescence’ 
neutrophil phenotype in patients with ischemic stroke (Weisenburger-Lile et al., 2019), 
defined as being CXCR4+CD62Ldim. Indeed, there was some evidence this may be increased in 
AECOPD - potentially suggesting this population is enhanced by acute systemic inflammation. 
The increase during acute inflammation, including from the previous study in ischemic stroke 
(Weisenburger-Lile et al., 2019), suggests a role of non-traditional senescent cells in acute 
inflammation and to a lesser extent in chronic inflammation. It cannot be overlooked, 
however, that only a small absolute percentage of neutrophils display this phenotype, and 
further investigation would be required to determine if this is of clinical importance.  
In contrast, levels of CXCR2 were reduced on neutrophils from patients with AECOPD, 
suggesting chemokine sensing may be altered in these cells. In addition, a similar decrease in 
surface CXCR2 on neutrophils has been observed in patients with sepsis (Rios-Santos et al., 
2007), suggesting another similarity between systemic inflammation and the impact on 
neutrophils in both sepsis and AECOPD. Alterations in CXCR2 may suggest a potential 
mechanism for the reduced migratory accuracy of neutrophils from patients with COPD and 
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AECOPD – a defect that has been previously described (Sapey et al., 2011). The reduction in 
CXCR2 expression described here may also explain the lack of clinical efficacy in some studies 
of CXCR2 inhibitors in COPD (Lazaar et al., 2020), as these may be targeting a mechanism that 
is already downregulated in patients with AECOPD. Furthermore, this thesis demonstrated 
that several genes were upregulated in neutrophils from patients with AECOPD that were 
linked to positive regulation of cell chemotaxis (including SPARC, SRPX2 and ITGB3). Whilst 
relatively under-investigated in neutrophil chemotaxis, previous studies have suggested 
SRPX2 increases cell motility in cancer (Tamaka et al., 2009) and SPARC appears to reduce 
clustering and activation of several integrins in ovarian cancer (Said, Socha and Motamed, 
2007). Upregulation of these genes may link to changes to a loss in cell polarity leading to 
reduced migration accuracy and the potential for increased collateral damage. However, 
further investigation would be required to identify the direct functional impact of the 
increased expression of these genes in human neutrophils. 
6.3.3 Neutrophil maturity 
Acute inflammation has previously been reported to lead to premature neutrophil release into 
the circulation (referred to as emergency granulopoiesis), seen during sepsis (Taneja et al., 
2008), after invasive cardiac  surgery (Orr et al., 2005) and in severe COVID-19 (Carissimo et 
al., 2020). 
The data presented here showed that in AECOPD, there was no change in either CD10 or CD16 
expression, and therefore maturity of circulating neutrophils, indicating an absence of 
emergency granulopoiesis. The lack of circulating immature neutrophils in AECOPD is perhaps 
surprising given the acute inflammatory stimulus, but may suggest chronic inflammation 
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prevents or significantly diminishes emergency granulopoiesis and shows divergence in 
AECOPD compared with sepsis. 
6.3.4 Inflammatory status and reverse transmigration 
Neutrophils have also been reported to acquire a pro-inflammatory phenotype through the 
expression of an antigen presentation molecule, HLA-DR (Vono et al., 2017) or anti-
inflammatory properties by inhibiting T cell responses via PD-L1 (Keir et al., 2008; Wei et al., 
2013). CD11c has also been linked with a predictive marker in SIRS (Lewis et al., 2015) and 
CD54 with neutrophil reverse transmigration (Buckley et al., 2006).  
In this study, little or no HLA-DR expression was detected on neutrophils from any participant, 
with no changes in CD11c or CD54 expression in AECOPD – suggesting neutrophils do not 
display pro-inflammatory or reverse transmigration properties in these patients. The similar 
low expression of CD54 expression also suggests that it is unlikely that pro-inflammatory 
conditions in the lung could lead to systemic effects by altering the neutrophil phenotype 
before they return to the circulation. 
However, a small yet significant change in PD-L1 was observed in patients with AECOPD 
compared with stable COPD, suggesting an appearance of an anti-inflammatory neutrophil 
phenotype. A similar phenotype of neutrophils has been reported in patients with SLE, 
showing increased PD-L1 expression that correlated with disease severity scores (Luo et al., 
2016), providing some parallels to the impact of systemic inflammation. However, increasing 
PD-L1 expression on neutrophils in both AECOPD and SLE does not demonstrate these 
populations are beneficial. Given the small change in PD-L1 expression in AECOPD, further 
investigation is required to determine firstly if this has functional relevance, and indeed if this 
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neutrophil population exhibits immunosuppressive and indeed protective properties. The lack 
of increase in CD11c expression suggests a divergence from the potential anti-inflammatory 
phenotype observed in SIRS and sepsis (Lewis et al., 2015).  
A further potentially immunosuppressive neutrophil phenotype, defined as CD16+CD62Ldim, 
has been identified in healthy human volunteers injected with systemic LPS (Pillay et al., 2012). 
There was no increase in this population of neutrophils in AECOPD compared with stable 
COPD, suggesting this immunosuppressive phenotype does not appear in AECOPD. 
6.3.5 Neutrophil heterogeneity 
Going beyond the constraints of traditional gating, dimension-reduction clustering and 
visualisation revealed broadly similar phenotypes are observed in both stable COPD and 
AECOPD, suggesting whilst differences are observed in individual markers, there is a fine and 
subtle shift in surface expression across individual cells. The lack of statistical significance 
between the proportion of neutrophils within each cluster may be a result of the number of 
clusters and number of neutrophils selected for analysis – however, subtle distinctions could 
be identified that built upon the individual marker analysis: two clusters, increased in AECOPD, 
showed higher CD11b and CD66b expression compared to two clusters, reduced in AECOPD, 
that had lower CD11b and CD66b expression.  
Taking both traditional and multi-dimensional analyses together suggest systemic activation 
of neutrophils does occur in AECOPD, but neutrophils are not activated equally. Furthermore, 
overlap of neutrophils expressing higher levels of CD11b, CD66b and CD11c builds on 
differences seen in the single-marker analysis and suggests a small role of CD11c in the 
activated neutrophil phenotype. The sorting of these cells may reveal true heterogeneity 
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between neutrophil populations and may provide insight to why neutrophils may respond to 
systemic signals differently. These analyses highlight not only that neutrophil phenotypes are 
complex, but further suggest a sepsis-like phenotype in AECOPD, as CD11c expression was 
increased on neutrophils from patients with sepsis (Lewis et al., 2015). 
6.3.6 The impact of gene expression on neutrophil phenotype 
A total of 102 differentially expressed genes between stable COPD and AECOPD, providing 
evidence that neutrophils are transcriptionally active cells. Many genes associated with 
functional processes were upregulated in neutrophils from patients with AECOPD, showing 
increased expression of genes related to cell adhesion, a function of activated neutrophils and 
could potentially explain increased influx of neutrophils into inflamed tissue, such as the lung, 
in these patients. Another study comparing ICU vs non-ICU patients with COPD suggested that 
multiple neutrophil proteases were upregulated (Almansa et al., 2012), although the 
comparison was done on whole blood and not isolated neutrophils, potentially explaining the 
lack of overlap in differentially expressed genes identified between their study and the data 
in this thesis.  
Whilst genes associated with activation were increased, several surface G-protein coupled 
receptors (GPCRs) linked with detection of external chemical signals, referred to as drugs in 
the GO database, were downregulated. Further investigation is necessary to assess the impact 
of reduced expression of chemokine receptors. For instance, CCR3 was found to be expressed 
at a lower level in neutrophils AECOPD compared with stable COPD, but the surface expression 
has been suggested to increase in neutrophils in the lung during influenza pneumonia (Rudd 
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et al., 2019). Together, these data may point to an inability of neutrophils in patients with 
AECOPD to mount appropriate responses to infection.  
In addition, upregulation of integrins ITGA7, ITGB3, ITGA2B and the gene for a calcium channel 
CACNG6 (linked with hypertrophic, dilated and arrhythmogenic right ventricular 
cardiomyopathy) may suggest evidence for the role of neutrophils in right-sided heart failure 
seen in patients with COPD (Díez, Morgan and García, 2013; Mullerova et al., 2013) and the 
increased cardiovascular burden during an exacerbation. 
Despite the identification of alteration in processes linked with activation and chemical 
sensing, genes linked with the surface markers investigated within the phenotyping panel 
(6.2.2) related to these processes were not significantly altered – but are underpowered to 
draw conclusions and requires further investigation. However, changes in gene expression 
may present novel avenues for future research, as altered gene expression may suggest an 
inability of neutrophils to respond effectively when stimulated by inflammatory or pathogenic 
cues. Indeed, as RNASeq becomes more accessible, the ability to use this technique to provide 
insight to neutrophil biology at the clinical interface becomes a greater reality – a recent study 
of whole blood RNASeq in COVID-19 patients demonstrated neutrophil-activation signatures 
associated with disease severity (Aschenbrenner et al., 2021). 
One key caveat may exists with all these gene expression analyses: neutrophil preparations 
will not have been 100% pure and, therefore, results could be skewed by contaminating cell 
types with higher levels of RNA than neutrophils. A previous study compared the effect on 
RNASeq data when neutrophil purity was 95-99% compared with 82-90% and found only 23 
genes were reported as differentially expressed between these two methods (Thomas et al., 
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2015). Three of these genes, SIGLEC8, CLC and SMPD3, were also identified in this thesis as 
being differentially expressed – however, none of these genes were independently associated 
with changes in biological or molecular processes. Overall, neutrophil purity is unlikely to have 
substantially impacted the findings from these analyses. 
6.3.7 Summary and limitations 
Here, evidence from a novel antibody panel suggests that neutrophils from patients with 
AECOPD show systemic neutrophil activation and could link to an increased cardiovascular 
burden in AECOPD. In addition, lower CXCR2 expression was observed, suggesting an 
inflammatory-mediated regulation of CXCR2 expression that could influence neutrophil 
migration and increased collateral damage in AECOPD. During an acute exacerbation, a small 
(but significant) increase in PD-L1 expression on neutrophils from patients with AECOPD 
provides evidence of an immunosuppressive response in these patients compared with stable 
COPD. Together, these changes have similarities with neutrophils in patients with sepsis – 
potentially impacting clinical care of these patients.  
The nature of COPD exacerbations, along with the recruitment of patients once admitted to 
hospital, present several challenges and limitations. All patients recruited were hospitalised 
and, therefore, likely reflect only the most severe exacerbations - although these events do 
represent the greatest burden of disease with the greatest impact on patient morbidity and 
mortality, as well as healthcare costs. Furthermore, many patients who have previously 
experienced an AECOPD are provided with ‘rescue packs’ – steroids and antibiotics that can 
be taken at the onset of an exacerbation to help prevent further symptoms and 
hospitalisation. It was not recorded which patients had used their rescue packs, or how long 
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ago, and presents a possible source of variation within these data as glucocorticoids have been 
suggested to promote neutrophil survival (Saffar, Ashdown and Gounni, 2011). 
Here, for the first time, comprehensive neutrophil phenotyping reveals subtle neutrophil 
phenotype differences in patients with an exacerbation, including changes at the gene 
expression level, that do not appear to be due to increased immaturity of neutrophils or 
classical senescence. Instead, changes were consistent with activation and migration. These 
changes may provide mechanisms of neutrophil dysfunction, such as migration, and potential 
for therapeutics that could promote anti-inflammatory phenotypes – but further investigation 
would be necessary to determine if this provided clinical benefit. 
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7 CHAPTER 7: 
FUNCTIONAL ANALYSIS OF 
NEUTROPHILS IN COPD 
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7.1 Brief Introduction 
Neutrophils carry out a number of functions that protect from pathogen attack and in 
response to tissue damage (Hughes, Sapey and Stockley, 2019). In order to perform these 
roles, they must first successfully navigate to the correct area of the body, following either 
inflammatory signals of damage or infection – a process known as chemotaxis (Wilkinson, 
1985). In the absence of any chemoattracting agent, human neutrophils still move in a process 
called chemokinesis (Campoccia et al., 1993) - random and non-specific movement. The 
accuracy of neutrophil chemotaxis has previously been shown to decline with age and is 
impaired in patients with COPD compared to age-matched healthy individuals (Yoshikawa et 
al., 2007). It has been previously shown that neutrophils incubated with PI3K inhibitors can 
rescue the age-related decline in neutrophil chemotaxis (Sapey et al., 2014). Accurate 
migration is not only essential to neutrophils successfully getting to the site of inflammation, 
but has been suggested as a potential mechanism for increased lung tissue damage (Naccache 
and Lefebvre, 2014).  
Much is known about neutrophil chemotaxis to common chemical mediators of inflammation 
such as CXCL8, which activates neutrophils seen both as increases in CD11b and CD66b surface 
expression (Detmers et al., 1990) and an increase in neutrophil chemotaxis (Moore and 
Kunkel, 2019). However, far less attention has been given to their response to CXCL12 – the 
major ligand of CXCR4. As discussed, CXCR4 expression on neutrophils has been linked to 
senescence (Martin et al., 2003). Previous work has indicated HeLa cells over-expressing 
CXCR4 are capable of sensing and migrating towards CXCR4 (Dillenburg-Pilla et al., 2015) and 
that CXCL12 can retain neutrophils at sites of inflammation in zebrafish (Isles et al., 2019) and 
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in the bone marrow of mice (Martin et al., 2003) and humans (Kawai and Malech, 2009). The 
CXCR4/CXCL12 axis may, therefore, be a potential mechanism for neutrophil retention in the 
lungs of patients with COPD. 
Specific patterns of protein surface expression by neutrophils, referred to as the neutrophil 
phenotype, can be altered by the inflammatory environment and subsequently impact on 
neutrophil chemotaxis; for example, human serum altered neutrophil migration behaviour 
though agarose gel in vitro (Dahl and Lindroos, 1979). The neutrophil phenotype is also 
influenced by the local environment, with an intense interest in the cause or effect 
relationship between chronic disease and neutrophil phenotype (Hellebrekers, Vrisekoop and 
Koenderman, 2018; Rosales, 2018; Hughes, Sapey and Stockley, 2019; Maréchal et al., 2020). 
Understanding how the inflammatory environment in patients with COPD influences changes 
in neutrophil function is of paramount importance to assist the development of potential 
therapeutics.  
7.1.1 Aims and hypothesis 
To help address some of these questions, healthy volunteers and patients with COPD (but 
without stratification based on multimorbidity) were recruited and the levels of CXCL12 in 
peripheral blood samples were measured using an ELISA. Whilst the previous two chapters 
revealed no differences in CXCR4 expression on neutrophils between healthy volunteers and 
patients with COPD, it was hypothesised that functional differences may exist in the receptor 
or downstream signalling, and chemotaxis of isolated neutrophils towards CXCL12 using Insall 
chambers (Muinonen-Martin et al., 2010) and time-lapse light microscopy was assessed. In 
addition, isolated neutrophils were pre-incubated with serum and plasma from both healthy 
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volunteers and patients to determine its impact on both neutrophil phenotype and 
subsequent chemotaxis.  
It was hypothesised that patients with COPD would show increased migration towards CXCL12 
compared with healthy controls. Due to potentially higher levels of inflammatory cytokines in 
peripheral blood of patients with COPD, neutrophils exposed to serum and plasma from these 
patients would show increased activation and mimic changes in CXCR2 expression observed 
in the previous chapters.  
7.2 Results 
7.2.1 CXCL12 and neutrophil chemotaxis 
7.2.1.1 Plasma CXCL12 concentration  
CXCL12 is the major ligand for CXCR4 – a receptor implicated in neutrophil senescence  (Martin 
et al., 2003). Using an ELISA, plasma CXCL12 concentrations from study participants ranged 
from 0.685ng/mL to 2.1ng/mL, with a significantly lower CXCL12 concentration in both COPD 
groups compared to healthy (Figure 7.1). These data indicated CXCL12 levels in these healthy 
volunteers was consistent with previously published findings and provided evidence that 
CXCL12 was reduced in patients with both stable and acute exacerbations of COPD, potentially 
having implications for the control of neutrophil homeostasis in these patients. 
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Figure 7.1: Plasma concentration of CXCL12 from healthy individuals and patients with 
stable and exacerbations of COPD 
 
Plasma was separated from whole blood from healthy elderly participants (HE, n=10), 
patients with stable COPD (n=15), or patients with an acute exacerbation of COPD 
(AECOPD, n=15) and frozen prior to testing. Vials were thawed and plasma CXCL12 levels 
measured using an ELISA. In each case, the horizontal lines indicate the median value with 
interquartile range. Statistical analysis performed using a Kruskal-Wallis test (K) with 
Dunn’s multiple comparison, compared to the HE group. 
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7.2.1.2 Healthy young neutrophil chemotaxis towards CXCL12 
Using the concentration of CXCL12 from plasma samples in both healthy volunteers and 
patients with COPD, neutrophil chemotaxis towards three concentrations of CXCL12 was 
assessed: 1, 10 and 100ng/mL; where RPMI served as the negative control and CXCL8 as the 
positive control. Increases in speed, velocity and chemotaxis index were observed towards 
CXCL8 compared with RPMI (Figure 7.2a, b and c), albeit only reaching statistical significance 
for velocity. There was also an increase in displacement (significant; Figure 7.3a) and distance 
travelled (not significant; Figure 7.3b) between CXCL8 and RPMI, but no change in persistence 
(Figure 7.2d) or directness (Figure 7.3c).  
Unlike with CXCL8, neutrophils from HY individuals showed no change in speed, velocity, 
chemotaxis index towards CXCL12 when compared to RPMI (Figure 7.2), although statistical 
analysis of persistence could not be completed due to inadequate data for one sample (Figure 
7.2d). The was also no difference observed in displacement, distance travelled or directness 
of neutrophils from HY participants towards CXCL12 compared to RPMI (Figure 7.3). Together, 
these data support that neutrophils from healthy individuals could migrate towards CXCL8, 
but not CXCL12.  
When the same experiment was performed with neutrophils from patients with stable COPD, 
again, a significant increase in speed (Figure 7.4a), chemotaxis index (Figure 7.4c) 
displacement (Figure 7.4a), distance travelled (Figure 7.4b) and directness (Figure 7.4c) was 
observed towards CXCL8 compared to RPMI control. No significant change between CXCL8 
and RPMI was observed in velocity (Figure 7.4b) or persistence, although complete statistical 
analysis could not be performed due to a missing data point (Figure 7.4d).  
Chapter 7  Page | 290  
In contrast, no significant differences in any parameter were observed in neutrophils from 
patients with COPD towards CXCL12 compared with RPMI (Figure 7.4 and Figure 7.5). There 
was some evidence of a response at 10ng/mL based on both chemotaxis index (Figure 7.4c) 
and directness (Figure 7.5c), but did not reach statistical significance.  
Overall, these data suggest neutrophils from patients with COPD responded to CXCL8, albeit 
less robustly than neutrophils from HY participants. There was also a greater variation in the 
response to CXCL12 of neutrophils from patients with COPD compared with HY, suggesting 
neutrophils from some patients may show a small response to CXCL12. 
  

















































































































Figure 7.2: Average speed, velocity, chemotaxis index and persistence of neutrophils 
isolated from healthy individuals towards CXCL12 
 
Neutrophils were isolated from healthy young participants (n=6) and incubated on glass 
coverslips before inverting onto an Insall chamber with each chemoattractant as indicated. 
Roswell Park Memorial Institute (RPMI) media was used as a negative control and 100nM 
CXCL8 as the positive control. Ten neutrophils were selected for analysis from each 12-
minute time lapse and results averaged to give a) speed, b) velocity, c) chemotaxis index 
and, d) persistence, per sample. Solid horizontal lines indicate the median value with 
interquartile range. Statistical analysis performed using a Wilcoxon matched-pairs signed 
rank test between RPMI and CXCL8 or a Freidman test with Dunn’s multiple comparison 
compared to RPMI and doses of CXCL12. *Indicates statistical analysis could not be 
performed due to missing values for one sample at 100ng/mL CXCL12. 


















































































Figure 7.3: Average displacement, distance travelled and directness of neutrophils 
isolated from healthy individuals towards CXCL12 
 
Neutrophils were isolated from healthy young participants (n=6) and incubated on glass 
coverslips before inverting onto an Insall chamber with each chemoattractant as indicated. 
Roswell Park Memorial Institute (RPMI) media was used as a negative control and 100nM 
CXCL8 as the positive control. Ten neutrophils were selected for analysis from each 12-
minute time lapse and results averaged to give a) displacement, b) total distance travelled 
and c) the directness, per sample. Solid horizontal lines indicate the median value with 
interquartile range. Statistical analysis performed using a Wilcoxon matched-pairs signed 
rank test between RPMI and CXCL8 or a Freidman test with Dunn’s multiple comparison 
compared to RPMI and doses of CXCL12. 
 
















































































































Figure 7.4: Average speed, velocity, chemotaxis index and persistence of neutrophils 
isolated from patients with COPD towards CXCL12 
 
Neutrophils were isolated from patients with COPD participants (n=6) and incubated on 
glass coverslips before inverting onto an Insall chamber with each chemoattractant as 
indicated. Roswell Park Memorial Institute (RPMI) media was used as a negative control 
and 100nM CXCL8 as the positive control. Ten neutrophils were selected for analysis from 
each 12-minute time lapse and results averaged to give a) speed, b) velocity, c) chemotaxis 
index and, d) persistence, per sample. Solid horizontal lines indicate the median value with 
interquartile range. Statistical analysis performed using a Wilcoxon matched-pairs signed 
rank test between RPMI and CXCL8 or a Freidman test with Dunn’s multiple comparison 
compared to RPMI and doses of CXCL12. *Indicates statistical analysis could not be 
performed due to missing values for one sample at 100ng/mL and 10ng/mL CXCL12. 
 
















































































Figure 7.5: Average displacement, distance travelled and directness of neutrophils 
isolated from patients with COPD towards CXCL12 
 
Neutrophils were isolated from patients with COPD (n=6) and incubated on glass coverslips 
before inverting onto an Insall chamber with each chemoattractant as indicated. Roswell 
Park Memorial Institute (RPMI) media was used as a negative control and 100nM CXCL8 as 
the positive control. Ten neutrophils were selected for analysis from each 12-minute time 
lapse and results averaged to give a) displacement, b) total distance travelled and c) the 
directness, per sample. Solid horizontal lines indicate the median value with interquartile 
range. Statistical analysis performed using a Wilcoxon matched-pairs signed rank test 
between RPMI and CXCL8 or a Freidman test with Dunn’s multiple comparison compared 
to RPMI and doses of CXCL12. 
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7.2.2 Neutrophil chemotaxis following phosphoramidon treatment 
Initial data from the phenotyping panel (Section 5.2.3.7) suggested there may be altered 
surface expression of CD10 and this may play a role in controlling chemotaxis towards fMLP. 
As CD10 can be pharmacologically blocked using phosphoramidon, neutrophil chemotaxis 
following phosphoramidon incubation was assessed. Previous data have shown that 
phosphoramidon achieves 50% inhibition (IC50) of CD10 at 0.034 µM (Kukkola et al., 1995), but 
can also inhibit endothelin-converting enzyme and angiotensin-converting enzyme with an 
IC50 of 3.5 µM and 78 µM respectively (Kukkola et al., 1995). 
Chemotaxis of neutrophils following pre-treatment with various concentrations of 
phosphoramidon was assessed towards fMLP, where RPMI served as a negative control and 
CXCL8 and fMLP the positive control. Statistically significant increases in speed, velocity, 
chemotaxis index (Figure 7.6a, b and c), displacement and distance travelled (Figure 7.7a and 
b) towards fMLP was observed when compared with RPMI. No change was seen in persistence 
(Figure 7.6d) or directness (Figure 7.7c) between fMLP and RPMI.  
A potentially small concentration-dependent decline in overall speed was observed with 
phosphoramidon treatment compared to RPMI treatment, approaching statistical significance 
at 50µM (Figure 7.6a), but not with velocity, chemotaxis index or persistence (Figure 7.6b, c 
and d) or displacement and directness (Figure 7.7a and c) – although sample-to-sample 
variation may impact this assessment. Again, there was a suggestion that 50µM of 
phosphoramidon reduced the total distance travelled compared to untreated neutrophils 
towards fMLP, reaching significance at the group level (Figure 7.7a and b).  
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Together, these data suggest phosphoramidon may alter overall neutrophil speed and 
distance at 50µM, however, did not impact accuracy or reach statistical significance at any 
dose and requires further samples to fully investigate the potential effect on neutrophil 
migration.  






























































































































Figure 7.6: Impact of phosphoramidon treatment on the speed, velocity, chemotaxis 
index and persistence of neutrophils isolated from healthy individuals towards fMLP 
 
Neutrophils were isolated from healthy young participants (n=6) and pre-treated with 
Roswell Park Memorial Institute (RPMI) media or phosphoramidon (PA) for 30 minutes 
before incubation on glass coverslips and inverting onto an Insall chamber. Ten neutrophils 
were selected for analysis from each 12-minute time lapse and results averaged to give a) 
speed, b) velocity, c) chemotaxis index and, d) persistence, per sample. Solid horizontal 
lines indicate the median value with interquartile range. Statistical analysis performed 
using a Wilcoxon matched-pairs signed rank test between RPMI and fMLP or a Freidman 
test with Dunn’s multiple comparison compared to fMLP for doses of PA.  


























































































Figure 7.7: Impact of phosphoramidon treatment on the displacement, distance travelled 
and directness of neutrophils isolated from healthy individuals towards fMLP 
 
Neutrophils were isolated from healthy young participants (n=6) and pre-treated with 
Roswell Park Memorial Institute (RPMI) media or phosphoramidon (PA) for 30 minutes 
before incubation on glass coverslips and inverting onto an Insall chamber. Ten neutrophils 
were selected for analysis from each 12-minute time lapse and results averaged to give a) 
displacement, b) total distance travelled and c) the directness, per sample. Solid horizontal 
lines indicate the median value with interquartile range. Statistical analysis performed 
using a Wilcoxon matched-pairs signed rank test between RPMI and fMLP or a Freidman 
test with Dunn’s multiple comparison compared to fMLP for doses of PA. 
Chapter 7  Page | 299  
7.2.3 Inducible phenotype using pooled plasma 
In patients with stable COPD, neutrophils will be exposed to potentially raised levels of 
cytokines for a prolonged period due to chronic inflammation in the lungs. To test if 
neutrophils from healthy individuals exposed to potentially inflammatory conditions would 
display an altered phenotype, plasma from patients with COPD was collected and pooled 
before incubating with isolated neutrophils from HE participants. Equally, to test if the altered 
neutrophil phenotype identified in patients with AECOPD could be replicated ex vivo, 
neutrophils from patients with stable COPD were exposure to pooled plasma from patients 
with AECOPD. These experiments are summarised in Figure 7.8.  
7.2.3.1 Validation of serum and plasma exposure 
Neutrophils isolated neutrophils from HY participants incubated with 10-50% autologous 
serum resulted in a significant decline in the percentage of live neutrophils (Figure 7.9). To 
determine if this effect was replicated when using plasma, neutrophils from HY participants 
were incubated with autologous plasma (AP) at the same concentrations, which had less of an 
effect on neutrophil viability (Figure 7.9). Therefore, plasma was used to investigate the 
influence of chronic inflammation on the phenotype of circulating neutrophils. 
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Figure 7.8: Schematic overview of pooled plasma experiments 
 
Neutrophils from healthy elderly volunteers were isolated from whole blood and 
incubated for 30 minutes with either no plasma, autologous plasma, pooled healthy 
plasma or pooled plasma from patients with COPD. Neutrophil phenotypes were then 
assessed using surface expression of key markers as detailed in Section 2.6. 
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Figure 7.9: Effect of autologous serum and plasma on isolated neutrophils from healthy 
young participants 
 
Neutrophils from whole blood were isolated and incubated for 30 minutes with either 
autologous serum (n=6) or autologous plasma (n=3) at various concentrations before 
staining with viability dyes. The percentage of live neutrophil events were recorded for 
each participant. For each concentration, the point indicates the median value with 
interquartile range. Statistical analysis performed using a Freidman test for both 
conditions. 
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7.2.3.2 Effect of stable COPD plasma on neutrophils from healthy age-matched participants  
Previous investigations revealed that activation markers were not significantly altered in 
neutrophils from healthy participants and patients with stable COPD, but there was a 
significant decrease in CXCR2 expression (Section 5.2.3). To investigate if the change in 
neutrophil phenotype is blunted or otherwise altered due to the chronic exposure to 
inflammatory stimuli, acute exposure of neutrophils from HE donors to pooled plasma from 
patients with stable COPD was carried out. 
Despite validation experiments revealing limited impact of pooled plasma incubation on 
neutrophil viability with neutrophils from HY participants, neutrophils from HE participants 
showed a marked reduction in the percentage of live cells per sample (Figure 7.10), with the 
majority of non-live neutrophils being apoptotic. It was then assessed if inclusion of apoptotic 
cells in the calculation of MFI differed from only including live cells to negate samples where 
very few cells would be included in the live cell gate. A good correlation was observed in all 
markers across all conditions (Figure 7.11), with outliers occurring when the percentage of live 
cells was very low. Therefore, only dead or necrotic cells were excluded from analysis allowing 
a more accurate MFI to be calculated from both live and apoptotic cells. 
Incubation of neutrophils from HE participants in pooled plasma from stable COPD patients 
resulted in a significant increase in CD11b expression (Figure 7.12a) and decline in CD62L 
expression (Figure 7.12c) compared to AP. With both CD11b and CD62L, no significant change 
in expression was seen on neutrophils incubated with no plasma or pooled HE plasma 
compared to AP, indicating the changes observed were specifically caused by plasma from 
patients with COPD (Figure 7.12a and c). In contrast, a significant change in CD66b expression 
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was observed between no plasma and AP, but not between AP and pooled plasma from either 
group (Figure 7.12b), indicating a non-specific change due to incubation of neutrophils with 
plasma. 
No change in CXCR2 expression was observed between AP and pooled COPD plasma 
treatment, however, significant changes were observed between AP and both no plasma and 
pooled HE plasma controls (Figure 7.13a). In contrast, CD10 expression was significantly higher 
in pooled COPD plasma compared to AP (Figure 7.13b), although there did also appear to be 
a slight, but not statistically significant, increase even with AP treatment. No difference was 
seen in CD16 expression between AP and pooled COPD plasma treatment, however treatment 
with pooled HE plasma showed a significant reduction compared with AP treatment – albeit a 
very small absolute change (Figure 7.13c).  
Together, changes in CD11b and CD62L suggest increased activation of healthy neutrophils 
when incubated in the presence of pooled COPD plasma, with a small increase in CD10 
expression. Changes in CD66b and CXCR2 and CD16 appear related to plasma treatment rather 
than specifically to COPD plasma. 
As shown previously, neutrophils from HE participants incubated with AP showed a significant 
decrease in viability compared to neutrophils incubated with no plasma (Figure 7.10). To 
investigate if the viability impacted on the surface expression, linear regression analysis was 
performed of viability against surface expression for all participants and conditions (Figure 
7.14). A weak, but statistically significant, correlation was observed with viability and CD66b, 
CD62L (Figure 7.14b and c), CXCR2 and CD10 (Figure 7.14d and e). There was not a statistically 
significant correlation between viability and CD11b (Figure 7.14a) or CD16 (Figure 7.14f) 
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expression. These data suggest that cell viability may be a contributing factor to the change in 
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Figure 7.10: The effect of pooled plasma from patients with stable COPD on neutrophil 
viability from healthy participants 
 
Neutrophils from healthy elderly participants (n=13) were isolated from whole blood and 
incubated with either autologous plasma (AP), pooled plasma from patients with stable 
COPD (COPD), no plasma (control) or pooled plasma from healthy elderly participants (HE, 
control). The percentage of live neutrophil events were recorded for each participant. In 
each case, the horizontal line indicates the median value with interquartile range. 
Statistical analysis performed using a Freidman’s test (F) with Dunn’s multiple comparison, 
compared to the no plasma group. 
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Figure 7.11: Comparison of the median fluorescence intensity of surface markers 
between only live or live and apoptotic neutrophils from healthy elderly participants 
 
Neutrophils from healthy elderly participants (n=13) were isolated from whole blood and 
incubated with either autologous plasma, pooled plasma from healthy elderly participants 
or pooled plasma from patients with stable COPD. The median fluorescence intensity (MFI) 
for a) CD11b, b) CD66b, c) CD62L, d) CD10, e) CD16 and f) CXCR2 were recorded for either 
only live cells, or both live and apoptotic cells. The line of best fit using linear regression is 
shown. 
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Figure 7.12: The effect of pooled plasma from patients with stable COPD on neutrophil 
activation markers from healthy participants 
 
Neutrophils from healthy elderly participants (n=13) were isolated from whole blood and 
incubated with either autologous plasma (AP), pooled plasma from healthy elderly 
participants (HE) or pooled plasma from patients with stable COPD (COPD). The median 
fluorescence intensity (MFI) of a) CD11b, b) CD66b, and c) CD62L were measured. In each 
case, the horizontal line indicates the median value. Statistical analysis performed using a 
Freidman’s test (F) with Dunn’s multiple comparison, compared to the AP treatment group. 
 
Chapter 7  Page | 308  
  














































Figure 7.13: The effect of pooled plasma from patients with stable COPD on neutrophil 
chemokine and maturity markers from healthy participants 
 
Neutrophils from healthy elderly participants (n=13) were isolated from whole blood and 
incubated with either autologous plasma (AP), pooled plasma from healthy elderly 
participants (HE) or pooled plasma from patients with stable COPD (COPD). The median 
fluorescence intensity (MFI) of a) CD11b, b) CD66b, and c) CD62L were measured. In each 
case, the horizontal line indicates the median value. Statistical analysis performed using a 
Freidman’s test (F) with Dunn’s multiple comparison, compared to the AP treatment group. 
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Figure 7.14: Correlation between neutrophil viability and surface expression of 
activation, chemokine and maturity markers on neutrophils from healthy participants 
following plasma treatment 
 
Neutrophils from healthy elderly participants (n=13) were isolated from whole blood and 
incubated with either autologous plasma, pooled plasma from patients with stable COPD, 
no plasma (control) or pooled plasma from healthy elderly participants (control). The 
percentage of live neutrophil events was plotted against the median fluorescence intensity 
(MFI) of a) CD11b, b) CD66b, c) CD62L d) CXCR2, e) CD10 and f) CD16. In each case, linear 
regression (solid line) is shown with 95% confidence intervals (dotted line). The goodness 
of fit (r2) and p-values are indicated for each linear regression. 
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7.2.3.3 Effect of patient plasma on neutrophil chemotaxis 
To further evaluate changes in neutrophils in response to plasma, the chemotaxis of isolated 
neutrophils towards CXCL8 using Insall chambers was assessed. It was noted that significantly 
less neutrophils adhered to the coverslips after pre-treatment with either AP or pooled plasma 
from patients with COPD compared to RPMI treated neutrophils (Figure 7.15). This resulted in 
less than 10 cells on some coverslips, meaning these conditions could not be analysed. These 
results suggest plasma pre-treatment altered the ability of neutrophils to adhere to the 
coverslip. 
7.2.3.4 Time-lapse microscopy of neutrophils during plasma incubation 
Due to the reduced numbers of neutrophils bound to glass coverslips during plasma 
incubation, time-lapse imaging was used to visualise the binding dynamics of neutrophils 
incubated in human plasma. Cells kept in RPMI showed little signs of activation (spreading out 
of the cell), but adherence after 10 minutes (Figure 7.16). In contrast, cells incubated in pooled 
plasma show flattening of the cell, indicating activation, but do not appear to properly bind 
the coverslip (Figure 7.16). After a single wash, as usually performed in these experiments, 
neutrophils show a less extreme flattening morphology compared to pooled plasma alone, 
but still do not appear to bind to the coverslip (Figure 7.16). These results suggest incubation 
with plasma alters the ability of neutrophils to properly adhere to the coverslip. 
Due to the lack of adherence and number of cells to track, chemotaxis was not analysed 
further. 
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Figure 7.15: Number of neutrophils within the viewing frame of the Insall chamber for 
each slide imaged 
 
Neutrophils from whole blood from either healthy elderly (HE, n=4) or patients with COPD 
(n=1) were isolated and incubated with either RPMI, autologous plasma (AP), or pooled 
plasma (PP) from patients with stable COPD (in the case of HE donors) or an acute 
exacerbation of COPD (in the case of COPD donors) and allowed to migrate towards  either 
RPMI or CXCL8. The total number of neutrophils within the microscope view were counted 
for each slide. Each participant is linked by the grey line. Statistical analysis performed 
using a Freidman’s test (F) with Dunn’s multiple comparison, compared to the RPMI-RPMI 
treatment group. 
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Figure 7.16: Time-lapse microscopy of neutrophils in pooled plasma 
 
Neutrophils from whole blood from healthy young participants (n=2) were isolated and 
incubated on BSA-coated slides with either RPMI, pooled plasma (PP) from healthy elderly 
(HE) participants without washing, or after washing once in RPMI. Images were acquired 
every 20 seconds for 20 minutes during incubation with RPMI or plasma to observe 
adherence to the slide. Representative images for 0 minutes, 10 minutes and 20 minutes 
are shown. Scale bar indicates 50µm in length. 
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7.3 Discussion 
Chemotaxis is fundamental process by which neutrophils can migrate towards signals of 
damage, inflammation and infection, or respond to signals to remain or leave the bone 
marrow. Here, it was shown that circulating neutrophils from both healthy volunteers and 
patients with stable COPD are not able to migrate towards CXCL12, the major ligand for CXCR4. 
As CXCL12 allows retention in the bone marrow and return after senescence, these data 
suggest that circulating neutrophils in COPD do not show increased senescence. In addition, 
inhibition of CD10 was not able to significantly alter neutrophil chemotaxis towards fMLP, 
suggesting a limited role for targeting CD10 to modify neutrophil chemotaxis.  
In addition, the increase in activation markers on healthy neutrophils exposed to plasma from 
patients with stable COPD suggest that systemic inflammatory conditions are present in stable 
COPD that are capable of activating neutrophils. 
7.3.1 Circulating neutrophils show no migratory response to CXCL12 
There is interest in the role of different cytokines in patients with COPD as potential 
therapeutic avenues (Henrot et al., 2019). Neutrophil responsiveness to CXCL12 may alter 
homing of neutrophils to the bone marrow following senescence and several studies that have 
reported on neutrophil migration towards CXCL12, with one study suggesting a functional 
response to synthetic CXCL12 (Ueda et al., 1997), but another study showing no response to 
natural CXCL12 (Bleul et al., 1996). Here, Insall chambers were used to assess neutrophil 
chemotaxis. 
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The Insall chamber provides a unique assessment of neutrophil chemotaxis, allowing cells to 
be tracked under brightfield microscopy in a stable chemical gradient (Muinonen-Martin et 
al., 2010). From time-lapse microscopy, multiple parameters can be derived to assess different 
aspects of cell movement as described in Section 2.7.2. Derivation of these parameters is 
unique to slide-based migration chambers, as Transwell migration chambers, commonly used 
in multiple studies (Mócsai et al., 2006; Németh et al., 2010) only allow counting of neutrophils 
that pass through small membrane pores into a chemoattractant well. In addition, relatively 
steep chemoattractant gradients are formed with pore-based migration chambers (Wilkinson, 
1988; Shutt et al., 1998) compared to shallow gradients formed in the Insall chamber 
(Muinonen-Martin et al., 2010). Not only are shallow gradients likely more physiologically 
relevant, but some studies have also suggested that gradient steepness impacts on cell 
migration and reliance on PI3K signalling. In shallow gradients there was no reliance on PI3K 
for migratory accuracy (Andrew and Insall, 2007), in contrast to migration in steep gradients 
(Huang et al., 2003) – where both studies used the model organism Dictyostelium. Whilst 
these may not directly show differences with human neutrophils, the chemoattractant 
gradient could also influence neutrophil migration. However, Insall chambers do not allow 
recovery of cells after chemotaxis, whereas migrated cells in Transwell systems can be used 
for further analysis.  
As previously discussed, neutrophil CXCR4 (the receptor for CXCL12) can be increased on the 
surface of neutrophils when left to ‘age’ ex vivo (Weisel et al., 2009). The data presented in 
this chapter assesses chemotaxis within a short timeframe (less than 3 hours after blood 
collection) to assess the functional response with native CXCR4 receptor levels and 
demonstrated that neutrophils from HY individuals do not show a chemotactic response to 
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CXCL12. These results are consistent with previous data with freshly isolated human 
neutrophils from peripheral blood, albeit using a Transwell system (Martin et al., 2003). In 
addition, data here showed limited evidence that neutrophils from patients with COPD could 
respond to CXCL12, suggesting unaltered dynamics of neutrophil responses to CXCL12 in COPD 
compared with health, although further investigation may reveal some response. These 
analyses are hindered, however, by the reduced signal window as neutrophils from patients 
with COPD migrate less accurately to fMLP. These data may contrast to neutrophils in the 
lungs as neutrophils have been reported to have increased CXCR4 expression in both LPS-
treated mice (Yamada et al., 2011) and patients with COPD (Hartl et al., 2008). Given the 
possible differences between circulating and tissue neutrophils, the ability of neutrophils to 
increase CXCR4 expression in both health and disease may be worth investigating as these 
may alter dynamics within the tissue. 
The concentration of CXCL12 in plasma from healthy and various disease groups has 
previously been shown to be around 1-2ng/mL (Mehta et al., 2014; Łukaszewicz-Zając et al., 
2016). Identification of reduced levels of CXCL12 was perhaps surprising given previous studies 
suggesting circulating CXCL12 levels were either unaltered in both stable and AECOPD (Dupin 
et al., 2016) or raised in these patients (Kuźnar-Kamińska et al., 2016). Both of these previous 
studies utilised different methods for measuring CXCL12 and the impact of using non-platelet 
poor plasma may have impacted the accuracy of determining CXCL12 levels. Given the low 
responsiveness to CXCL12, it is unlikely the difference in circulating CXCL12 alters neutrophil 
dynamics, but may have implications for other cells expressing CXCR4. However, circulating 
levels does not necessarily relate to bioavailability on endothelial surface and lower circulating 
levels may, therefore, be due to CXCL12 being bound to endothelial cells. 
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7.3.2 CD10 inhibition may alter speed, but not accuracy, of neutrophils from healthy 
donors to fMLP 
The pharmacological inhibition of CD10 (e.g. by phosphoramidon) has been shown previously 
to increase neutrophil transmigration either across cell monolayers (Hofman et al., 1998) or 
polycarbonate membranes (Shipp et al., 1991) to fMLP. The current study identified that the 
accuracy of neutrophil chemotaxis was unaffected by CD10 inhibition, but that higher 
concentrations of phosphoramidon may reduce the overall speed of migration and distance 
travelled, indicating subtle control of neutrophil migration responses by CD10.  
It is hard to directly compare these results to previous studies, as both previous studies 
mentioned (Shipp et al., 1991; Hofman et al., 1998) measured total neutrophil migration in a 
binary manner instead of migration characteristics as investigated here. However, it has been 
shown that the primary fMLP receptor, formyl peptide receptor 1, is rapidly internalised and 
recycled to the leading edge of neutrophils during chemotaxis (Subramanian, Moissoglu and 
Parent, 2018). Furthermore, neutrophils showed greater movement even in RPMI than 
observed during validation work (not shown here), suggesting a reduced signal window to 
detect changes due to phosphoramidon treatment here. There was also a large variation in 
responses from individual donors and may indicate large donor variability in this assay. 
In theory, blockade of CD10 activity would increase the local concentration of fMLP, as CD10 
also functions to hydrolyse fMLP. This may then increase receptor internalisation and slow the 
response to fMLP without altering directionality. Further studies would be required to identify 
if indeed inhibition of CD10 significantly altered neutrophil chemotaxis and if it occurred by 
this mechanism, especially in a population of patients with COPD. Limited use of 
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phosphoramidon is reported in clinical trials. Two studies have used nebulised 
phosphoramidon in patients (at a concentration of 1µM) with asthma, showing some increase 
in bronchodilation, but did not investigate any impact specifically on neutrophils (Crimi et al., 
1994; Polosa et al., 1997). The fine-tuning of the neutrophil response to fMLP may provide 
therapeutic benefits, as multiple attempts have been made to modulate neutrophil migration 
to reduce the overall neutrophil load in the lungs of patients with COPD (Mårdh et al., 2017), 
where subtle changes in chemotaxis may be more beneficial than those that directly block 
chemokine receptors.  
7.3.3 Serum and plasma alter neutrophil phenotype 
7.3.3.1 Apoptosis 
The data presented here show that incubation with autologous serum resulted in a rapid 
increase in apoptotic neutrophils, identified by annexin V binding, and a subsequent drop in 
cell viability. Initially, this was thought to be due to serum preparation increasing platelet 
constituents (Garcia-Aguilar, Lanser and Brown, 1988) or complement proteins (such as C4d 
and C3a) in serum (Yang et al., 2015). These factors may potentially alter neutrophil behaviour 
and viability (Nabizadeh et al., 2016), as a similar effect was not replicated with autologous 
plasma.  
However, neutrophils isolated from HE participants and used to assess surface expression in 
response to plasma demonstrated a similar rapid increase in apoptotic neutrophils and 
reduction in the percentage of live neutrophils, both with autologous plasma and pooled 
plasma. These results potentially contrast to other studies where 10% autologous plasma 
supplementation resulted in prolonged neutrophil survival and resistance to apoptosis 
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(Alipour et al., 2020). Another study, although not specifically investigating apoptosis, 
suggested incubation with 50% human serum resulted in reduced neutrophil chemotaxis 
(Keller, Hess and Cottier, 1974), determined using a Boyden chamber (a pore-based chamber). 
The reduction in migration of cells across the membrane may in part be due to a reduced 
ability to bind the membrane (similar to what was demonstrated in Section 7.2.3.4), as 
neutrophils require a surface to migrate along.  
Only a slight decrease in neutrophil viability was observed with HY donors incubated with 
autologous plasma, two clear populations could be seen when neutrophils from HE donors – 
7 donors showing less than 10% live neutrophils and a further 5 showing similar viability to no 
plasma controls. The differences in response to plasma ex vivo may further highlight 
heterogeneity in the participant population. It is unclear if the increased apoptosis in these 
neutrophils was in response to initial serum starvation followed by reintroduction to 
processed serum, as previously reported using a neutrophil cell line with foetal bovine serum 
(Park et al., 2012). It calls into question whether the observed increase in annexin V binding 
to the neutrophil surface, in this case, was indeed due to neutrophil apoptosis. Previous work 
has suggested that neutrophil apoptosis, after incubation at 37oc for 18-24 hours, was also 
accompanied by a loss in the surface expression of CD16 (Dransfield et al., 1994; Homburg et 
al., 1995; Noguera et al., 2004). As demonstrated here, similar levels of CD16 expression were 
observed in both annexin V negative and positive neutrophils. In addition, previous studies 
investigating neutrophil apoptosis report apoptosis after 4-24 hours (Afford et al., 1992; 
Coxon et al., 1996; Zhang et al., 2003), suggesting the increase in annexin V binding observed 
here may represent very early apoptosis prior to the alteration in other surface markers. A 
study of neutrophils in endometriosis also reported only around 65% apoptotic neutrophils 
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after incubation of control neutrophils with 10% autologous plasma (Kwak et al., 2002), but 
this was assessed using neutrophil morphology and not annexin V staining. 
Whilst it was not part of the primary investigation, neutrophils from HE participants incubated 
in pooled plasma from patients with COPD showed consistently higher viability than with 
pooled plasma from HE participants. These results suggest that, whilst apoptosis was 
increased compared to no plasma, pooled COPD plasma could partially prevent neutrophil 
apoptosis – a process that has been described in neutrophils obtained from the sputum in 
patients with COPD when compared with healthy non-smokers (Brown et al., 2009). Indeed, 
previous studies have indicated prolonged neutrophil survival after migration into tissue and 
exposure to cytokines such as IL-1β and G-CSF (Taneja et al., 2004). The identification of 
apoptotic neutrophils here may represent increased sensitivity of neutrophils to ex vivo 
manipulation but did not prevent identification of the neutrophil surface phenotype. 
7.3.3.2 Neutrophil activation 
As discussed in Chapter 5, classical neutrophil activation has been previously described by 
increases in CD11b and CD66b (Costantini et al., 2010), along with shedding of CD62L (Mann 
and Chung, 2006). Treatment of neutrophils from HE donors with pooled plasma from patients 
with stable COPD showed significant increases in CD11b expression with a reduction of CD62L 
expression. This alteration in neutrophil phenotype closely resembles more classical 
neutrophil activation in response to inflammatory cytokines (Wittmann et al., 2004), 
suggesting that the systemic conditions in patients with stable COPD are capable of causing 
neutrophil activation in vitro. However, these observations must be held in balance with the 
significant change in CD11b expression also observed when neutrophils from the same donors 
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were incubated with pooled plasma from HE volunteers, suggesting partial activation in 
response to pooled HE plasma. Therefore, isolation of neutrophils may influence their 
sensitivity to activation.  
Regardless of treatment condition, CD11b, CD66b, CXCR2 and CD10 expression showed weak 
correlations with neutrophil viability in neutrophils from HE volunteers in all treatment 
conditions – whilst this may suggest a link between these changes and apoptosis, these may 
be an artefact due to the increase in apoptosis observed in all plasma treatment conditions.  
7.3.3.3 Neutrophil chemokine sensing and maturity 
Incubation of neutrophils from HE donors with both pooled plasma from other HE donors or 
patients with stable COPD resulted in a decline in CXCR2 expression – although this did not 
reach statistical significance in the COPD plasma-treated group. The reduction in CXCR2 
expression appears to be associated with neutrophil activation. A previous study also 
identified that CXCR2 expression was downregulated on neutrophils from patients with ANCA-
associated vasculitides that correlated with serum levels of CXCL8 and TNF-α (Hu et al., 2011), 
suggesting a link with activation status. It is possible, therefore, that the decline in CXCR2 
levels observed here is due to receptor internalisation, a process that has been shown to occur 
rapidly upon neutrophil activation with CXCL8 (Nasser et al., 2007). 
Lower CD10 expression is associated with neutrophil immaturity, observed in acute 
inflammation due to the rapid release of neutrophils that have not yet reached full maturity 
(Manz and Boettcher, 2014). The data in this thesis suggested that a step-wise increase in 
CD10 expression was observed in neutrophil CD10 expression following incubation of 
neutrophils from HE participants in pooled plasma from other HE volunteers or patients with 
Chapter 7  Page | 321  
stable COPD – reaching significance in the latter condition. Clearly, changes ex vivo cannot be 
due to changes in the release of granulocytes and may not necessarily represent previously 
studied changes in neutrophil maturity. However, these data could suggest that, along with 
increased neutrophil activation, factors in the circulation of patients with COPD may promote 
the maturation of neutrophils in the circulation. 
7.3.3.4 Changes due to autologous plasma 
It was expected that incubation of neutrophils with autologous plasma would not result in 
significant phenotypic changes in neutrophils. However, neutrophils from HE participants 
showed significant changes in CD66b and patients with COPD showed significant changes in 
CXCR2 with autologous plasma incubation. A previous study investigating neutrophils in 
patients with sepsis and healthy controls identified that the addition of autologous plasma at 
low concentrations (5%) was able to induce a ROS response in as little as 30 minutes in both 
cases (Pascual et al., 1998). Another study, incubating neutrophils from healthy individuals in 
100% autologous plasma, showed an increase in spontaneous IL-6 production (Oishi and 
Machida, 1997). These data highlight caution is required when using autologous plasma in 
neutrophil studies. 
In addition, the binding properties of neutrophils to BSA-coated glass slides were altered, 
demonstrated by a reduction in adherent cells and visualisation of morphological changes in 
neutrophils whilst incubating on these slides. Therefore, autologous plasma is likely to alter 
neutrophils even over short periods of time and this may be concentration-dependant. A 
follow-on study comparing both early cellular apoptosis and surface phenotype over a broader 
range of plasma concentrations may elucidate neutrophil phenotype changes further. These 
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results may have broader implications for the study of neutrophils in vitro, especially if media 
is routinely supplemented with autologous plasma. 
7.3.4 Summary and limitations 
This chapter demonstrates the use of an Insall chamber to assess various aspects of neutrophil 
chemotaxis towards physiological neutrophil chemoattractants. These data showed that 
patients with both stable COPD and AECOPD have lower circulating levels of CXCL12 that may 
have potential implications for neutrophil trafficking, However, it was also demonstrated that 
neutrophils from healthy volunteers and patients with stable COPD did not migrate towards 
CXCL12 at any concentration tested.  
There was also limited evidence that neutrophil chemotaxis could be altered using a readily 
available CD10 inhibitor, phosphoramidon, but further investigation is required to determine 
if subtle changes are present that may be of therapeutic benefit – balancing altered migration 
without complete inhibition of neutrophil chemotaxis. Future work could address the 
responses of neutrophils from patients with COPD in response to phosphoramidon inhibition, 
as well as altered downstream signalling pathways that may be implicated in this response.  
These data also highlight caution when using autologous serum or plasma to supplement 
neutrophil media (Murray et al., 1996; Gray et al., 2018), as this may alter neutrophil viability. 
The detection of a high percentage of apoptotic neutrophils following serum and plasma 
incubation potentially confounded the changes in surface expression of other markers, 
however, the inclusion of apoptotic cells did not appear to alter the detected surface 
expression. In addition, the lack of binding of these neutrophils to BSA-treated glass slides 
provided a major limitation to the assessment of chemotaxis after plasma treatment. Further 
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wash steps, increased incubation time or an alternative format to assess chemotaxis may 
overcome this limitation. 
Key to deciphering if neutrophils in patients with COPD are fundamentally altered or represent 
a plastic population of cells altered by an inflammatory environment, neutrophils from healthy 
volunteers show an altered phenotype when incubated in pooled plasma from patients with 
stable COPD. These changes reflect increased activation, loss of CD62L and CXCR2 and an 
increase in CD10 expression and represent systemic conditions that may promote neutrophil 
activation and maturation in patients with COPD. The step-wise increase from incubation with 
other pooled healthy plasma and plasma from patients with COPD also suggests an element 
of accelerated ageing based on increasing circulating factors that influence neutrophil 
phenotypes. Importantly, these results highlight that plasma from patients with COPD altered 
the phenotype of neutrophils from healthy donors in vitro to show increased activation and 
potentially enhanced maturity. 
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8 CHAPTER 8: 
GENERAL DISCUSSION 
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Neutrophils are known to play a role in the pathogenesis of COPD and are the most abundant 
white blood cells found in lung secretions of patients diagnosed with COPD (Pesci et al., 1998) 
and both the number and products of neutrophils are linked with multiple aspects of disease 
in animal and cell models (Shapiro et al., 2003; Singh et al., 2010; J. Liu et al., 2017). There is 
still a need for disease-modifying therapies and therapeutics targeting neutrophils may allow 
for fine-tuning of the immune response to reduce collateral damage whilst still maintaining 
good immune protection from pathogens. The fact many patients with COPD experience 
persistent and recurrent infection (Patel et al., 2002) despite the presence of neutrophils in 
the lungs suggests that neutrophil function is altered in COPD, and changes in the circulating 
neutrophil population may influence the development of other related conditions such as CVD 
and T2D. 
This thesis aimed to investigate the phenotype of neutrophils in healthy ageing, stable COPD 
and during an exacerbation- the hypothesis that changes in phenotype, specifically increased 
systemic activation, accelerated ageing and senescence, may enhance our understanding of 
COPD pathogenesis and progression. Furthermore, stratification of patients based on the 
presence of co-morbidities may reveal nuanced changes in neutrophil phenotypes that may 
help guide more tailored therapies and provide a possible explanation to the lack of efficacy 
of neutrophil-targeted therapeutics in the general COPD population.  
The phenotypes investigated here were linked with several previously described changes 
related to key neutrophil functions, including activation (Särndahl et al., 2007), senescence 
(Martin et al., 2003), maturity (Marini et al., 2017), pro-inflammatory or anti-inflammatory 
(McNab et al., 2011; Scrimini et al., 2013) and reverse transmigration (Buckley et al., 2006). 
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These phenotypes may have functional consequences in disease, including chronic 
inflammatory conditions, such as COPD and multimorbidity (Hughes, Sapey and Stockley, 
2019).  
Overall, there was no indication of an accelerated-ageing phenotype in patients with COPD – 
in part due to the lack of changes during healthy ageing and the absence of a senescence signal 
and in contrast to the hypothesis. There was also no evidence of increased systemic activation 
in stable COPD compared with health, however, this signal did exist in patients experiencing 
an acute exacerbation of COPD. In both cases, there was also no evidence of increased 
senescence, but a reduction in the expression of CXCR2 that was exaggerated with 
multimorbidity and during an acute exacerbation,  specifically in patients with COPD and CVD 
with or without T2D, highlighting the differential influence of CVD and T2D on neutrophil 
phenotype. Indeed, changes in CXCR2 may be influenced by the systemic nature of CVD, 
highlighting an important mechanism that may increase the disease burden on patients with 
COPD and CVD. Furthermore, incubation of neutrophils from healthy individuals with pooled 
plasma from patients with stable COPD resulted in marked increases in activation and maturity 
markers, suggesting neutrophils from patients with COPD are fundamentally resistant to 
systemic inflammatory signals. Together, these results reveal subtle changes in the neutrophil 
phenotype due to both chronic and acute inflammation and the impact of multimorbidity that 
may direct neutrophil-targeted therapeutics.  
8.1 Investigating neutrophils 
First and foremost, careful handling of neutrophils ex vivo is essential to ensure reliable and 
accurate conclusions can be made from the data. Here, neutrophils were isolated from 
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heparinised whole blood by dextran sedimentation of red blood cells followed by 
discontinuous Percoll gradient isolation, allowing for isolation of live neutrophils and the 
ability to compare surface phenotype with functional data. Recently published data has shown 
that Percoll gradient isolation resulted in a higher neutrophil purity compared with similar 
gradient-based Ficoll isolation following dextran sedimentation (Alipour et al., 2020) and that 
a priming response can be stimulated in vitro with LPS, TNF-α and PAF (Condliffe et al., 1996), 
suggesting this isolation method does not cause substantial alteration of the neutrophil 
priming response.  
8.2 Neutrophil heterogeneity and phenotypes 
Neutrophil heterogeneity has become a topic of debate over several years (Hellebrekers, 
Vrisekoop and Koenderman, 2018; Rosales, 2018; Silvestre-Roig et al., 2019). Importantly, 
altered neutrophil phenotypes have been identified independently in the circulation in 
patients with COPD, CVD and T2D (Reviewed in Hughes, McGettrick and Sapey, 2020). These 
changes may provide insight into both disease pathogenesis, outcomes, and avenues for 
therapeutic intervention. Whilst changes in individual markers between HY, HE and patients 
with stable COPD were limited, multi-dimensional cluster analysis highlighted a gradient of 
expression of each marker rather than distinct subpopulations. These subtle gradient-like 
changes suggest neutrophil phenotypes are fluid and less discrete than absolute changes in a 
single marker. The implications of this are two-fold: it is unlikely a pathogenic subpopulation 
of neutrophils exist in COPD and therapeutics targeting neutrophils that cause small shifts in 
neutrophil behaviour may provide the most clinical benefit – allowing neutrophils to perform 
their protective role and reduce collateral damage. 
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8.2.1 Systemic activation of neutrophils 
Given that many inflammatory cytokines have been shown to be raised in COPD, AS and T2D, 
including TNF-α (Fahim, Halim and Kamel, 2004; Hatanaka et al., 2006; Singh et al., 2018) and 
IL-6 (Barnes and Celli, 2009), it would not be surprising if there was increased systemic 
neutrophil activation in these patients, especially those with multimorbidity. Several studies 
have suggested systemic activation of neutrophils in COPD based on increased ROS production 
(Noguera et al., 2001; Vaguliene et al., 2013) and the presence of systemic NE or MPO 
(Vaguliene et al., 2013), however, these do not provide direct evidence of neutrophil 
activation. 
The data presented in this thesis shows that systemic neutrophil activation, measured using 
CD11b, CD66b and CD62L, was not significantly altered either with increasing age or the 
presence of stable COPD – regardless of multimorbidity. These observations are supported by 
similar data generated from Dr Sapey’s group where comparable levels of CD11b and CD62L 
were observed on neutrophils from HE donors and patients with stable COPD (J. Stockley, 
2015). Whilst overall no increase in activation was observed, a subset of patients 
demonstrated raised levels of CD11b and CD66b – however, these did not correlate with 
clinical severity of COPD or smoking history, suggesting other factors may play a role in causing 
increases in systemic neutrophil priming and activation that requires further investigation. 
Indeed, direct measurement of circulating cytokines in these patients may explain these 
differences in activation status. All these observations were supported by no overall increase 
in the percentage of CD11bbrightCD66bbright neutrophils between groups. Whilst not statistically 
significant, it appeared that gene expression of both CD11b (ITGAM) and CD66b (CEACAM8) 
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were increased in patients with COPD compared to both healthy groups, suggesting a 
potential to upregulate these surface proteins. There was no correlation between gene 
expression and surface expression data, albeit only available for a subset of samples, that may 
suggest increased intracellular stores of these proteins – however further investigation would 
be necessary to draw this conclusion. 
Specifically addressing surface marker expression, a previous study suggested that neutrophil 
priming occurs in peripheral neutrophils from patients with COPD, identified by a reduction in 
CD62L expression, but no change in CD11b expression (Lokwani, Wark, Baines, Fricker, et al., 
2019). Notably, this study performed antibody staining in whole blood before red blood cell 
lysis. Another study again indicated similar CD11b expression levels between patients with 
COPD and healthy controls (both smokers and non-smokers), although data was only shown 
for apoptotic neutrophils (Noguera et al., 2004). The same group had, however, previously 
shown an increase in CD11b expression in neutrophils from patients with stable COPD 
(Noguera et al., 1998) - although these patients had lower lung function and neutrophils were 
isolated by a different isolation procedure. Collectively, the impact of isolation method and 
patient group examined may explain subtle differences between both the data in this thesis 
and other studies, further highlighting the necessity for careful handling of cells ex vivo and 
the need for multiple studies to build a clear picture. As ex vivo stimulation of neutrophils from 
healthy individuals to pooled plasma from patients with COPD demonstrated a loss of CD62L 
expression – exposure of neutrophils to activation signals during handling may cause the 
decline in CD62L in some previous studies. 
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Direct comparison of neutrophils from both healthy donors and patients with COPD suggest 
that systemic neutrophil activation is not a predominant feature of stable COPD and partial 
priming or activation of neutrophils may be differentially impacted by the isolation technique 
employed. However, neutrophils from HE volunteers incubated with pooled plasma from 
COPD showed changes in the surface expression of CD11b and CD62L that appear consistent 
with classical neutrophil activation (Wittmann et al., 2004; Vogt et al., 2018). Together these 
data suggest that factors, such as cytokines and other signalling molecules, are present in the 
circulation of patients with COPD and are capable of activating healthy neutrophils ex vivo. 
The lack of systemic activation in patients with COPD, therefore, may be due to a reduction in 
the sensitivity of these neutrophils to pro-inflammatory stimuli. Another possible hypothesis 
is that activated neutrophils in patients with COPD leave the circulation and enter the lung or 
other inflammatory compartment, following chemokine gradients – although an increase in 
total circulating neutrophils in these patients makes this explanation less likely (Günay et al., 
2014).  
Furthermore, during an acute exacerbation, increased systemic neutrophil activation was 
identified by increased expression of CD11b and CD66b (including the percentage of 
CD11bbrightCD66bbright neutrophils) compared with stable COPD. The observation of increased 
neutrophil activation in AECOPD is in line with the systemic inflammation seen in other studies 
of AECOPD (Aaron et al., 2001; Hurst, Perera, et al., 2006; Sapey and Stockley, 2006). In 
addition, neutrophils stimulated in vitro with GM-CSF and TNF-α (Koenderman et al., 2000) 
showed a similar phenotype to neutrophils in patients with AECOPD shown in this thesis and 
a previous study (Koenderman et al., 2000). It should be noted that it has been suggested 
these changes in CD11b and CD66b expression systemically are more aligned with neutrophil 
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priming prior to extravasation,  as CD54 expression, a marker not altered in these samples, 
represents the final stages of neutrophil activation after extravasation into the tissue (Pillay 
et al., 2012). 
Of note, CD62L expression remained similar between both stable and AECOPD, suggesting  
priming or activation similar to that identified in vitro with PAF (Condliffe et al., 1996). A lack 
of CD62L shedding, but an increase in other neutrophil activation markers, has also been 
observed in patients with sepsis (Lewis et al., 2015), potentially suggesting the increased 
systemic inflammatory burden in AECOPD contributes to maintenance of CD62L.  
Notably, a subset of patients did not show an increase in these activation markers, potentially 
suggesting not all patients presenting with AECOPD have the same level or type of systemic 
inflammatory burden. An increase in the inflammatory burden, especially one seen 
systemically here in neutrophils, may link to the increased mortality due to cardiovascular 
complications (Austin et al., 2016; El-Shabrawy and Eldamanhory, 2017). In addition, 
similarities to patients with sepsis may suggest similar mechanisms of peripheral neutrophil 
activation, allowing aspects of the clinical management of patients with sepsis to be applied 
to patients with AECOPD. 
8.2.2 Changes in other neutrophil markers 
Novel phenotypes of neutrophils may provide further insight into the dysfunction of these 
cells in patients with COPD. The data presented here demonstrated similar expression of HLA-
DR, CD11c, CD54 and CD10 on neutrophils from HY, HE, stable COPD and in AECOPD. As well 
as surface expression, no statistically significant differences in gene expression for these 
markers was observed. 
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Both HLA-DR and PD-L1 expression on neutrophils have been linked with inflammatory status, 
where HLA-DR indicates pro-inflammatory and PD-L1 anti-inflammatory neutrophils. Neither 
marker has been shown to be expressed by neutrophils in the circulation taken from healthy 
volunteers (Reinisch et al., 2003; Luo et al., 2016). Expression of HLA-DR by neutrophils has 
been linked with exposure to GM-CSF both in vitro (Gosselin et al., 1993) and in vivo 
(Mudzinski et al., 1995) that can cross-present antigens to T cells  – although the in vivo study 
only included two patients. A single study reported increased HLA-DR expression in the 
circulating neutrophils compared with healthy non and current smokers in a large cohort of 
patients (n=53), but showed large variation in HLA-DR expression in each group (Scrimini et 
al., 2013). Nevertheless, the data in this thesis shows almost complete lack of surface 
expression on neutrophils from any group tested, suggesting neutrophils in COPD do not 
acquire cross-presentation properties that activate T cells in the circulation.  
Similarly, PD-L1 expression was only detected at very low levels on all healthy control and 
stable COPD samples. Neutrophils from patients with AECOPD showed a small, but statistically 
significant, increase in PD-L1. PD-L1 expression has previously been shown on neutrophils in 
mice and patients with sepsis (Wang et al., 2015) and may represent an anti-inflammatory 
response as PD-L1 supresses T cell responses (Keir et al., 2008). Combined with the changes 
in the activation of neutrophils also showing a similar phenotype to sepsis, the increase in PD-
L1 may, therefore, represent a balancing mechanism in patients with COPD during increased 
in systemic inflammation, one that could be enhanced to reduce further inflammatory 
responses in other compartments of the immune system. These data provide an exciting 
potential avenue for therapy that requires more investigation to identify if indeed such low 
expression of PD-L1 by neutrophils provides any clinical benefit, or if it could be increased. 
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An increase in the presence of CD54 expressing neutrophils in the circulation may have 
indicated neutrophils that had previously been within the inflamed lung re-entering the 
circulation – providing a link between COPD, CVD and T2D whereby neutrophils could be 
activated in one compartment and move back into the circulation, causing damage within 
another organ. Previous work has indeed linked an increase of reverse transmigrated 
neutrophils with increased lung injury during acute pancreatitis in human (Wu et al., 2016) 
and with atherosclerosis (Buckley et al., 2006) – although in both cases the percentage of 
neutrophils with this phenotype was very low. In this thesis, there was no increase in this 
population in patients with COPD compared to healthy volunteers, suggesting reverse 
transmigration of neutrophils is not enhanced in patients with COPD.  
Equally, the maturity status of circulating neutrophils appeared similar in all population groups 
measured in contrast to previously published studies where inflammatory signals seen during 
sepsis (Taneja et al., 2008), invasive cardiac surgery (Orr et al., 2005) or severe COVID-19 
(Carissimo et al., 2020) promoted the release of immature neutrophils. There does not appear 
to be previous studies that have investigated the expression of CD10 on neutrophils in the 
circulation in COPD, CVD or T2D.  
Of note, incubation of neutrophils from HE donors with pooled plasma from patients with 
COPD appeared to increase CD10 expression. These data may suggest circulating factors that 
may promote an acceleration in maturation in patients with COPD, allowing for unaltered 
maturity status of neutrophils in the circulation despite the potential for emergency 
granulopoiesis. 
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Together, these suggest that neutrophils in patients with COPD, regardless of exacerbation or 
the presence of multimorbidity, do not show evidence of increased immaturity, reverse 
transmigration or a pro-inflammatory phenotype. Here, there is some evidence that an anti-
inflammatory phenotype of PD-L1 expressing neutrophils may emerge during AECOPD. 
8.3 Neutrophil senescence in COPD 
The use of senolytics, drugs that selectively remove senescent cells, have been discussed as 
potential therapies for patients with COPD as senescent cells show, in general, reduced useful 
functionality compared to non-senescent cells (Drew, Wilson and Sapey, 2018; Baker, 
Donnelly and Barnes, 2020). Both CVD and T2D have also been linked with an increased 
burden of senescent cells with β-cell replication slowing past the age of thirty, limiting repair 
(Perl et al., 2010) with a reduction in functional β-cells (Butler et al., 2003),  and vascular 
smooth muscle cells and endothelial cells around atherosclerotic plaques becoming more 
senescent (Vasile et al., 2001; Libby et al., 2002). However, as mature neutrophils do not 
replicate (Klausen et al., 2004), neutrophil ‘senescence’ requires a more complex 
interpretation than replicative senescence as coined by Hayflick and Moorhead (Hayflick and 
Moorhead, 1961; Kaplon et al., 2013). CXCR2 and CXCR4 are both key chemokine receptors 
for neutrophils and have repeatedly been shown to control neutrophil retention and 
subsequent release from the bone marrow into the circulation and then migration to sites of 
inflammation (Strydom and Rankin, 2013). It is these two receptors that have been implicated 
in neutrophil senescence, where CXCR4 is increased and CXCR2 reduced, allowing ‘homing’ 
back to the bone marrow as a mechanism of neutrophil clearance from circulation (Martin et 
al., 2003; Eash et al., 2010; Casanova-Acebes et al., 2013).  
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However, there is very little evidence for neutrophil senescence in vivo in human, with 
previous studies observing this phenotype during in vitro ageing (Nagase et al., 2002; Yildirim 
et al., 2005; Weisel et al., 2009). The findings from murine studies may, therefore, not directly 
relate to neutrophil behaviour or phenotype in human. Nevertheless, assessment of these two 
receptors may identify a senescent phenotype and indicate if an increased burden of 
senescent neutrophils in the circulation may impact on COPD and link with accelerated ageing 
and multimorbidity. 
8.3.1 Chemokine sensing via CXCR2 and CXCR4 
As CXCR4 expression remains low and unaltered in all groups tested and neutrophils from both 
HY and patients with stable COPD show no functional chemotaxis to CXCL12, these data do 
not support a change in neutrophil senescence in COPD or multimorbidity. Low levels of CXCR4 
expression on mature neutrophils has previously been shown to be unresponsive to CXCL12 
(Martin et al., 2003), supporting the findings here. Despite some studies suggesting that the 
CXCL12-CXCR4 axis may play a role in COPD in other cell types (Henrot et al., 2019), it appears 
CXCR4 expression by circulating neutrophils has not been investigated in COPD, CVD or T2D. 
Here, CXCR2 expression was not altered during healthy ageing, but is reduced in stable COPD 
and further reduced in AECOPD. These changes suggest that neutrophils in these patients have 
a reduced ability to sense chemokines, impacting on the ability of these neutrophils to 
appropriately respond to these inflammatory signals. Further investigation revealed that 
CXCR2 expression was not significantly reduced in patients with COPD alone, but in patients 
that also had CVD as a co-morbidity, revealing a role of multimorbidity in neutrophil 
phenotype. Previous observations of increased CXCL2 levels, another cytokine that signals 
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through CXCR2, in patients with CVD (Guo et al., 2020) may suggest why CXCR2 levels are 
reduced specifically in patients with COPD and CVD, as CXCL2 binding may increase CXCR2 
internalisation. However, the same reduction in CXCR2 was not induced to the same extent in 
neutrophils from HE volunteers with pooled plasma from patients with COPD. Together, these 
data are suggestive of altered chemokine sensing, but not of senescence, and that there may 
be a chronic change in CXCR2 expression by neutrophils from patients with COPD.  
Reduced CXCR2 surface expression may pose a possible explanation to reduced migratory 
accuracy observed previously in patients with COPD (Sapey et al., 2011), and patients with 
AECOPD are likely, therefore, to have even more collateral damage caused by ineffective 
sensing of chemokines. RNASeq performed in this thesis highlighted multiple genes linked 
with chemotaxis were also altered in the neutrophils of patients with AECOPD compared with 
stable disease, further providing evidence that neutrophil chemotaxis is significantly impacted 
during exacerbations.  
Altered CXCR2 expression may also have implications for therapeutics targeted at this 
receptor. CXCR2 inhibitors have been repeatedly shown capacity to reduce neutrophil 
infiltration into the tissue in animal models, first in reduced neutrophil margination in rabbits 
(White et al., 1998). Several other papers have supported that blockade of CXCR2 reduced 
neutrophilic inflammation: in CS-exposed rats (Stevenson et al., 2005); in an acute lung injury 
model in mice (Lomas-Neira et al., 2004); in an LPS airway challenge model in guinea pigs 
(Gordon, 2005); and recently in murine models of neutrophilic airway inflammation (Mattos 
et al., 2020). Despite in vitro and in vivo biological evidence, trials in humans have yielded little 
success, either due to lack of clinical efficacy (Keir et al., 2020; Lazaar et al., 2020), or safety 
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concerns linked with neutropenia (Aaron, 2015; Rennard et al., 2015). Targeting a receptor 
that has reduced expression on neutrophils in COPD compared with health may provide a 
contraindication to the use of these therapies in COPD, especially those patients with 
underlying CVD. 
The data within this thesis suggests that a decline in CXCR2 receptor expression may impact 
on both the ability of these drugs to perform well in patients with COPD, but also that blocking 
CXCR2 may, in part, further reduce the ability of neutrophils to accurately migrate towards 
the inflammatory site, inadvertently increasing long-term tissue damage. Overall, reduced 
expression of CXCR2 by neutrophils in patients with COPD, particularly those with CVD or 
during an exacerbation, could result in inaccurate migration and increased collateral damage, 
both in the lungs and if recruited to other sites of inflammation. 
8.4 Do these changes represent accelerated ageing? 
One key aspect to investigate was the concept of accelerated ageing specifically for 
neutrophils in COPD. Previous work have indeed suggested that COPD is a disease of 
accelerated ageing, showing many aspects of ageing such as a decline in lung function, 
increased cellular senescence and loss of anti-ageing processes (Ito and Barnes, 2009; Barnes, 
2017). For neutrophils, it was expected that an accelerated ageing phenotype would be shown 
by either: a change occurring between healthy young and elderly populations that is 
exaggerated in patients with COPD; or an increase in the proportion of senescent cells in 
patients with COPD. The data presented in this thesis do not convincingly suggest either. 
Neutrophils from healthy young and elderly volunteers showed very similar phenotypes in 
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terms of surface expression, one that is carried through to patients with COPD with only one 
notable exception – CXCR2 expression.  
Previous data has suggested that an age-related decline in neutrophil chemotaxis does exist 
and is further reduced in COPD – supporting accelerated ageing (Sapey et al., 2011, 2014). In 
this thesis, reduced CXCR2 expression was observed in patients with COPD, further reducing 
during an exacerbation, but there was not evidence of this change with ‘healthy’ ageing. These 
data suggest changes in CXCR2 expression are, therefore, a contributary factor in reduced 
migratory accuracy, but not wholly responsible for age-related declines in neutrophil 
migration accuracy.  
It must be stated, however, that these data only highlight changes specifically in neutrophils 
and do not conflict with evidence of accelerated ageing in other cell types (such as endothelial 
cells and fibroblasts) or processes that have been previously described (Ito and Barnes, 2009; 
MacNee, 2009). Indeed, they suggest that neutrophils themselves only have very a limited 
role in the overall accelerated ageing phenotyping in COPD, further supported by the lack of 
changes in gene expression with ageing.  
8.5 Study limitations 
In all the elements of the study shown in this thesis, neutrophils were isolated from peripheral 
blood. This enables specific investigation of neutrophil function and identification of systemic 
neutrophil phenotypes that may link multiple diseases. However, it is known neutrophils 
within the lungs are fundamentally altered compared to the periphery (Fortunati et al., 2009) 
and are where many pathogenic effects of neutrophils are observed within COPD. Therefore, 
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the study of neutrophils in the periphery only provides one view on neutrophil function and 
phenotype. 
The process of isolating neutrophils for in vitro study also has the possibility to alter neutrophil 
phenotypes, including the methodology employed in this thesis. The sedimentation of red 
blood cells with dextran was previously shown to increase neutrophil activation, potentially 
due to monocyte interactions with neutrophils during this procedure (Quach and Ferrante, 
2017) and gradient-based isolation may reduce the ability of neutrophils to respond to 
subsequent stimulation (Mosca and Forte, 2016). These changes may influence the data in 
this thesis, although a consistent method should not alter comparisons between groups. 
Whilst a limitation, common alternatives such as red blood cell lysis (Vuorte, Jansson and 
Repo, 2001), fixation of samples from whole blood (van Staveren et al., 2018) or antibody-
based isolation (Hasenberg et al., 2011) can also alter neutrophil phenotype, inherently 
precludes functional analysis or have a large cost implication.  
In addition, the study of neutrophils in isolation removes the influence of other cell types. This 
may be of particular consideration in a complex disease such as COPD, as other cell types, 
especially macrophage, are known to influence the severity and progression of COPD and the 
interaction of neutrophils with the lung is likely to alter their phenotype. 
Whilst every effort was made to appropriately age and sex-match HE participants with the 
relevant patient populations, it was not possible to provide a good match on smoking history. 
As smoking is known to have multiple impacts both on neutrophils, other immune cells and 
the inflammatory environment of the lung, better matching patients and controls based on 
smoking history would provide a more robust comparison. 
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In addition, during the stratification based on multimorbidity, it was not possible to match all 
patient groups based on lung function or GOLD Stage due to the patient pool available and 
possibly also due to the impact multimorbidity may have on the severity of COPD. Therefore, 
it is not possible to rule out the effect of reduced lung function as a confounder to the 
differences observed – however, it may also be a feature of interest that multimorbid patients 
present with the most severe disease. 
It is important to consider the impact neutrophil function and phenotype has on clinical 
parameters and disease progression. Whilst generally smoking history and lung function data 
was available for patients with COPD (both stable and exacerbating), other clinically important 
metrics, such as symptom scores and exacerbation history, were not available for all patients. 
The collection of these data at appointments may have provided further insight to the impact 
of the investigated neutrophil phenotypes on disease-relevant parameters. In addition, it was 
not possible to obtain lung function data on healthy controls due to technical limitations, that 
may have elucidated some variation observed in the control group. 
The inhibition of neutrophil binding during the assessment of neutrophil chemotaxis 
prevented the analysis of pooled plasma treated neutrophils. Therefore, it was not possible to 
investigate the link between the neutrophil phenotype and migration in these conditions. 
Inevitably, conclusions drawn from some of the data presented were limited due to the 
number of patients recruited – particularly those with multimorbidity and for samples used to 
investigate the effect of pooled plasma. Unfortunately, the research study was halted 
prematurely due to the COVID-19 pandemic. In addition, correlations of surface expression 
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with clinical metrics are underpowered and would require a greater number of patients to be 
investigated fully.  
8.6 Future work 
Multiple aspects of neutrophil phenotypes have been investigated in this thesis, building upon 
data both from other members of this research group, and the increasing wealth of 
information regarding neutrophil phenotypes. However, it also raised additional questions 
that would require further investigation. 
1. As neutrophils will primarily cause damage when in the lung of patients with COPD, it 
is important to understand the phenotype and function of these cells in the lung and 
collection of both blood and lung secretions would enable more detailed phenotyping 
in patients with COPD, especially as lung neutrophils would be the primary target for 
therapeutics being administered by inhalation (Axson et al., 2020). Previous 
comparisons of neutrophils isolated from sputum and peripheral blood in healthy 
volunteers identified that neutrophils in the sputum (and therefore had undergone 
migration into the lung) displayed higher expression of CD11b and HLA-DR, suggestive 
of an inflammatory phenotype (Alexis et al., 2000). 
2. Investigating how migration through the lung tissue alters the neutrophil phenotype 
may further reveal differences in healthy ageing and in COPD. Studies using a lung slice 
model would allow this to be investigated and assess the influence of other 
physiologically relevant cell types on neutrophil phenotype. In addition, an alternative 
model of neutrophil chemotaxis could be investigated both to alleviate the lack of 
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neutrophil binding to glass slides after incubation with plasma and provide further 
confirmation of the findings in this thesis. 
3. Investigating if the shift in neutrophil phenotype seen in AECOPD recovers following 
the exacerbation by following up patients to at least 56 days (generally accepted when 
a patient is clinically stable) and comparing this to patients with stable COPD. 
4. Furthermore, whilst technical challenges exist, it would be beneficial to monitor the 
neutrophil phenotype in COPD prior to an exacerbation to determine if fundamental 
differences exist in neutrophils either prior to an exacerbation and may be predictive 
of frequent exacerbators.  
5. Lung function decline in patients with COPD is variable and has a large quality of life 
impact on patients. Repeat sampling of the same patients over time would allow for 
longitudinal studies on neutrophil phenotypes to determine if these change over time, 
and if this correlates, or could be predictive of, lung function decline. Expanding the 
number of patients recruited would also allow for better matching of patients based 
on both lung function and disease severity parameters. 
6. As CXCR2 was a major receptor altered both in stable COPD and during an 
exacerbation, further work could build on both this and previous investigations of 
receptor signalling to uncover potential downstream alterations in neutrophil 
behaviour due to reduced CXCR2 expression and the impact therapeutic blockade. In 
addition, expression of receptors for other chemoattractants such as fMLP could be 
investigated to identify if a similar alteration is observed that may be suggestive of a 
common mechanism of reduced migrational accuracy.  
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7. Further targeted gene expression analysis could be conducted following on from the 
data presented here, using more concise gene expression arrays to allow for increased 
sample number, especially between HE and stable COPD samples. This could also be 
expanded to allow for stratification of patients with COPD based on multimorbidity to 
further investigate the role multimorbidity may play in neutrophil gene expression, 
revealing potentially discrete neutrophil populations. 
8. The identification of ARHGAP24 as a differentially expressed gene in neutrophils 
between HE participants and patients with COPD warrants further investigation to 
determine if this has any functional relevance to the role of neutrophils in COPD.  
9. Aspects of accelerated ageing were investigated, however, the impact of a loss in anti-
ageing processes was not investigated. These analyses, including looking for epigenetic 
changes, may reveal an aspect of accelerated ageing not yet studied in both 
neutrophils and multimorbidity within COPD. 
8.7 Overall findings and conclusion 
There is an abundance of evidence to support that neutrophils play a critical role in COPD. 
Here, a robust method for examining the surface expression of key functional markers on 
neutrophils is described using a well-validated flow cytometry panel, providing a platform for 
future studies.  
Broadly, neutrophils from patients with COPD do not show evidence of increased systemic 
activation, immaturity, pro or anti-inflammatory phenotypes or increased reverse 
transmigration compared with healthy age-matched controls. These phenotypes were not 
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altered by the presence of multimorbidity nor do they show elements of accelerated ageing, 
but heterogeneity within the study population was identified. 
Instead, a reduction in CXCR2 expression was observed on neutrophils from patients with 
COPD with CVD, with or without T2D, suggesting that neutrophil chemokine sensing through 
CXCR2 may be altered specifically in these multimorbid patients. Furthermore, a reduction in 
CD16 was observed in patients with COPD with or without T2D and without CVD, suggesting 
a potential banded neutrophil population that may have functional consequences such as 
reduced phagocytosis. These data begin to highlight the importance of multimorbidity in 
differentially altering systemic neutrophil phenotypes that may also have broader implications 
for future therapeutics targeting neutrophils, allowing more tailored options by 
understanding the influence inflammatory diseases have on each other. 
However, an activated phenotype could be induced in healthy neutrophils in vitro by pooled 
plasma from stable COPD patients – suggestive that a fundamental alteration in circulating 
neutrophils from patients with COPD may make them less sensitive to low-level inflammatory 
mediators, or represent a form of exhaustion.  
In contrast, multiple changes occur both at the gene level and surface expression level during 
an acute exacerbation. Increased systemic activation, like that seen in sepsis, reduced CXCR2 
expression and a small, but significant increase in PD-L1 expression, indicative of anti-
inflammatory activity, are seen in neutrophils from patients with AECOPD. Combined, these 
results show both plasticity in the circulating neutrophil population, but also insights into 
altered neutrophil function in patients with AECOPD. 
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Together, these data suggest that subtle heterogeneity exists in circulating neutrophils, and 
that different phenotypes of neutrophils are differentially observed in multimorbid patients 
and further altered in AECOPD compared to stable disease. Accelerated ageing of neutrophils 
was not observed based on either stepwise changes in phenotype during ageing and the 
presence of COPD, or by increased senescence. These data highlight the importance of 
understanding patient heterogeneity in COPD based on multimorbidity and exacerbation 
status. They also draw attention to alterations in circulating neutrophil phenotypes in COPD 
that do not necessarily manifest by direct comparisons of health to COPD, but instead by the 
potential of healthy neutrophils to be altered by exposure to the inflammatory conditions in 
COPD. 
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10.1 Appendix 1: Participant exclusion and inclusion criteria 
Participants without COPD 
 
Inclusion for Participants without COPD 
1. Provision of informed written consent 
2.  Age 18 years or over 
 
Exclusion for Participants without COPD 
1. Significant respiratory symptoms including breathlessness and cough 
2. Diagnosis of COPD, Asthma, Interstitial Lung disease, Bronchiectasis, Lung Cancer, Previous 
Lung resection 
3. Haematological malignancy 
4. Immunosuppressive medications 
5. Lack of capacity to provide informed consent  
 
Participants with COPD 
 
Inclusion Criteria for stable COPD patients 
1. Diagnosis of COPD with post bronchodilator FEV1/ FVC ratio <0.7 according to GOLD 
guidance 
2. At least 10 pack year history of smoking 
3. Provision of informed written consent 
4. Age 40 years or over 
5. For COPD patients with Cardiovascular disease*:  a physician confirmed diagnosis of 
previous myocardial infarction, angina or left ventricular dysfunction thought secondary to 
atherosclerosis  
6.  For COPD patients with Diabetes**: a physician confirmed diagnosis of type 2 diabetes. 
 
Exclusion Criteria for stable COPD patients 
1. Diagnosis of Asthma, Interstitial Lung disease, Bronchiectasis, (fibrosis related to 
emphysema or bronchiectasis related to COPD is not an exclusion), Lung Cancer, Previous Lung 
resection 
2.  Lack of capacity to provide informed consent 
3. Age 39 years or under 
4. Participation in CTIMP in past 6 months* 
5. Taking oral prednisolone for COPD or immunosuppressive medications 
6.  Haematological malignancy 
7.  Exacerbation within preceding 6 weeks 
*  To assess previous participation in a CTIMP, the potential participant will be asked if this is 
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Participants with acute COPD exacerbations: 
 
Inclusion Criteria  
1. Suspected or proven clinical diagnosis of COPD  
2. At least 10 pack year history of smoking 
3. Provision of informed written consent 
4.  Diagnosis of exacerbation of COPD being primary reason for admission to hospital 
5.  Consent and first blood samples taken within 48 hours of admission to hospital 
6.  Age 40 years or over 
 
Exclusion Criteria  
1. Diagnosis of Asthma, Interstitial Lung disease, Bronchiectasis, (fibrosis related to 
emphysema or bronchiectasis related to COPD is not an exclusion), Lung Cancer, Previous Lung 
resection 
2.  Lack of capacity to provide informed consent 
3. Participation in CTIMP in past 6 months 
4. Taking immunosuppressive medications (excluding oral prednisolone for exacerbation 
which is not an exclusion) 
5.  Haematological malignancy 




10.2 Appendix 2: Work during the COVID-19 pandemic 
As the laboratory closed and the study was paused, I joined the COVID-19 taskforce producing 
reports and infographics for frontline healthcare staff and the general public on the latest 
scientific research on SARS-CoV-2 and COVID-19. 
These reports and graphics are available to view at https://rapidcomms.wordpress.com/. 
Reports were generated as part of a team, with graphical concept and design completed by 
myself with input from the team.  
In 2020, the site was accessed over 2,500 times from 58 different countries, with over 400 
downloads of the available infographics. These infographics were also adopted by multiple 
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10.3 Appendix 3: Publication agreement with Taylor and Francis Group 
The following document pertains to the use of original figures by the author of this thesis that 
have also been published as referenced in the forwards of this thesis. 
I acknowledge that Figure 1.1, Figure 1.2, Figure 1.3 and Figure 1.5 are also, in part, published 
in “Neutrophil Phenotypes of Chronic Lung Disease” (October 2019) by Taylor and Francis, 
available online http://www.tandfonline.com/doi/abs/10.1080/17476348.2019.1654377.  
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